INDEX TO VOLUME 57—1989

AUTHOR INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), book reviews (B), and reprinted article (R).

Abalos, R. M., (A) 318, 344, 899
Abdulkadir, S., (A) 314, 708
Abe, M., (A) 303, (O) 752
Abel, L., (O) 465
Abraham, A., (A) 901
Abram, G., (A) 318
Abrusci, V., (A) 919
Achenbach, R. E., (A) 891
Adams, E., (A) 318
Agarwal, A., (A) 580
Agarwal, J. S., (A) 892
Agarwal, U. S., (A) 306
Aggarwal, S. K., (A) 567, 588
Aggarwal, T. D., (A) 710
Agnihotri, N., (C) 870
Agrawal, J. K., (A) 569
Agrawal, J. S., (A) 313
Agrawal, S. K., (C) 867
Agrewala, J. N., (C) 687
Agusni, I., (A) 333
Akuffo, H. O., (A) 727
Alcalde, M. A., (A) 334
Alexander, T. A., (A) 354
Algaba, F., (A) 134
Allen, W., (A) 915
Alvarez Mesa, M., (A) 586
Amaral, R. R., (A) 351
Ambrose, E. J., (A) 315, 893
Amicosante, G., (A) 914
Amorim, M. G. M., (A) 707
Anantharaman, D. S., (A) 577
Andersen, B. R., (A) 718
Anderson, D. C., (A) 136
Anderson, R., (A) 132, 727, 733
Andrade, V. L. G., (A) 335
Andre-Schwartz, J., (A) 576
Andreoli, A., (A) 312
Anilkumar, G., (A) 132, 132, 132
Anokhina, V. V., (A) 909
Antia, N. H., (C) 110, (A) 137, 315, 337, (E) 511, (A) 579, (C) 690, (A) 712, 716, 893, 893, 902
Antoine, I., (A) 142, 320
Aoki, F. H., (A) 708
Appelberg, R., (E) 73
Arcalis Arce, L., (A) 917
Arce, P., (C) 879
Arora, P. N., (A) 567, 588
Arora, S. K., (A) 709, 710, 894, 894, 918
Arunthathi, S., (A) 346
Arupova, A. K., (A) 910
Asano, K., (A) 731
Aschhoff, M., (A) 129, 129
Ashby, P., (A) 578
Ashton, L., (A) 595
Ashton, L. E., (O) 33
Ashton, P., (O) 33, (A) 595
Astbury, L., (A) 318, 318, 583
Ati, M. A., (A) 592
Atkin, S. L., (A) 895
Attah, E. B., (A) 347
Augustine, S. M., (C) 695
Ausina, V., (A) 917
Autee, G. S., (A) 132
Aveleira, J. R., (A) 335
Aytekin, A. H., (A) 143, 144
Aytekin, H., (A) 324, 911
Azulay, R. D., (A) 310

Babron, M.-C., (O) 465
Babu, G. R., (A) 341, 346
Baccarelli, R., (A) 342
Bach, M.-A., (A) 128, 574, (O) 794, (A) 897, 899, 901
Bagga, A., (A) 567
Bagga, A. K., (O) 458, 472
Bagshawe, A., (A) 722
Bahr, G. M., (A) 592
Bajaj, M. M., (A) 138
Bajpai, H. S., (A) 569
Bakaya, V., (A) 708
Bal, V., (A) 582
Balakrishnan, M., (A) 146
Balakrishnan, S., (A) 129, 129, 707, 911
Balina, L. M., (A) 325, 325, 715
Balybin, E. S., (A) 895
Banerjee, A., (A) 905
Banerjee, D., (A) 328
Banerjee, D. K., (A) 350
Banerji, J. B., (A) 315
Banks, P. M., (A) 918
Bapat, C. V., (A) 349, (C) 874
Baquillon, G., (A) 339
Bardin, C. E., (A) 345
Barroso, M. S., (A) 351
Barry, M. E., (A) 136
Barwick, S., (A) 308
Basavaraj, G. C., (A) 711
Baskin, G. B., (A) 310
Bass, J. G., (A) 898, 903
Basten, A., (A) 318, 318, 583, (O) 777
Basu, S. K., (A) 918

Batanero Bernabeu, M. C., (A) 569
Batoni, G., *et al.*, (A) 594
Batra, P. P., (A) 912
Battaraj, S. P., (A) 344
Baule, M.-S., (O) 465
Bechelli, L. M., (A) 305, 311
Beck, J. S., (A) 318, 346, 575, 575, 576, 576, 727
Becx, M., (A) 325, 326
Becx-Bleumink, M., (A) 335, 337, (Ob) 552, (E) 540, (A) 714
Bedenbender, H., (A) 307
Beezer, A. E., (A) 916
Behrens, R., (A) 581
Behse, F., (A) 137
Beine, A. O., (A) 725
Beline, J., (A) 723
Bell-Krotoski, J., (A) 337
Bellahmer, F., (A) 324
Bellein, M., (A) 133
Bellinger, R., (A) 346
Benjamin, J., (A) 308
Benjamin-Huntley, R., (A) 335
Benjamins, J. A., (A) 711
Bennett, C., (O) 33
Beoletto, C., (A) 316
Bera, A., (A) 905
Berchmans, J., (O) 801
Bercovier, H., (A) 142, 585, 593
Berhe, D., (A) 337
Bernheimer, H., (A) 304
Berry, G., (A) 722
Besra, G. S., (A) 908
Bhanage, N. D., (A) 129
Bharadwaj, V. P., (A) 303, 329, 574, (O) 615, (A) 906
Bharathi, S., (A) 134
Bhate, R. D., (A) 892
Bhate, R. P., (A) 892
Bhatia, A. S., (O) 24, 458
Bhatia, V. N., (A) 132, 132, 142, 568, 714, 728, 906
Bhatki, W. S., (A) 136, 144
Bhattacharya, C. P., (A) 589
Bhoopat, L., (A) 312
Bhume, J. I., (A) 132
Bhutani, L. K., (O) 633
Bian, J.-G., (A) 353
Billent, I., (A) 329
Binford, C. H., (A) 310
Birdi, T. J., (A) 137, 315, 337, (E) 511, (A) 712, 902
Birke, J. A., (A) 725, 725, 726
Bishburg, E., (A) 728
Blaauwgeers, J. L. G., (A) 912
Blacklock, Z. M., (A) 596
Blair, A. L., (A) 575
Blake, L. A., (A) 147
Blanc, M., (O) 465
Blom-Potar, M.-C., (A) 730, 912, 913, 920
Bloom, B. R., (A) 320, 327, 713, 715, 719, 907, 907
Bobin, P., (A) 313, 335, (O) 607, 794, (A) 899, 899
Boccato, R. S. B. S., (A) 708
Boddingius, J., (A) 913
Boerrigter, G., (A) 306, 314
Bois, E., (O) 465
Bolton, R. C., (A) 908
Booth, R., (A) 318
Booth, R. A., (A) 319
Booth, R. J., (A) 575, 583, 719
Borges, M. V., (A) 334
Borovok, M. I., (A) 591
Bose, T. K., (O) 499
Bosmans, R., (A) 590
Botasso, O., (A) 731
Bothamley, G., (A) 902
Bothamley, G. H., (A) 727
Boucher, P., (A) 339, 342, 343
Bouchier, V. A., (A) 323
Bouree, P., (A) 565
Bourland, J., (A) 336, 340
Boutin, J.-P., (A) 722, (O) 810
Bouwer, I., (A) 310
Branchini, M. L. M., (A) 708
Brandsma, J. W., (A) 306
Brennan, P. J., (A) 140, 303, 320, 321, 349, 712, 712, 713, 715, (O) 744, (A) 901, 906
Brenner, M. B., (A) 327
Brethes, B., (O) 794
Brett, S. J., (A) 589
Brewer, J. A., III, (A) 726
Briceno, L., (A) 919
Brightmer, M. I., (A) 322
Britton, S., (A) 727
Britton, W. J., (A) 318, 583
Brock, N. F., (A) 729
Brown, A. R., (A) 913
Brown, L. M., (A) 315
Brown, L. P., (A) 309
Brucker, G., (O) 607
Buchalla, C. M., (A) 345
Buchanan, T. M., (A) 136, 303, 901
Buford, W. L., Jr., (A) 726
Bunker, C., (A) 149
Burchfield, H. P., (A) 308
Burgess, P. J., (A) 144
Burtonboy, G., (A) 921
Butcher, P. D., (A) 149
Butler, R., (A) 589
Butter, C., (A) 310
Byrd, S., (A) 303, (O) 744

Cakiner, T., (A) 324, 354, 355, 911
Cales-Quist, D., (A) 335
Callahan, R. E., (A) 711
Camacho Martinez, F., (A) 574, 574
Carayon, A., (A) 342
Caree, N., (A) 565
Carneiro, R. M., (A) 565
Carranza Martinez, J. M., (A) 323
Carrasco Gellida, S., (A) 323, 351
Carraza Martinez, J., (A) 351

Carrillo, M., (A) 339
Cartel, J.-L., (A) 313, 325, 335, (O) 607, (A) 722, (O) 735, 810, (A) 897
Carvalho Costa, I. M., (A) 565
Casablanca, M. N., (A) 339
Celerier, P., (O) 735, 810
Cellona, R. V., (A) 318, 339, 899
Cem Mat, M., (A) 144
Chacko, C. J. G., (A) 344, (O) 801
Chacko, P., (A) 346
Chadda, V. S., (A) 710
Chakkalath, H. R., (A) 579
Chakrabarty, A. K., (A) 131, 311
Chakrabarty, A. N., (A) 308, 582, 589
Chand, A., (A) 903, 914
Chanda, M., (A) 565
Chandrasekaran, V., (A) 568
Chandrasekhar, H. R., (A) 711
Chang, F. K., (A) 732
Chang, W.-K., (A) 897
Chanteau, S., (A) 325, (O) 735, 810, (A) 897
Chastel, D., (A) 133
Chatterjee, D., (A) 712, 906
Chatterjee, G., (A) 569
Chattopadhyay, S. P., (A) 588, 892, 895, 895
Chaturvedi, R. M., (A) 136
Chaturvedi, V. K., (A) 140
Chaudhary, S. D., (A) 569
Chaudhary, V. N., (A) 132
Chaudhuri, G., (A) 918
Chaudhury, A., (A) 893
Chaudhury, S., (A) 708
Chaudhury, S. K., (A) 708
Chauhan, V. S., (A) 146
Chehl, S. K., (A) 349
Chen, D., (A) 144
Chen, J., *et al.*, (A) 707
Chen, J.-K., (A) 342
Chen, M.-Y., (A) 901
Chen, P. C. Y., (A) 127, 145
Cheng, C.-S., (A) 901
Cherayil, B. J., (A) 575
Cherian, E., (A) 132
Cherian, J., (Ob) 883
Chernushenko, E. F., (A) 591
Chi, Y.-L., (A) 334
Chiang, T., (O) 766
Chien, C. G., (A) 732
Chiodini, R., (A) 149
Chirmule, N. B., (A) 137
Cho, S.-N., (A) 303, 303, 712, (O) 744, (A) 897
Choi, I.-H., (A) 897
Chopra, N. K., (A) 313, 892
Chou, P., (A) 330
Choudhary, A., (A) 573
Chowdhury, A., (A) 565
Christian, M., (A) 128, 145, 331, 337, 340, (E) 526, (O) 647
Chu, Z., *et al.*, (A) 723
Chu, Z.-Z., (A) 332
Chuah, J., (A) 722
Chujor, C. S. N., (A) 304
Chullawala, R. G., (A) 136
Cicuta, M. E., (A) 724
Clarbour, J., (A) 733
Clark-Curtiss, J. E., (A) 327, 583, 585, 719, 906
Clavel-Sérès, S., (A) 914, 917
Clement, F., (A) 914, 917
Cochrane, I. H., (A) 575
Cocito, C., (A) 142, 320
Coene, M., (A) 142, 320
Cohen, M. L., (A) 140
Cohn, Z. A., (A) 325, 577, 714
Coleman, W. C., (A) 725
Collazo Cabellero, S., (A) 580
Collins, C. H., (A) 151, 728
Collins, R. J., (A) 590
Colston, M. J., (A) 309, 310, 325, 327, 328, 717
Connolly, M., (A) 733
Consorte, J., (A) 723
Constant-Desportes, M., (A) 133, 335, (O) 607
Converse, P., (A) 311, 325, 326, 714
Convit, J., (A) 715, 919
Coovadia, H. M., (A) 730
Coovadia, Y. M., (A) 730
Cordeiro, R. A., (A) 725
Cornwall, M. W., (A) 725
Costa, M. L., Jr., (A) 345
Cottenot, F., (A) 323, 571
Courbil, L. J., (A) 342
Courtright, P., (A) 354, 355
Cowley, S. A., (A) 310, (B) 888
Crawford, C. L., (A) 308
Cree, I. A., (A) 318, 346, 575, 575, 576, 576
Crome, P., (A) 130
Cruaud, P., (A) 913
Cruz, R. C., (A) 334
Cuadra Meiro, M. J., (A) 351
Cui, C., *et al.*, (A) 128
Cunha, M. G. S., (A) 334
Curtis, J., (A) 308, 310
Cutler, S. J., (A) 589
Cynamon, M. H., (A) 732

da Silva e Goncalves, N. N., (A) 723
Daffe, M., (A) 913, 918
Dale, J. W., (A) 327, 720
D'Amaro, J., (A) 727
Dambreville, M., (A) 306
Dandekar, S. R., (A) 910
Daniel, L. L., (A) 565
Das, B. S., (O) 499
Das, P. K., (A) 708, 898, 903, 912, 914
Das, S., (A) 308, 582
Dastidar, S. G., (A) 582, 589
Dastur, D. K., (A) 337
Datta, A. K., (A) 321, (O) 615, (A) 906, 907

David, H. L., (A) 151, 730, 905, 912, 913, 913, 914, 914, 917, 918, 920, 920
David, J. R., (A) 730
Davies, E. M., (A) 347
Davignon, L., (A) 592
Davis, J. R., (A) 592
Day, R. S., (C) 340
de Abreu, M. H., (A) 146
de Almeida, I. S., (A) 146
de Bruyn, J., (A) 590
de Burgh, S., (A) 722
de Chastellier, C., (A) 914
De Kesel, M., (A) 320
de la Barrera, S., (A) 325, 325, 715
de la Cruz, E. C., (A) 899
De Libero, G., (A) 898
de Menezes, J. A., (A) 569
De Millan, S. G., (A) 724
De Muynck, A., (A) 336
de Oliveira, I. M., (A) 146
de Oliveira, S., (A) 342
De Rott, M. I. O., (A) 724
de Vries, R. R. P., (A) 136, 139, 141, (C) 554, (A) 713, 717, 727, (O) 788
de Wit, M., (A) 129, 310
de Wit, M. Y. L., (A) 899
Debanbu, V., (O) 801
Debbage, P. L., (A) 308
Declercq, E., (A) 323, 332, 341
Declercq, E. E., (O) 599
Delgado Rodriguez, M., (A) 569
Demenais, F., (O) 465
Demidov, S. V., (A) 591
Deo, M. G., (A) 136, 137
Deresinski, S. C., (A) 732
Desai, A. R., (A) 896
Desai, S. D., (A) 137, 712
Deschamps, M. M., (A) 306
Desfontaine, M., (A) 323
Desforges, S., (O) 735, 794, (A) 899, 899
Desikan, K. V., (A) 141, 329, 349, 570
Desta, Z., (A) 335
Devasthale, S. V., (A) 316
Devasundaram, B., (A) 346
Dewapura, D. R., (A) 910
Dey, B., (A) 355
Dey, S. K., (A) 565, 708
Dhandayuthapani, S., (A) 132, 728
Dharma Rao, T., (A) 133
Dharmaraj, S., (A) 572
Dharmendra, (B) 888
Dharmshaktu, N. S., (A) 347
Dhiman, R. K., (A) 895
Dhople, A. M., (A) 142, 320
Diaz, H. B., (A) 322
Diaz Chavero, P., (A) 323, 351
Diaz de la Rocha Quevado, A., (A) 580
Diaz Garcia, M. A., (A) 580
Dick, W. C., (A) 895
Dietz, M., (A) 325, 338, 350, 714
Dieye, A., (A) 901
Diggs, C., (A) 309
Dijkman, H. P., (A) 913
Dilawari, J. B., (A) 896
Dilger, P., (C) 866
Diouf, F., (A) 343
Diwaker, M., (A) 311
Dixit, G. M., (A) 136
Dixit, V. B., (A) 569
Docherty, M. A., (A) 583
Dockrell, H. M., (A) 329, 581, (O) 766
Doherty, T. M., (A) 719
Donald, J., (A) 318
Dong, L.-W., (A) 342
Dorairaj, A., (A) 147
dos Santos, I. B., (A) 707
Douglas, J. T., (A) 303, 308, 712, 899
Dowlati, Y., (O) 38, 45, (A) 320, 349, 350
Doyle, D., (A) 309, 310
Doyle, D. D., (A) 338
Drahmane, S., (A) 565
Draper, C., (A) 144
Draper, P., (A) 321, 328, 920
Drevet, D., (A) 323
du Moulin, G. C., (A) 590
Duan, C.-X., (O) 622
Duan, Z.-X., (A) 336
Due, L. K., *et al.*, (A) 332
Duerksen, F., (A) 347
Duggan, D. B., (A) 311, 576
Durai, V., (A) 135
Durgambal, K., (A) 330, 911
Dwuvedi, M. P., (A) 146

Eatock, W., (A) 344
Eggelte, T. A., (A) 310
Ehrenberg, J., (A) 326
Ekambaram, V., (A) 708
El-Ghobarey, A., (A) 895
Elangeswaran, N., (A) 714
Ell, S. R., (E) 825
Ellard, G. A., (A) 128
Ellis, C., (A) 902
Ellis, C. J., (A) 319
Enarson, D. A., (A) 151
Eng, R. H. K., (A) 728
Engers, H. D., (A) 326
Eriyagama, N. B., (A) 579
Ermolin, G. A., (A) 140
Errazquin S. Tejada, L., (A) 574
Ersoy, N., (A) 354
Espinoza, C. G., (A) 732
Estrada-G., I., (A) 325, 327
Extremera Castillo, F., (A) 569

Fajardo, T., (A) 339
Fajardo, T. T., (A) 318, 899
Fan, Y.-L., (A) 333
Fang, H.-J., (A) 315
Farooq, A., (A) 312, 313

Farshchi, Y., (O) 38, 45
Farthing, C., (A) 733
Fattorini, L., (A) 914
Fehniger, T. E., (A) 727
Feingold, N., (O) 465
Ferracci, C., (A) 339
Ferreira, C. S. A., (A) 902
Ferreira, M. S., (A) 146
ffytche, T., (A) 354
Fibach, E., (A) 593
Figueiredo, A. A., (A) 905
Fikri, M., (A) 324
Filley, E., (A) 312
Fine, P. E. M., (A) 144, 307, 314, 330, 352, 572, 586, (E) 671, (A) 728, 896
Finley, K., (A) 344
Fiorentino, D., (A) 914
Fisher, D., (A) 896
Fisher, T. R., (A) 309, 310, 338
Flageul, B., (O) 607
Fleming, S., (A) 127
Flesch, I., (A) 898
Fleury, R. N., (A) 314, 344, 345
Floch, H. A., (A) 566
Floch, H. H., (A) 566
Forster, G., (A) 351
Foss, N. T., (A) 311, 312, 717, 904
Fowler, M. E. R., (A) 147
Franceschini, N., (A) 914
Frankel, R. I., (A) 313, 587
Franzblau, S. G., (A) 316, 566, 566, 577, (B) 705
Frederic, M., (O) 607
Frehel, C., (A) 326, 914, 915, 915, 920
Freitas, P., (A) 352
Fritschi, E. P., (A) 343
Fujimori, C., (A) 573
Fujiwara, T., (A) 304, 712
Fumey, S. M., (A) 567
Fung, S. C., (A) 722
Furuta, M., (A) 345

Gadelha, A. R., (A) 920
Gaisne, E., (A) 314
Gan, S. C., (A) 583
Gan, S. N., (A) 583
Ganapati, R., (O) 33, (A) 129, 350, 595, 890, 910
Gandhi, B. M., (A) 710
Ganguly, N. K., (O) 20, (A) 141, 580, 586, 718, (C) 870, (A) 896, 900
Garcia Ochaita, J. L., (A) 351
Garg, R., (A) 569
Garg, S. K., (A) 708
Garg, U. C., (O) 20
Garsia, R., (A) 318
Garsia, R. J., (A) 318, 583
Gayed, S. L., (A) 130
Gazzard, B., (A) 733
Gebhard, J. F., (A) 344
Gebre, N., (A) 326
Gelber, R. H., (A) 303, 317, 349, 352, (O) 744
Gentilini, M., (A) 148, 588
George, H., (A) 594
Georgiev, G. D., (A) 570
Gerone, P., (A) 310
Gerras, G., (A) 711
Ghaswala, P. S., (C) 690
Ghazi Saidi, K., (O) 38, 45, (A) 320, 349, 350
Ghei, S. K., (C) 687, (A) 709
Gheorghiu, M., (A) 906
Ghorpade, A., (A) 133
Gibbels, E., (A) 137
Gibson, J. J., (A) 719
Gicquel-Sanzey, B., (A) 906
Gidoh, M., (A) 721
Giles, F., (A) 149
Gill, H. K., (C) 112, (A) 319
Gillen, J., (A) 352
Gillis, T. P., (A) 309, 319, 328, 577, 909
Girdhar, A., (A) 338, (O) 472, (A) 567
Girdhar, B. K., (O) 24, (A) 303, 305, 338, (O) 472, (A) 567, 573, (O) 652, (C) 687, (A) 709
Girdhar, M., (A) 709, 894, 894
Godal, T., (C) 112, (A) 319, 585
Godbole, P., (A) 128
Goldstone, A., (A) 149
Golecki, J., (A) 339
Golecki, J. R., (A) 717, 900
Gollmer, E., (A) 137
Gomez Echevarria, J. R., (A) 342
Goncales, F. L., Jr., (A) 708
Goncalves, A., (A) 342, 723
Gonzalez, A. B., (A) 335
Gonzalez, V. M., (A) 323
Gonzalez del Cerro, S. M. A., (A) 911
Gonzalez Fuente, T., (A) 917
Gonzalez-Abreu, E., (A) 335
Gonzalez-Abreu Castel, E., (A) 714
Gonzalez-Mendoza, A., (C) 879
Gonzalez-Rodriquez, L., (A) 714
Gonzalez-Segredo, A., (A) 714
Goodman, D. D., (B) 562
Gopa, A. K., (A) 890
Gopal, A. R., (A) 895
Gopal, P. K., (A) 352
Gormus, B. J., (A) 309, 310, 354
Gorzynski, E. A., (A) 915
Goto, K., (A) 916
Goyal, N., (A) 331
Goyder, E. C., (A) 145
Graham, S. L., (A) 726
Grandison, P. M., (A) 575
Grant, K. A., (A) 329, 581
Green, E. P., (A) 916
Green, K. J., (A) 320
Grillone, S., (A) 336, 340
Groenen, G., (A) 336, 340
Groothuis, D. G., (A) 898
Groothuis, D. J., (A) 903
Gross, A., (A) 919

Grosset, J. H., (A) 313, 316, 316, 317, 325, 335, 335, 336, (E) 529, (O) 607, (A) 722, (O) 810
Grossetete, G., (A) 336
Grosskinsky, C. M., (A) 719
Gruer, P. J. K., (A) 307
Grugni, A., (A) 146, 567
Grzybowski, S., (A) 151
Gschmeissner, S., (A) 310
Gu, J.-Z., (A) 342
Guelpa-Lauras, C.-C., (A) 316, 316, 317, 325, 335, (O) 607
Gueye, M. M., (A) 572
Guidi, C., (A) 313, 335
Guido, L. S., (A) 318
Guillaume, J.-C., (O) 607
Guillet, G., (A) 133
Guillet, M. H., (A) 133
Guirintano, D. J., (A) 726
Gupta, C. M., (A) 892
Gupta, H. P., (A) 140, 580
Gupta, R., (A) 322, 328
Gupta, R. K., (A) 710
Gupta, S. K., (A) 138, 579
Gupte, M. D., (A) 570, 577
Gutierrez de la Solana Dumas, J., (A) 586
Gutman, S. I., (A) 915

Ha, D. K. K., (A) 590
Haaijman, J. J., (A) 304
Haas, M., (A) 350, 350
Hadley, W. K., (A) 596
Hah, Y., (A) 339
Haldar, S. R., (A) 133
Halperin, M., (A) 898
Hammond, C. J., (A) 570
Hamono, B., (A) 323
Han, Y., (A) 916
Hancock, G., (A) 714
Handa, A. K., (A) 306
Hanyalioglu, E., (A) 355
Harada, N., (A) 345
Harding, D. R. K., (A) 719
Hardwicke, P. M. D., (A) 308
Hari, L., (A) 568
Harrington, N., (A) 594
Harris, D. P., (A) 319
Harris, E. B., (A) 309, 316, 317, 323, 349, 720
Hartskeerl, R. A., (A) 328
Hasan, R., (O) 766
Hastings, R. C., (O) 12, (E) 82, (A) 150, 309, 315, 316, 317, 319, 323, 349, 566, 577, (O) 659, (Ob) 697, (A) 721
Haupt, W. F., (A) 137
Hawkins, D., (A) 733
Hay, R. J., (A) 564
Hazama, S., (C) 873
Hazra, S., (A) 708
He, H., (A) 916
He, H.-M., *et al.*, (A) 326
Hedley-Whyte, J., (A) 590
Heifets, L. B., (A) 149
Hellqvist, L., (A) 318, 318, 583
Hendriks, J. T., (A) 724
Henke-Lubke, U., (A) 137
Henry, P., (A) 339
Hermans, P. W. M., (A) 717
Hermon-Taylor, J., (A) 149, 916
Hernandez Angula, M., (A) 344
Hess, A. D., (A) 732
Hilson, G. R. F., (A) 350
Hily, M., (A) 133
Hiranras, S., (A) 305
Hirsch, D. S., (A) 899
Hodes, R. M., (A) 307
Hoffner, S. E., (A) 590, 729, 916
Hogeweg, M., (A) 314
Holdiness, M. R., (A) 893
Holmes, R. M., (O) 33
Holt, P., (A) 318
Holton, J., (A) 149
Holzer, T. J., (A) 718
Hong Kong Chest Service/British Medical Research Council, (A) 591
Hong, B.-Y., (A) 306
Hong, Y. P., (A) 151
Hooper, M., (A) 316
Horai, Y., (A) 567
Hottat, F., (A) 320
Houthoff, H. J., (A) 912
Hua, H., (A) 916
Huang, H., (A) 568
Huang, J.-W., (A) 322
Huang, W.-B., (O) 622
Huerre, M., (O) 794, (A) 899
Hunink, M., (A) 306
Hunter, S. W., (A) 140, 320, 321, 349, 713, 715, 906
Huson, A., (A) 343
Hussain, R., (O) 766
Hussein, N., (A) 354, 355
Hussein, S., (A) 308
Hussen, A., (O) 652
Husser, J. A., (A) 336

Ignatia, (A) 131
Ikawa, H., (A) 916
Ikeda, M., (A) 304
Ilampurnam, K. J., (A) 596
Ilias, M. I., (A) 333
Imongan, W. I., (A) 709
Inamadar, A. C., (A) 711, 711
Inderlied, C. B., (A) 591
Irshad, M., (A) 710
Irudaya Raj, P. P., (A) 129, 129
Isenberg, D. A., (A) 304, 581, 582
Ishaque, M., (C) 115, (A) 321
Ishida, Y., (A) 345
Ishizaki, T., (A) 567
Ito, T., (A) 316, 328, 329, 339, (O) 817
Itty, B. M., (A) 304, 309

Ivanyi, J., (A) 138, 319, 326, 582, 714, 727, 902, 904
Izumi, S., (A) 304

Jackson, M., (A) 725
Jacob, M., (C) 114, (A) 338, 355
Jacobs, J. M., (A) 716
Jacobs, W. R., Jr., (A) 719, 907, 907
Jacobson, R. R., (O) 12
Jadhav, V. H., (A) 710
Jagannathan, R., (A) 321, 584
Jain, M. K., (A) 890
Jain, V. K., (A) 569
Janis, E. M., (A) 900
Janson, A. A. M., (A) 136, 717
Janssen, F., (A) 571
Janssens, L., (A) 336, 340
Jardine, I., (A) 906
Jawade, G. K., (A) 132
Jayabal, P., (A) 588
Jayaraman, T., (A) 319
Jazwinska, E. C., (A) 145
Jedra, J. M., (A) 333
Jekkel, A., (A) 907
Jenner, P. J., (A) 325
Jesudasan, K., (A) 128, 145, 147, 331, 337, 340, 346, (E) 526, (O) 647
Jeugmans, J., (A) 921
Jeyaseelan, L., (A) 723
Jha, P. K., (A) 129
Ji, B.-H., (A) 336, (E) 529
Ji, Z.-M., (O) 65
Jiang, C., (A) 353
Jiang, Z.-L., (A) 306
Jidoi, J., (O) 628
Job, C. K., (O) 12, (A) 308, 323, (E) 532, (O) 659, (A) 714, 720, 721, (B) 889
Johnson, C. J., (A) 354
Joone, G., (A) 727
Jopling, W. H., (Ob) 553
Josse, R., (A) 323
Josseran, R., (A) 323
Jouy, N. F., (A) 329
Juwano, O., (A) 332

Kaboto, M., (A) 921
Kahkonen, M. E., (O) 12, (A) 309
Kahmann, L. R. M., (A) 343
Kaleab, B., (A) 311
Kallenius, G., (A) 729, 916
Kalyanasundaram, K., (A) 714
Kamel, M., (A) 895
Kanatani, F., (A) 306
Kane, A. W., (A) 572
Kaneda, K., (A) 916
Kang, W.-X., (A) 332
Kannan, K. B., (A) 906
Kannan, S., (A) 570
Kaplan, G., (A) 325, 577, 714
Kar, H. K., (A) 133, 351
Kar, P. K., (A) 129
Karacorlu, M. A., (A) 354, 355
Karanth, S. S., (A) 578
Karapetyan, E. T., (A) 918
Kardjito, T., (A) 727
Karhahunga, C., (A) 921
Kari-Lefvert, A., (A) 576
Karthikeyan, S., (A) 707
Kashyap, A., (A) 131, 311, (C) 867
Kato, L., (C) 693
Katoch, K., (A) 312, 321, 329, 340, (O) 451, 458, 615, 652, (C) 687, (A) 709, 900, 906
Katoch, V. M., (A) 321, (O) 451, 615, (A) 900, 906, 907
Kaufmann, S. H. E., (A) 141, 339, 717, 729, 898, 900, 900
Kaur, H., (A) 580
Kaur, I., (A) 134, 569, 900
Kaur, P., (A) 587
Kaur, S., (O) 20, (A) 134, 141, 569, 580, 586, 708, 718, (C) 870, (A) 896, 900, 901
Kazda, J., (A) 310, 322, 717, 900, 908
Kebede, B., (A) 326
Kempsell, K., (A) 327
Ketova, N. A., (A) 729
Keulen, W. J., (A) 717
Khaldi, M., (A) 324
Khanna, V., (A) 134
Khanolkar, S. R., (O) 652, (A) 901
Kharkar, R. D., (A) 317
Khedker, M. Y., (A) 132
Khuller, G. K., (A) 592, 593, 729
Khuong, M. A., (A) 571
Khupulsup, K., (A) 305
Kieser, T., (A) 907
Kiessling, R., (A) 311, 325, 326, 714
Kim, D., (A) 339
Kim, D.-I., (A) 303, 303, 897
Kim, J.-D., (A) 303, 897
Kim, S., (C) 873
Kim, S.-H., (A) 897
Kim, S. J., (A) 151
King, J. W., (A) 147
Kingston, A. E., (A) 325
Kini, M., (A) 567
Kini, M. S., (A) 146
Kinteh, S. B., (A) 323
Kirihara, J., (A) 596
Kist, P., (A) 894
Klatser, P., (A) 310
Klatser, P. R., (A) 141, 899
Klebanoff, S. J., (A) 139
Kleeberg, H. H., (A) 733
Klenerman, P., (A) 570, 901
Klingmuller, G., (A) 137
Kohli, M., (O) 20, (A) 900
Kohsaka, K., (A) 316, (O) 817, (A) 908
Kok, A., (A) 898
Kolk, A. H. J., (A) 141, 322, 717
Kollo, B., (A) 323
Kolonosky, P. T., (A) 591

Kongsuebchart, K., (O) 752
Koseki, M., (C) 873
Kostromin, A. P., (A) 591
Kouka-Bemba, D., (A) 323
Koziatek, E., (A) 726
Krahenbuhl, J. L., (A) 140, 150, 577
Kremsner, P. C., (A) 351
Kreye, W., (A) 912
Krishnan, R., (A) 132
Krishnan, S. A. R., (A) 343
Krishnaram, A. S., (A) 572
Krom, R. A. F., (A) 918
Krotoski, W. A., (A) 309
Kuijper, S., (A) 322
Kulkarn, S. N., (A) 316
Kumagal, M. T., (A) 146
Kumar, A., (A) 135, 140, 307, 330, 568
Kumar, B., (A) 134, 134, 141, 586, 708, 718, (C) 870, (A) 896
Kumar, B. K., (A) 588
Kumar, K. K., (A) 710
Kumar, M., (A) 130
Kumar, N., (A) 571
Kumar, P., (A) 138
Kumar, T. S., (A) 341, 346
Kumar, V., (A) 138
Kumaravelu, P., (A) 911
Kumaresan, J. A., (A) 334
Kuntjoro, (A) 333
Kunze, Z. M., (A) 720
Kuriakose, T., (A) 354
Kurz, X., (A) 341
Kurz, X. M., (O) 599
Kushwaha, S. S., (A) 146
Kuze, F., (A) 731

Laal, S., (A) 311, 319, 577
Labidi, A., (A) 917, 917
Lackman-Smith, C., (A) 732
Lal, R., (A) 708
Lamb, F. I., (A) 325, 327, 328
Lamb, J., (A) 902
Lamb, J. R., (A) 319, 582, 714
Lamoureux, G., (A) 592
Landon, D., (A) 579
Landry, M., (A) 309, 323
Lane, H. C., (A) 594
Lang, T., (A) 914
Lange, K., (A) 146
Languillon, J. L., (A) 341
Lanza, A. P., (A) 345
Lary, C. H., (A) 147
Lastoria, J. C., (A) 314
Laszlo, A., (A) 918
Lathigra, R., (A) 714
Launois, P., (A) 574, 899, 901
Lavania, R. K., (O) 472
Laverdiere, M., (A) 592
Law, A. S., (A) 352
Lawton, J. W. M., (A) 590
Lazlo, A., (A) 914
Lazraq, R., (A) 917
Lebastard, M., (A) 593
Lechat, M. F., (A) 323, 332
Lee, A. M., (A) 732
Leelarusamee, A., (A) 305
Leeuwen, J. V., (A) 322
Lefford, M., (A) 326
Lefford, M. J., (A) 711
Lefvert, A. K., (A) 311
Lei, S.-G., (C) 554
Leigh, I., (A) 304, 582
Levene, M. M., (A) 578
Levis, W. R., (A) 304, 345
Levy, D., (A) 578
Levy, L., (A) 142, 593
Lévy-Frébault, V., (A) 730
Lewallen, S., (A) 355
Li, F., (A) 303, (O) 744
Li, F.-T., (A) 342
Li, H.-Y., (A) 336, (O) 622
Li, W., (A) 568
Li, W., *et al.*, (A) 567
Li, W.-Y., (A) 332
Li, W.-Z., (A) 341
Li, X., (A) 581
Li, X.-Y., (A) 305, 305
Li, Y., (A) 334
Lian, Z.-J., (A) 315
Liang, Z., (A) 127
Libonati, J. P., (A) 592
Lilly, L., (A) 129, 129
Lin, T. P., (A) 151
Lindholm-Levy, P. J., (A) 149
Lindner, B., (A) 350, 350
Linington, C., (A) 308
Liu, J., *et al.*, (A) 578
Liu, K.-S., (A) 322
Liu, M.-F., (A) 901
Liu, Q., (A) 305, 581
Liu, T.-C., (O) 65
Liu, Z., *et al.*, (A) 134
Livorato, F., (A) 146
Lobo, D., (A) 347
Lockwood, D., (A) 595
Lockwood, D. N. J., (O) 33, (A) 592
Locniskar, M., (A) 304, 581, 581, 582
Lombardi, C., (A) 345
Long, H. T., (A) 724
Lopez, F., (A) 917
Lopez-Bravo, L., (A) 324, 330
Lord, R., (O) 801
Lorentsen, M., (A) 564
Louhenapessy, A. A., (A) 332, 336
Louis, M. J. F. G., (A) 343
Love, S. G., (A) 719
Lowe, A. C. R. E., (A) 325, 717
Lu, B.-X., *et al.*, (A) 355
Lu, W., (A) 568
Lucas, S., (A) 578

Lucas, S. B., (O) 652
Lugosi, L., (A) 907, 907
Luna Herrera, J., (O) 641
Luo, J., (A) 341
Luquin, M., (A) 917
Ly, H. M., (A) 724

Ma, J.-F., (O) 622
Ma, X., (A) 127
Ma, Z.-X., (A) 305
Macedo, P. M., (O) 54, (A) 329
Mackenzie, C. D., (O) 652
Mackworth-Young, C., (A) 311, 576
Madarang, M. G., (A) 303, 899
Madlener, P., (O) 38
Magnusson, M., (A) 908
Mahadevan, P. R., (A) 321, (O) 483, (A) 584, 903
Mahenthiralingam, E., (A) 328
Mahon, A. C., (A) 326
Maillere, B., (A) 901
Maine, M., (A) 307, 330, 352, 728
Majoroh, T. O., (A) 709
Makino, M., (A) 328
Makokha, S., (A) 341
Malarkannan, S., (A) 579
Malaviya, G. N., (A) 138, (O) 472
Malkovsky, M., (C) 866
Mallya, S., (A) 584
Malo, E., (A) 353
Malo, W., (A) 353
Mandich, D., (A) 715
Mane, I., (A) 342
Manghani, D. K., (A) 337
Mangia, A., (A) 728
Manglani, P. R., (A) 133
Mani, K., (O) 647
Mankiewicz, E., (A) 592
Mann, S. B. S., (A) 134
Mariano, M., (A) 902
Marino-Albernas, J., (A) 714
Maris, M. M., (A) 707
Marks, S. C., Jr., (A) 315
Maroja, F., (A) 920
Marolia, J., (O) 483
Marques, A. B., (A) 335
Martin Gonzalez, V., (A) 351
Martin-Casabona, N., (A) 917
Martinez, A. R., (A) 724
Martinez Granja, R., (A) 580
Martodihardjo, S., (A) 333
Mat, C., (A) 355
Matemera, B. O., (A) 336
Mathai, R., (C) 114, (A) 338
Mathen, P., (A) 318
Mathur, D., (A) 306
Mathur, N. K., (A) 306, 577
Matreja, V. S., (A) 709
Matsuoka, M., (A) 329, (O) 817
Matthews, C. M. E., (A) 347, (E) 844
Maurice, P. D. L., (A) 149
Max, E., (O) 476
Mayers, D. L., (A) 729
McAdam, K. P. W. J., (A) 304, 311, 329, 576, 581, 581, 582, (O) 652, (A) 901
McCormick, G. T., (O) 659, (A) 720
McDermott-Lancaster, R. D., (A) 350
McDougall, A. C., (C) 114, (A) 570
McEntegart, A., (O) 24, (A) 305
McFadden, J. J., (A) 149, 328, 916
McManus, I. C., (A) 592
McNeil, M., (A) 320, 713, 715, 906
Meeker, H. C., (A) 345
Meeran, K., (A) 709
Mehlert, A., (A) 582, 719, 904
Mehra, R., (A) 579
Mehra, V., (A) 713, 715
Mehrotra, S. D., (A) 895
Mehta, J. M., (A) 710
Mehta, P. K., (A) 592, 593, 729
Mehta, R., (A) 902
Meisels-Navon, L., (A) 348
Melancon-Kaplan, J., (A) 327
Melton, R. E., (A) 907
Mendez, P., (C) 879
Mendez-Samperio, P., (A) 319, 582, 902
Meng, M., *et al.*, (A) 584
Meng, M.-B., (A) 322
Mengistu, G., (A) 895
Merlin, M., (A) 323
Mester de Parajd, M., (A) 315, 893
Metrai, S., (A) 339
Meyers, W. M., (A) 309, 310, 345, 346, (O) 506, (A) 581, 919
Millan, J., (A) 339, 342, (O) 465, 607
Minnikin, D. E., (A) 908
Mishra, A. D., (A) 139, 710
Mishra, B., (A) 146, 338, (O) 472, (A) 567
Mishra, R., (A) 138, 710
Mishra, R. S., (A) 311, 577
Misra, R. S., (A) 345, 351, (O) 506
Misson, C. B., (A) 314, 323
Mistry, N. F., (C) 110, (A) 315, 337, (C) 690, (A) 893
Mittal, A., (A) 306
Mittal, B. N., (A) 347
Miyachi, T., (A) 920
Miyata, Y., (A) 316
Modlin, R. L., (A) 320, 327, 327, 713, 715, 902
Mohagheghpour, N., (A) 349
Mohan, L., (A) 709, 710, 894, 894
Mohinuddin, S. K., (A) 568
Mohr, H., (A) 346
Mongkolwongroi, P., (O) 752
Moniz-Pereira, J., (A) 906, 917
Monson, J., (A) 349
Montserrat Perez, (A) 134
Mor, N., (A) 142
Moreau, J.-P., (O) 794
Moreno, C., (A) 138
Moreno, O. S., (A) 143

Morini, J. C., (A) 731
Morris, C. D. W., (A) 149
Mosca, W., (A) 919
Moss, M. T., (A) 327, 916
Moudgil, K. D., (A) 138, 579, 579, 710
Moulia-Pelat, J. P., (A) 342
Mozhi, N. M., (A) 340
Mshana, R. N., (A) 150, 309, 315, 319
Mudd, D. W., (A) 304, 311, 576
Mukherjee, A., (A) 345, (O) 506
Mukherjee, R., (A) 304, 309, 351, 579
Mukhija, R. D., (A) 709, 894, 894
Mukhopadhyay, A., (A) 918
Muktha Bai, B., (A) 134
Mulherkar, R., (A) 137
Muliyil, J., (A) 903
Muller, A., (O) 465
Mullins, R. J., (O) 777
Mumford, J. W., (A) 148
Mumford, S. P., (A) 148
Muralidharan, M., (A) 347
Murphy, P. M., (A) 729
Murray, L., (A) 317, 349
Mustafa, A. S., (O) 1, (C) 112, (A) 319, 585
Muthiah, B., (A) 911
Muthukkaruppan, V., (A) 579
Muthuswami, T. C., (C) 695
Mutis, T., (O) 788
Mwantha, J., (A) 138
Myazaki, N., (A) 344
Myers, L. M., (A) 726

Naai, D., (A) 595
Nadkarni, N. J., (A) 146, 567
Nagarajan, M., (A) 568
Nagata, A., (A) 328
Nagesha, C. N., (A) 584
Naik, R., (A) 134
Naik, S. S., (A) 128, 129, 130, 910
Nair, N. G. K., (A) 588
Naish, C., (O) 801
Nakamura, K., (A) 721, 722
Nakamura, M., (A) 908
Nakata, A., (A) 328, 329, (O) 817
Nalini, N., (A) 728
Nampalle, V. B., (A) 132
Nanda, A., (A) 718
Narang, B. S., (A) 579
Narayanan, R. B., (A) 138, 900
Nash, D. R., (A) 596
Nassos, P., (A) 596
Nath, I., (A) 311, 319, 577, (O) 633
Nathani, P. J., (A) 132
Natrajan, M., (O) 458, (A) 900
Naudin, J.-C., (A) 343
Nawaz, J. M., (A) 132
Nawoczenski, D. A., (A) 725, 726
Nayagam, A. S., (A) 339
Nayak, K. C., (A) 710
N'Deli, L., (A) 316, 317, 325
Ndiaye, N., (A) 572
Neelan, P. N., (A) 135, 307
Neill, M. A., (A) 139
Nell, H., (A) 149
Nerland, A. H., (A) 585
Nigam, P. K., (A) 130
Nikolayan, L. T., (A) 918
Nilsen, R., (A) 895
Nishimura, Y., (A) 304
Nishiura, M., (A) 138
Nkoko, B., (A) 921
Noble, S., (A) 894
Nogueira, N., (A) 905
Nogueira, W., (A) 348
Nomaguchi, H., (A) 329, (O) 817
Noordeen, S. K., (A) 324, 326, 330, 336
Nores, J. M., (A) 148, 588
Novisky Gallo, M. A., (A) 569
Nurlingn, A., (A) 326
Nusrat, A, (A) 577
Nyabenda, J., (A) 590
Nyawalo, J., (A) 341

Obara, A., (A) 345
Oberlin, C., (A) 343
Obura, M., (A) 341
Ohashi, D. K., (A) 309
Oka, S., (A) 916, 916
Okelo, C., (A) 341
Okhandiar, R. P., (A) 139, 710
Okuku, P., (A) 341
Olivares, L. M., (Ob) 698
Oliveira, M. L. W., (A) 333
Olivier, H. R., (A) 565
Oltra, A., (C) 879
Opromolla, D. V. A., (A) 314, 344, 347, 723
Oratore, A., (A) 914
Orefici, G., (A) 914
Orege, P. A., (A) 341
Osborne, L. J., (A) 142, 320
Ostler, H. B., (A) 354, 355
O'Sullivan, J. F., (A) 566
Otal Entraigas, J., (A) 917
O'Toole, L., (A) 894
Ottenhoff, T. H. M., (A) 139, 141, 311, 325, 326, 714
Owen, J. P., (A) 895
Ozawa, T., (O) 752
Ozbakir, F., (A) 144

Padovani, C. R., (A) 723
Pagnano, P. M. G., (A) 311
Pahwa, V. K., (A) 133
Pal, N. K., (A) 308, 582
Palmer, G. S., (A) 732
Pan, B., *et al.*, (A) 587
Pan, Z.-Y., (A) 315
Panayach, J. S., (A) 129
Pandey, S. S., (A) 587
Pandya, P. G., (A) 313, 892

Panja, S. K., (A) 565
Pannikar, V., (E) 526
Pannikar, V. K., (A) 128, 145, 331, 337, 340
Papa, F., (A) 151, 905, 913, 918
Papaiordanou, P. M. de O., (A) 708
Pape, J. W., (A) 306
Paramasivan, C. N., (A) 596
Pardoll, D. M., (A) 900
Parent, M., (A) 339, 342, 343
Parenti, F., (A) 730
Parimalam, S., (C) 695
Parkhe, S. M., (A) 330
Parking, A. A., (A) 894
Parlett, J. H., (A) 908
Parreira, V. L., (A) 334
Parvathi, C. N., (A) 584
Patel, R. J., (A) 730
Patel, T. K., (A) 896
Patil, D., (A) 321, 584
Patil, S. A., (A) 303
Patki, A. H., (A) 710
Patnaik, J. K., (O) 499
Patra, A. K., (A) 895, 895
Pattyn, S. R., (A) 336, 340, 572
Paula Motta, C., (A) 333
Pauwels, P., (A) 921
Pavithran, K., (A) 130, 134, 711
Pe, H., (A) 726
Pean, C., (A) 306
Pearson, J. M. H., (A) 338
Pedro, R. de J., (A) 708
Pedroso, M., (A) 342
Pelletier, P. A., (A) 590
Pemajayantha, V., (A) 579
Peng, J.-H., (A) 342
Penna, G. O., (A) 333
Pennec, J., (A) 571
Perani, E., (A) 316
Perani, E. G., (A) 316
Pereira, G. F. M., (A) 348
Perez Dube, M., (A) 586
Perez-Alfonzo, R., (A) 919
Perez-Martinez, C. S., (A) 714
Perkins, J. D., (A) 918
Petchclai, B., (A) 303, 305
Pfaltzgraff, R. E., (E) 103
Philip, P. A., (A) 130
Piessens, W. F., (A) 730
Pimsler, M., (A) 919
Pinrat, U., (O) 752
Pinto, M. R. M., (A) 579
Piquero-Martin, J., (A) 919
Plaksin, D. Y., (A) 140
Plichart, R., (A) 722, (O) 735, 810, (A) 897
Polak, J. M., (A) 578
Ponnighaus, I. M., (A) 314
Ponnighaus, J. M., (A) 144, 306, 307, 314, 330, 352, 572, 586, 728, 896
Portaels, F., (O) 54, (A) 310, 329, 585
Porto, J. A., (A) 905
Porwal, G., (A) 337
Pospelov, L. E., (A) 918
Prabhakar, R., (A) 568, 596
Prabhakaran, K., (A) 317, 720
Pradhan, S. P., (A) 344
Pradinaud, R., (A) 571
Prestidge, R. L., (A) 575
Price, J., (A) 595
Price, J. E., (O) 33
Prignot, J., (A) 921
Punikai'a, B. K., (A) 353

Qian, A., *et al.*, (A) 587
Qvigstad, E., (O) 1

Raat, H. S. M., (A) 318
Radford, A. J., (A) 583
Radhakrishna, S., (A) 588
Radl, J., (A) 304
Raffoux, C., (O) 465
Raghavia, M., (A) 314
Raj, C. A. D., (A) 570
Rajagopal, A., (A) 895
Rajagopalan, K., (O) 744
Rajagopalan, M. S., (A) 911
Rajan, M. A., (A) 355
Rajpathak, S. D., (A) 895, 895
Rakela, J., (A) 918
Ralhan, R., (A) 580
Ramachandra, S., (A) 567
Ramachandran, A., (A) 135
Ramadasan, P., (A) 133
Ramakrishnan, K. R., (A) 567
Ramamohan, Y., (A) 337
Raman, J., (A) 896
Ramanan, C., (A) 133
Ramanathan, U., (A) 312, 321, 340, (O) 451, 458, 615
Ramanathan, V. D., (A) 312
Ramasesh, N., (A) 316
Ramasoota, T., (A) 339, (O) 752
Rambukkana, A., (A) 898, 903
Ramirez, M. M., (A) 724
Ramkisson, A., (A) 730
Ramos, M. de C., (A) 708
Ramos, T., (E) 73
Ramu, G., (A) 146, 303, 312, 329, 340, (O) 451, 458, (A) 573, 707, 709, 715, (O) 801, (A) 911
Rana, N. S., (A) 580
Ranade, A., (A) 903
Rance, S., (A) 318
Rangdaeng, S., (O) 492
Rangwala, M. A., (A) 896
Rao, B. R., (A) 331
Rao, J. R., (A) 341, 346
Rao, K. N., (C) 867
Rao, M. K., (A) 708
Rao, P. R., (A) 138, 910
Rao, P. S., (A) 911
Rao, P. S. S., (A) 331, 723
Rao, S., (A) 906

Rastogi, N., (A) 326, 730, 912, 913, 914, 914, 915, 915, 920, 920
Ratcliffe, G. E., (A) 731
Ratledge, C., (A) 143
Rauzier, J., (A) 906
Ravindranathan, O., (A) 345
Ravisse, P., (A) 899
Razack, E. M. A., (A) 572
Rea, T. H., (A) 327, 327, 344, 715, 902
Reddy, B. B., (A) 895
Reddy, L. S., (A) 711
Reddy, P. K., (A) 131, 568
Reddy, R., (A) 147
Redondo, A., (A) 148, 588
Rees, A., (A) 904
Rees, R. J. W., (O) 33, 38, 45, (A) 319, 350, 595, 717, (O) 801, (A) 890
Reichel, M., (A) 715
Resnick, M., (A) 142, 593
Resoagli, E. H., (A) 724
Resoagli, J. P., (A) 724
Revankar, C. R., (O) 33, (A) 331, 350, 595, 890
Ribeiro, M. A. C. L., (A) 723
Ribeiro, W. S. M., (A) 146
Ridell, M., (A) 908
Ridley, D. S., (A) 307, 319
Rieder, J. T., (A) 913
Rocha de Almeida, S. M., (A) 569
Rodriguez-Contreras Pelayo, R., (A) 569
Rodriquez Garcia, M. A., (A) 580
Rogers, H. J., (A) 130
Roggero, E., (A) 731
Rojas-Espinosa, O., (O) 641, (C) 879
Rollier, R., (A) 324
Rook, G. A. W., (O) 45, (A) 312
Roopkumar, K. S. B., (A) 347
Roscom, R. H., (A) 303
Rose, P., (A) 333, 335
Rotberg, A., (C) 864
Rothbard, J. B., (A) 714
Rothrick, A., (A) 594
Rottenberg, M., (A) 311
Roudaut, M., (A) 133
Roux, J., (A) 325, 722, (O) 735, 810, (A) 897
Roy, A., (A) 580
Roy, I. S., (A) 355
Roy, R. G., (A) 133, 568
Rumschlag, H. S., (A) 140
Runft, D., (A) 711

Sabate Diaz, J. J., (A) 574
Saenz Melgarejo, J., (A) 351
Sagaro Delgado, B., (A) 580
Saha, K., (A) 131, 311, (C) 867
Saha, P. K., (O) 499
Sahasrabudhe, R. V., (A) 130, 910
Sahu, A., (A) 131
Said, G., (A) 571
Saint-Andre, P., (A) 339
Saito, H., (A) 150, (O) 628, (A) 731, 904
Salafia, A., (A) 131, 317
Salem, J. I. (A) 920
Saleta, B., (A) 322
Salgame, P., (A) 327, 715
Salvini, B., (A) 335
Samant, S. G., (A) 128
Samanta, S. K., (A) 355
Sampath, S. R., (A) 725
Sampattavanich, S., (A) 303, 305, 339, (O) 752
Sampoonachot, P., (A) 303, 305, (O) 752
Samson, P. D., (A) 330, (O) 801
Sanada, K., (C) 873
Sanchez, R., (A) 309, 323
Sanchez, R. M., (A) 317
Sanchez Nervion, M. F., (A) 323, 351
Sanchez Sanchez, S., (A) 586
Sanders, C., (A) 596
Sandoval, A., (A) 724
Sangal, R., (A) 710
Sans Gregorio, P., (A) 317
Sansarricq, H., (A) 324
Sant'Anna, I. P., (A) 707
Santos, G. W., (A) 732
Saraswat, P. K., (A) 571
Sarno, E. N., (E) 73, (A) 905
Sarojini, P. A., (A) 345
Sarthou, J.-L., (A) 901
Sasaki, N., (O) 752
Sasiain, M. del C., (A) 325, 325, 715
Sastrowidjojo, H., (A) 333
Sato, J., (A) 904
Sato, K., (A) 150, 731
Satoh, S., (A) 573
Satpathy, S. K., (O) 499
Sawant, K. V., (A) 129
Saxena, M., (A) 134
Saxena, N., (A) 573
Saxena, R., (A) 709
Saxena, R. K., (O) 458
Saylan, T., (A) 143, 144, 324, 354, 355, 911
Schnittman, S., (A) 594
Schreuder, G. M. T., (A) 727
Schuller-Levis, G., (A) 345
Schulzer, M., (A) 151
Schwartz, R. H., (A) 900
Schwartz, R. S., (A) 311, 576
Schwerer, B., (A) 304
Scoging, A., (A) 904
Scollard, D. M., (A) 312, (O) 492
Sedrati, O., (A) 324
Sehgal, S., (A) 147, 918
Sehgal, V. N., (A) 135, 135, 147, 311, 716, (C) 867, (A) 890
Sekkat, A., (A) 324
Sela, S., (A) 585
Selvaraj, A. M., (A) 572
Sen, R., (A) 569
Senesi, S., (A) 594
Sengupta, U., (O) 24, (A) 138, 303, 305, 312, 338, (O) 451, (A) 573, (C) 687, (A) 709

Serjeantson, S. W., (A) 145
Serrano Ortega, S., (A) 569
Seshadri, P. S., (A) 135
Seydel, J. K., (A) 317
Seydel, U., (A) 350, 350
Shaaban, M. A., (A) 592
Shah, B. H., (A) 894
Shah, D. H., (A) 910
Shall, S., (A) 582
Shanker, A., (A) 571
Shao, K.-W., (A) 306
Sharma, A. K., (A) 312, 313, 351, 579, (O) 633
Sharma, M. G., (A) 309
Sharma, N. K., (A) 710
Sharma, P., (A) 312
Sharma, R. P., (A) 573
Sharma, S., (A) 134
Sharma, S. P., (A) 709, 894
Sharma, U. C., (A) 587
Sharma, V., (A) 135, 716
Sharma, V. D., (A) 321, (O) 451, 615, (A) 906
Sharma, V. K., (A) 135, 135, 569, 580, 716, 900
Sharpe, S., (A) 575
Sheela, G. R., (A) 890
Sheftel, G., (A) 577, 714
Shenoi, S. D., (A) 135
Shepard, D. S., (O) 476
Sheriff, S., (A) 312, 313
Sherman, I., (A) 594
Shetty, J. N., (A) 584
Shetty, V. P., (A) 337, 716
Shin, J.-S., (A) 303, 897
Shinnick, T. M., (A) 140, 329
Shipina, L. K., (A) 140
Shivannavar, C. T., (A) 321, (O) 451, 615, (A) 906, 907
Shu, H.-W., (A) 305, 353
Shukla, V. K., (A) 708
Shulz, E. J., (A) 733
Sibley, L. D., (A) 140
Siddappa, K., (A) 135, 711, 711
Siddiqi, S. H., (A) 592
Silbaq, F., (A) 142
Silcox, V. A., (A) 596
Silva, C. L., (A) 312, 717, 904
Silva, M. T., (O) 54, (E) 73, (A) 329
Silveira, J. R., (A) 143
Sima, A., (A) 323
Simoes, A. L., (A) 311
Simono, F., (A) 322
Simpson, L. O., (A) 595
Singh, G., (A) 130, 569, 579, 587
Singh, M., (A) 586
Singh, N. B., (A) 140, 573, 580, 717
Singh, P. K., (A) 130
Singh, S. L., (A) 307
Singh, V. S., (A) 573
Sinha, E., (A) 139, 710
Sinha, R. K., (A) 139, 710
Sinha, S., (O) 24, (A) 138, 305, 573, (C) 687
Sircar, A. R., (A) 895
Sirumban, P., (A) 135, 307, 330, 714
Siu, P., (A) 317, 349
Skinsnes, O. K., (O) 65
Slob, A. W., (A) 912
Smida, J., (A) 908
Smith, S. M., (A) 728
Smith, T., (A) 312, (O) 492
Smith, V. B., (A) 314
Smith, W. C., (A) 318, 575, 576
Smith, W. C. S., (A) 330, 346
Snapper, S. B., (A) 907
Snehi, P. S., (A) 129
Soekanto, H., (A) 333
Soeparian, A. G., (A) 333
Sokhey, C., (A) 896
Solheim, T., (A) 564
Solomon, D. A., (A) 732
Solomon, M., (A) 330
Solomon, S., (A) 343, 346
Somasundaram, P. R., (A) 568
Somse, P., (A) 323
Sondij, S., (A) 322
Soni, N. K., (A) 136, 136, 314, 573
Sonvane, M. V., (Ob) 132
Sonvani, M. V., (A) 132
Soolingen, D., (A) 914
Sorensen, B. H., (A) 331, 331
Soshamma, G., (A) 896
Sotillo Gago, I., (A) 574, 574
Spies, J, (A) 914
Sponsler, T. A., (A) 919
Springall, D. R., (A) 578
Sreevatsa, (A) 141, 349, (O) 451, (A) 892
Srinivasan, P., (A) 910
Srinivasan, T., (A) 343
Srivastava, A., (A) 140
Srivastava, G., (A) 135, 890
Srivastava, L. M., (A) 138
Srivastava, P. K., (A) 569
Stackebrandt, E., (A) 908
Stager, C. E., (A) 592
Stanford, C. A., (O) 38, 45, (A) 349, 350, (O) 801
Stanford, J. L., (O) 33, 38, 45, (A) 320, 320, 328, 349, 350, 350, 592, 595, 724, (O) 801
Stanley, J. N. A., (A) 309, 310, 338
Stanley, P., (A) 319, 902
Staughton, R., (A) 733
Stefani, Sr. F., (A) 349
Steinhoff, U., (A) 141, 339, 717, 900
Stemberger, H., (A) 351
Sterioff, S., (A) 918
Stewart, C., (A) 712
Stoker, N. G., (A) 329, 581
Storrs, E. E., (A) 308
Stottmeier, K. D., (A) 590
Sturrock, N. D. C., (A) 575
Suarez, O., (A) 335
Subramaniam, K., (A) 315
Sugiene, R., (A) 336

Sugiyama, K., (A) 304
Sun, X., *et al.*, (A) 147
Sundar Rao, P. S. S., (O) 647
Suneetha, S., (A) 314, 315, 338
Surel, Z., (A) 354, 355
Surendran, D., (O) 801
Suriyanon, V., (A) 312, (O) 492
Suryawanshi, N., (A) 354, 356, 896
Suso, L., (A) 905
Sutlas, M., (A) 324, 354, 911
Suykerbuyk, M. E. G., (A) 328
Suzuki, Y., (A) 328
Svenson, S. B., (A) 729, 916
Swaroop, B., (A) 138
Swartz, R. P., (A) 595
Sweetser, D., (A) 585, 714
Swersie, S., (A) 345

Tadesse, G., (A) 311
Takeda, K., (A) 912
Takizawa, H., (A) 573
Talhari, S., (A) 334
Talwar, G. P., (A) 138, 304, 309, 351, 579, 579
Talwar, S., (A) 136
Tan, D., *et al.*, (A) 724
Tanaka, Y., (A) 583
Tao, M.-H., (A) 341
Tapia, F., (A) 919
Tare, S. P., (A) 332
Tasaka, H., (A) 731
Tayeb, N., (A) 893
Taylor, C., (O) 801
Taylor, R., (O) 810
Teferedegne, B., (A) 307
Teklemariam, S., (A) 325, 714
Terencio de las Aguas, J., (A) 320, 342
Teterissa, M. R., (C) 340
Thakur, M., (A) 718
Thamprasert, K., (A) 312, (O) 492
Thangaraj, E. S., (A) 348
Thangaraj, H. (A) 311, 328
Thangavel, N., (A) 903
Theetranont, C., (A) 312, (O) 492
THELEP Clinical Trials Subcommittee, (A) 131
Theuvenet, P. J. (A) 344
Theuvenet, W. J., (A) 344
Thiagarajan, M., (A) 714
Thiagarajan, N., (A) 347
Thoen, C. O., (A) 917, 917
Thole, J. E. R., (A) 141, 328, 717
Thomas, A., (A) 341, 346, 353, 568
Thomas, J. (C) 695
Thomas, M. V., (A) 353
Thomas, R. A., (A) 353
Thompson, D. E., (A) 726
Thompson, J., (A) 149
Thorel, M. F., (A) 914, 915
Thorpe, R., (C) 866
Thurman, P., (A) 920

Thuy, N. K., (A) 724
Tibrewala, K. D., (A) 896
Timmerman, H., (A) 894
Todd, J. R., (A) 147
Tomioka, H., (A) 150, (O) 628, (A) 731, 904
Torgal-Garcia, J., (A) 151, 905
Torigian, V. K., (A) 715
Torres, P., (A) 320
Trach, D. D., (A) 724
Tran, N. T., (A) 724
Trebucq, A., (A) 323
Trent, R. J., (A) 318, 583
Truffaut, G., (A) 323
Truman, R. W., (A) 334
Trygg, C. B., (A) 309
Tsai, P.-F., (A) 340
Tsang, A. Y., (A) 590
Tsang, M., (A) 317, 349
Tseng, H. M., (A) 732
Tsukahara, S., (A) 573
Tsukamura, M., (A) 596, 731, 920
Tsutsumi, S., (A) 721
Tsuyuguti, I., (A) 916
Tuan, N. A., (A) 724
Turcotte, R., (A) 592
Turk, J. L., (A) 308, 310, 890
Tutakne, M. A., (A) 133
Tuzun, Y., (A) 144
Tzourio, C., (A) 339

Udaya, K. K., (A) 314, 315, 338
Ueno, Y., (A) 916
Ura, S., (A) 314
Urlyapova, N. G., (A) 910
Uttley, A. H. C., (A) 151, 728

Vachula, M., (A) 718
Vadher, A., (A) 348
Vaidya, M. C., (A) 312, 313, 332
Vaishnavi, C., (O) 20, (A) 141, 569, 580, 586, 718, (C) 870, (A) 896, 900
Valdes-Miranda, V. V., (A) 586
Valdez, R., (A) 325, 325, 715
Valencia, L. B., (E) 847
van Asbeck-Raat, A. M. C., (A) 318
van Brakel, W., (A) 894
Van Droogenbroeck, J., (A) 342
van Embden, J. D., (A) 717
van Leeuwen, J. L., (A) 343
van Rens, R., (A) 310
van Rensburg, C. E., (A) 727
van Saane, P., (A) 894
van Schooten, W. C. A., (A) 136, 141, 717, (O) 788
van Vooren, J. P., (A) 590
Vanaja, G., (A) 132
Vanderveken, M., (A) 323
Vega-Lopez, F., (A) 581
Velayati, A., (A) 320
Vellut, C. M., (A) 323, 341, (O) 599
Venkataraman, P., (A) 596

Verez-Bencomo, V., (A) 714
Verghese, G., (A) 579
Vernery, C., (A) 148, 588
Vianna, F. R., (A) 335
Vidal Pla, R., (A) 917
Vieira, L. H. C., (A) 333
Vieira, L. M. M., (A) 905
Vijayakumaran, P., (A) 145, 337, (E) 526
Virmond, M., (A) 347
Vishnevetsky, F. E., (A) 909, 910
Visser, K., (A) 317
Vithayasai, V., (A) 303
Vladimirsky, M. A., (A) 140
Vogel, C.-W., (A) 595
Vogelsang, G. B., (A) 732
Volc-Platzer, B., (A) 351
Voller, A., (A) 581

Waaldijk, K., (A) 324
Wabitsch, K. R., (A) 346, 581
Wagner, D. K., (A) 312
Wagner, K. F., (A) 729
Wal, J. V. D., (A) 322
Walia, R., (A) 309, 351
Walker, M. C., (A) 592
Wallace, R. J., Jr., (A) 596
Wallach, D., (A) 128, 571
Wallerstrom, G., (A) 908
Walsh, G. P., (A) 309, 310, 354
Wang, C.-J., (A) 341
Wang, C.-R., (A) 901
Wang, H., (A) 568
Wang, Z.-M., (A) 342
Wangoo, A., (A) 900
Watanabe, I., (A) 573
Waters, M. F. R., (A) 307, 312, (C) 556
Watson, J. D., (A) 319, 575, 719, (E) 834
Webster, H. K., (A) 913
Wei, W.-H., (A) 305
Weisner, R. H., (A) 918
Weiss, Sr. F., (O) 38
Weitzel, P., (A) 317
Wele, D. S., (A) 348
West, B. C., (A) 147
Wheeler, P. R., (A) 143, 322, 720, 720, 909
Wiedermann, G., (A) 351
Williams, D. L., (A) 328, 909
Williams, J. C., (A) 921
Williams, W., (A) 304, 581, 582
Wilson, N. C., (C) 695
Wilson, R. C., (O) 33
Wirth, D. F., (A) 730
Witebsky, F. G., *et al.*, (A) 594
Wolf, R., (A) 354
Wondimu, A., (A) 325
Wong, C. S., (A) 732
Wong, M.-Y., (A) 897
Wong, R.-H., (A) 340
Worth, R. M., (A) 308
Wozel, G., (A) 707
Wright, E. P., (A) 724
Wu, D.-Y., (A) 315
Wu, M., (A) 591
Wu, Q., (A) 581
Wu, Q., *et al.*, (A) 718
Wu, Q.-X., (A) 305
Wu, Q.-Z., (A) 303, 305
Wu, W.-X., (A) 315

Xiong, S., *et al.*, (A) 719
Xu, M.-H., (A) 315
Xu, R., *et al.*, (A) 131
Xue, Z.-Y., (A) 305

Yajko, D. M., (A) 596
Yamada, Y., (O) 628
Yamagami, A., (C) 873
Yandava, C. N., (O) 633
Yande, R., (A) 134
Yanez Ordas, R., (A) 344
Yang, L., (A) 568
Yang, X.-Q., (A) 334
Yang, Z., (A) 588
Yangco, B. G., (A) 732
Yano, I., (A) 916, 916
Yates, M. D., (A) 316
Yazici, H., (A) 144
Ye, G.-Y., (Ob) 117, (A) 305, 305, 341, 353, (A) 581
Yeager, H., Jr., (A) 595
Yebra Sotillo, I., (A) 574, 574
Yellapurkar, M. V., (A) 332
Yemaneberhan, T., (A) 338
Yogi, Y., (A) 721, 722
Youle, M., (A) 733
Young, D. B., (A) 303, 582, 714, 719, 901, 904
Young, L. S., (A) 591
Young, R. A., (A) 575, 585, 714
Young, S. M. M., (A) 715
Yu, A.-X., (A) 332
Yu, B.-Y., (A) 306
Yu, H. S., (A) 732
Yu, L., (A) 568
Yu, X., *et al.*, (A) 568
Yu, X-L., (A) 336, (O) 622
Yuasa, Y., (A) 339
Yuksel, A., (A) 324, 911
Yuschenko, A. A., (A) 909
Yushin, M. Y., (A) 910

Zaheer, S. A., (A) 309, 351
Zainuddin, Z. F., (A) 720
Zalcberg-Quintana, I., (E) 73
Zaoui, F., (A) 324
Zeis, B. M., (A) 132, 733
Zhang, J., (A) 148
Zhang, J.-F., (A) 306
Zhang, J.-L., (A) 342
Zhang, M.-S., (A) 336, (O) 622
Zhang, S.-B., (O) 622
Zhang, Y.-L., (A) 322

Zhao, T., (A) 333
Zhao, X., (A) 148
Zheng, T., *et al.*, (A) 726
Zheng, T.-S., (A) 315
Zhou, D., *et al.*, (A) 589, 726
Zhou, D.-S., (A) 353
Zhou, L., (A) 581
Zhu, K., (O) 622
Zolfino, I., (A) 594
Zuiderhoek, B., (A) 332
Zumla, A., (A) 304, 581, 582
Zuniga G., M., (A) 333, 334

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), reprinted articles (R), abstracts (A), book reviews (B), and Supplement (S).

Acid, fatty,
Capillary gas chromatographic analysis of mycolic acid cleavage products, cellular fatty acids, and alcohols of *M. xenopi*. Luquin, M., *et al.* ..... (A) 917

Acid-fast bacilli,
Significance of culture granules of leprosy derived acid-fast chemoautotrophic nocardioform bacteria. Chakrabarty, A. N., *et al.* ..... (A) 582

Acquired immunodeficiency syndrome (AIDS),
AIDS and leprosy. Turk, J. L. and Rees, R. J. W. ..... (A) 890
Antimicrobial synergism against *M. avium* complex strains isolated from patients with acquired immune deficiency syndrome. Yajko, D. M., *et al.* ..... (A) 596
Association of leprosy and infection with the human immunodeficiency virus; two observations. Janssen, F., *et al.* ..... (A) 571
Challenging the stigma: from leprosy to AIDS. Law, A. S. ..... (A) 352
Diagnosis of *Mycobacterium* bacteremia in patients with acquired immunodeficiency syndrome by direct examination of blood films. Eng, R. H. K., *et al.* ..... (A) 728
Hypothesis: Does vaccination with bacille Calmette-Guérin protect against AIDS? Kallenius, G., *et al.* ..... (A) 729
Is prior mycobacterial infection a common predisposing factor to AIDS in Haitians and Africans? Lamoureux, G., *et al.* ..... (A) 592
Prevalence et evolution de l'infection au virus humain d'immunodeficience (VIM) chez les lepreux en Haiti. Pean, C., *et al.* ..... (A) 306

Adenosine triphosphate (ATP),
Effects of chemotherapy on viability of *M. leprae* as determined by ATP content, morphological index and FDA-EB fluorescent staining. Katoch, V. M., *et al.* ..... (O) 615
Measurement of ATP content of *M. leprae*—its application to the determination of viability and drug sensitivity screening. Katoch, V. M., *et al.* ..... (A) 321
Studies on adenylate kinase (ATP:AMP phosphotransferase) of *M. marinum* (ATCC 927). Batra, P. P., *et al.* ..... (A) 912

Africa,
African Regional Workshop on Youth Mobilization for Leprosy Work. ..... (N) 558
Enquetes d'evaluation par sondage de la prevalence de l'endemie lepreuse en Afrique Centrale. Josse, R., *et al.* ..... (A) 323
Is prior mycobacterial infection a common predisposing factor to AIDS in Haitians and Africans? Lamoureux, G., *et al.* ..... (A) 592
The anatomical distribution of single leprosy lesions in an African population, and its implications for the pathogenesis of leprosy. Ponnighaus, J. M., *et al.* ..... (A) 307

American Leprosy Missions (ALM),
Brazil rehabilitation expert elected to President's chair at American Leprosy Missions. ..... (N) 560

Amikacin,
Amikacin, ciprofloxacin, and imipenem treatment for disseminated *M. avium* complex infection of beige mice. Inderlied, C. B., *et al.* ..... (A) 591

Antibody(ies),
A 28-kDa protein from *M. leprae* is a target of the human antibody response in lepromatous leprosy. Cherayil, B. J. and Young, R. A. ..... (A) 575
An enzyme immunoassay (EIA) based on antibodies against human nerve antigen for diagnosis of all categories of leprosy patients. Itty, B. M., *et al.* ..... (A) 304
Antineural antibodies in leprosy sera: further characterization of the antigens. Benjamins, J. A., *et al.* ..... (A) 711

[Assay of antibody level in sera of leprosy patients with *M. smegmatis* ELISA.] Wu, Q., *et al.* ..... (A) 718
Association of tuberculosis and *M. tuberculosis*-specific antibody levels with HLA. Bothamley, G. H., *et al.* ..... (A) 727
Characterization of an antibody-binding epitope from the 18-kDa protein on *M. leprae.* Doherty, T. M., *et al.* ..... (A) 719
[Classes I and II antigens and levels of IgG antibodies in patients with infiltrative tuberculosis of the lungs.] Nikolayan, L. T., *et al.* ..... (A) 918
Demonstration of antidapsone antibody in leprosy patients. Agrewala, J. N., *et al.* ..... (C) 687
Detection of phenolic glycoplipid I of *M. leprae* and antibodies to the antigen in sera from leprosy patients and their contacts. Cho, S.-N., *et al.* ..... (A) 897
[Determination of antibodies to mycobacterial antigens in tuberculosis by the method of erythroimmunoadsorption with a rosette marker.] Plaksin, D. Y., *et al.* ..... (A) 140
Development of Epstein-Barr virus transformed human B-cell lines secreting anti-*M. leprae* antibodies. Moudgil, K. D., *et al.* ..... (A) 579
Effect of multidrug therapy on the levels of antibodies to *M. leprae* glycolipid-I in the leprosy spectrum. Vaishnavi, C., *et al.* ..... (A) 580
Effect of suppressor cells on antibody producing cells in mice infected with *M. leprae.* Vaishnavi, C., *et al.* ..... (A) 718
Evaluation of chemotherapy in leprosy by monitoring *M. leprae* specific antibody titers in patients. Sinha, S., *et al.* ..... (A) 305
Failure to detect antibodies to HIV-1 in sera from patients with mycobacterial infections. Malkovsky, M., *et al.* ..... (C) 866
Follow up of T cell subsets and anti-trisaccharide IgM antibody levels of leprosy patients during daily multidrug therapy. Desforges, S., *et al.* ..... (A) 899
Frequency and polyreactivity of human antibodies to phen GL-1 from leprosy patients defined by anti-idiotypes. Zumla, A., *et al.* ..... (A) 304
Lymphoproliferation and *in vitro* antibody synthesis in leprosy patients. Yandava, C. N., *et al.* ..... (O) 633
Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., *et al.* ..... (A) 325
Ontogenesis of antibodies in rhesus monkeys infected with *M. leprae.* Mukherjee, R., *et al.* ..... (A) 309
PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., *et al.* ..... (A) 897
PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Chanteau, S., *et al.* ..... (O) 735
Quantitative antibody ELISA for leprosy. Hasan, R., *et al.* ..... (O) 766
Selective coating of *M. leprae* surface antigens by species and genus-specific mycobacterial antibodies and its effect on phagosome-lysosome fusions in *M. leprae*-infected macrophages. Rastogi, N. and Frehel, C. ..... (A) 326
Serum antibodies of normals and leprosy patients show equal binding to peripheral nerve. Ghaswala, P. S., *et al.* ..... (C) 690
Serum antibodies to defined carbohydrate antigens during the course of treated leprosy. Gelber, R. H., *et al.* ..... (O) 744
Serum antibody responses to mycobacteria in leprosy patients and their contacts. Cree, I. A., *et al.* ..... (A) 576
Specific anti-*M. leprae* PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., *et al.* ..... (O) 794
Use of nonconventional antigen, *M. habana,* in detecting *M. leprae* antibodies from leprosy patients and contacts in FLA-ABS test. Rana, N. S., *et al.* ..... (A) 580

Antibodies, monoclonal,

A monoclonal antibody based competition radioimmunoassay for monitoring anti-M. leprae antibodies in leprosy patients and contacts. Sinha, S., *et al.* ..... (A) 573
Human gut wall reactivity to monoclonal antibodies against *M. avium* glycolipid in relation to Crohn's disease (preliminary results). Blaauwgeers, J. L. G., *et al.* ..... (A) 912
Human monoclonal antibodies to phenolic glycolipid-I from leprosy patients crossreact with poly(ADP-ribose) polynucleotides and tissue bound antigens. Zumla, A., *et al.* ..... (A) 582

Identification of *M. leprae* antigens in tissues of leprosy patients using monoclonal antibodies. Khanolkar, S. R., *et al.* ..... (O) 652
Monoclonal antibodies to 33 kD protein of *M. tuberculosis* with varying epitope specificities. Rambukkana, A., *et al.* ..... (A) 903
Monoclonal antibody based double antibody sandwich assay for detection of antigen in serum of leprosy patients. Patil, S. A., *et al.* ..... (A) 303
Polyspecificity of human monoclonal antibodies reactive with *M. leprae*, mitochondria, ssDNA cytoskeletal proteins, and the acetylcholine receptor. Duggan, D. B., *et al.* ..... (A) 576
Serology of mycobacteria: characterization of antigens recognized by monoclonal antibodies. Young, D. B. and Mehlert, A. ..... (A) 719
Use of an antigen-capture assay for characterization of monoclonal antibodies to mycobacterial lipoarabinomannan. Khanolkar, S. R., *et al.* ..... (A) 901
Use of monoclonal antibodies in the identification of mycobacterial antigens. Kolk, A. H. J., *et al.* ..... (A) 322

Antigen(s),
A competition ELISA for the detection of mycobacterial antigen in tuberculosis exudates. Ramkisson, A., *et al.* ..... (A) 730
A passive hemagglutination test for leprosy using a synthetic disaccharide antigen. Petchclai, B., *et al.* ..... (A) 305
A peptidoglycan protein complex purified from *M. leprae* cell walls contains most or all immunodominant *M. leprae* T-cell antigens. Mutis, T., *et al.* ..... (O) 788
A protein antigen of *M. leprae* is related to a family of small heat shock proteins. Nerland, A. H., *et al.* ..... (A) 585
A study of incidence of Australia antigen and derangements in liver function tests in leprosy. Nayak, K. C., *et al.* ..... (A) 710
An enzyme immunoassay (EIA) based on antibodies against human nerve antigen for diagnosis of all categories of leprosy patients. Itty, B. M., *et al.* ..... (A) 304
Antigenic profile of ICRC bacilli with special reference to isolation of immunogenic subunit. Chirmule, N. B., *et al.* ..... (A) 137
Antineural antibodies in leprosy sera: further characterization of the antigens. Benjamins, J. A., *et al.* ..... (A) 711
Arabinogalactan; a complementary antigen to phenolic glycolipid in leprosy diagnosis. Roy, A., *et al.* ..... (A) 580
Bacterial antigen processing in macrophages infected with the obligate intracellular bacterium, *M. avium*. de Chastellier, C. and Lang, T. ..... (A) 914
Chemical synthesis of an artificial antigen containing the trisaccharide hapten of *M. leprae*. Marino-Albernas, J., *et al.* ..... (A) 714
[Classes I and II antigens and levels of IgG antibodies in patients with infiltrative tuberculosis of the lungs.] Nikolayan, L. T., *et al.* ..... (A) 918
Comparative studies of antigenic glycolipids of mycobacteria related to the leprosy bacillus. Minnikin, D. E., *et al.* ..... (A) 908
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* ..... (A) 914
Demonstration of PGL I antigens in skin biopsies in indeterminate leprosy patients: comparison with serological anti-PGL I levels. Huerre, M., *et al.* ..... (A) 899
Detection of a specific *M. leprae* antigen in the urine of leprosy patients. Mahon, A. C., *et al.* ..... (A) 326
Detection of leprosy antigenuria through DOT-ELISA. Singh, N. B. and Choudhary, A. ..... (A) 573
Detection of phenolic glycolipid I of *M. leprae* and antibodies to the antigen in sera from leprosy patients and their contacts. Cho, S.-N., *et al.* ..... (A) 897
Differential recognition of *Leishmania aethiopica* antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Akuffo, H. O., *et al.* ..... (A) 727
Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65 kDa) in culture filtrates of mycobacteria. de Bruyn, J., *et al.* ..... (A) 590
Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* ..... (A) 917

Evaluation of an enzyme immunoassay based on sonicate supernatant antigens of *Mycobacterium w* for immunodiagnosis of leprosy. Moudgil, K. D., *et al.* ....(A) 138
Evaluation of *M. leprae* antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., *et al.* ....(A) 899
Evaluation of natural phenolic glycolipid (GP1) and artificial antigen in the serodiagnosis of leprosy. Wu, Q.-Z., *et al.* ....(A) 305
Genomic and amino acid sequence of the *M. leprae* 70 kD antigen is homologous to the higher conserved 70 kD heat shock protein (hsp70) of eukaryotes. Garsia, R. J., *et al.* ....(A) 318
Homology of the 70-kilodalton antigens from *M. leprae* and *M. bovis* with the *M. tuberculosis* 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., *et al.* ....(A) 583
Human monoclonal antibodies to phenolic glycolipid-I from leprosy patients crossreact with poly(ADP-ribose) polynucleotides and tissue bound antigens. Zumla, A., *et al.* ....(A) 582
Identification of *M. leprae* antigens in tissues of leprosy patients using monoclonal antibodies. Khanolkar, S. R., *et al.* ....(O) 652
Identification of mycobacterial antigens for "ELISA" serology in the diagnosis of leprosy and tuberculosis. Das, P. K., *et al.* ....(A) 898
Identification of mycobacterial antigens recognized by T lymphocytes. Lamb, J. R., *et al.* ....(A) 714
IIC8 hybridoma B cells can present recombinant 65-kDa mycobacterial antigen to T cells. Mshana, R. N., *et al.* ....(A) 319
Immunological response to homologous and heterologous phenolic glycolipid antigens in tuberculosis and leprosy. Torgal-Garcia, J., *et al.* ....(A) 905
Inyecciones de *M. vaccae* muertas inducen respuestas intradermicas frente antigenos solubles del *M. leprae* en 50% de pacientes lepromatosos. Torres, P., *et al.* ....(A) 320
Leprosy and hepatitis B surface antigen. Vaishnavi, C., *et al.* ....(A) 896
Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., *et al.* ....(A) 325
Monoclonal antibody based double antibody sandwich assay for detection of antigen in serum of leprosy patients. Patil, S. A., *et al.* ....(A) 303
PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., *et al.* ....(A) 897
PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Chanteau, S., *et al.* ....(O) 735
Preliminary evaluation of a *M. tuberculosis* phenolglycolipid antigen in the serologic diagnosis of tuberculosis. Torgal-Garcia, J., *et al.* ....(A) 151
Recognition of a category of responders to group ii, slow-grower associated, antigens amongst Kuwaiti senior school children, using a statistical model. McManus, I. C., *et al.* ....(A) 592
Recognition of M. leprae Antigens. Ottenhoff, T. and de Vries, R. R. P. ....(A) 139
Recognition of mycobacterial antigens by sera from patients with leprosy. Vega-Lopez, F., *et al.* ....(A) 581
Relapse in LL patients after antileprosy ICRC vaccine: its significance to antigenic variability of *M. leprae.* Bapat, C. V. ....(A) 349
Selection of recombinant DNA clones expressing the 12K and 36K *M. leprae* antigens in *E. coli* K12. Hartskeerl, R. A., *et al.* ....(A) 328
Selective coating of *M. leprae* surface antigens by species and genus-specific mycobacterial antibodies and its effect on phagosome-lysosome fusions in *M. leprae*-infected macrophages. Rastogi, N. and Frehel, C. ....(A) 326
Serologic responses to *M. leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* ....(A) 309
Serological responses of patients with lepromatous and tuberculoid leprosy to 30-, 31-, and 32-kilodalton antigens of *M. tuberculosis.* Rumschlag, H. S., *et al.* ....(A) 140
Serological tests in leprosy. The sensitivity, specificity and predictive value of ELISA tests based on phenolic glycolipid antigens, and the implications for their use in epidemiological studies. Burgess, P. J., *et al.* ....(A) 144

Serology of mycobacteria: characterization of antigens recognized by monoclonal antibodies. Young, D. B. and Mehlert, A. ....(A) 719
Serum antibodies to defined carbohydrate antigens during the course of treated leprosy. Gelber, R. H., *et al.* ....(O) 744
Skin lesion in strain 13 guinea pig induced by a human non-myelin antigen in dorsal roots. Crawford, C. L., *et al.* ....(A) 308
Specific lysis by CD8+ T cells of Schwann cells expressing *M. leprae* antigens. Steinhoff, U. and Kaufmann, S. H. E. ....(A) 141
Specificity and antigenicity of mycoside G and other glycolipids from *M. marinum.* Cruaud, P., *et al.* ....(A) 913
Specificity of proliferative response of human CD8 clones to mycobacterial antigens. Rees, A., *et al.* ....(A) 904
Stress proteins and the immune response to mycobacteria—antigens as virulence factors? Young, D. B., *et al.* ....(A) 582
T cell epitopes on the 36K and 65K *M. leprae* antigens defined by human T cell clones. van Schooten, W. C. A., *et al.* ....(A) 141
T cell reactivity of leprosy patients and their household contacts to mycobacterial sonicates and affinity purified antigens. Adams, E., *et al.* ....(A) 318
T cell responses to fractionated *M. leprae* antigens in leprosy. The lepromatous nonresponder defect can be overcome *in vitro* by stimulation with high molecular weight *M. leprae* components. Ottenhoff, T., *et al.* ....(A) 326
T-cell responses to the *M. leprae* 18 kD antigen. Harris, D. P., *et al.* ....(A) 319
The 65 kilodalton antigen of mycobacteria. Shinnick, T. ....(A) 329
The effect of clofazimine in cell mediated immunity: interference with antigen processing and presentation by macrophages. Brown, L. M., *et al.* ....(A) 315
The relationship between reactivities to lepromin A and soluble protein antigen of *M. leprae* and tuberculin. Pemajayantha, V., *et al.* ....(A) 579
The use of a "universal" yeast expression vector to produce an antigenic protein of *M. leprae.* Booth, R. J., *et al.* ....(A) 575
Use of an antigen-capture assay for characterization of monoclonal antibodies to mycobacterial lipoarabinomannan. Khanolkar, S. R., *et al.* ....(A) 901
Use of monoclonal antibodies in the identification of mycobacterial antigens. Kolk, A. H. J., *et al.* ....(A) 322
Use of nonconventional antigen, *M. habana,* in detecting *M. leprae* antibodies from leprosy patients and contacts in FLA-ABS test. Rana, N. S., *et al.* ....(A) 580
Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* ....(A) 717
Use of skin tests with *M. leprae* soluble antigen for epidemiological studies and vaccination trials. Zuniga, M. ....(A) 334
Use of soluble antigens in leprosy epidemiology. Gupte, M. D. and Anantharamun, D. S. ....(A) 577

Armadillo(s),
Armadillos in leprosy research: current status. Storrs, E. E. and Burchfield, H. P. ....(A) 308
Comparison of the distribution of indigenous human and armadillo leprosy in Louisiana, U.S.A. Truman, R. W. and Kumaresan, J. A. ....(A) 334
Light- and electron-microscopic study of *M. leprae*-infected armadillo nerves. Liu, T.-C., *et al.* ....(O) 65
Ocular leprosy in the armadillo and man—a histopathological study. Jacob, M. ....(A) 355
Serodiagnosis of leprosy infection in 9 banded armadillos. Eggelte, T. A., *et al.* ....(A) 310
Viability of *M. leprae* in soil and dead armadillo tissue and its significance. Harris, E. B., *et al.* ....(A) 323
[Wild leprosy in *Dasypus novemcinctus.*] Martinez, A. R., *et al.* ....(A) 724

Arthritis,
Clinical and laboratory studies of arthritis in leprosy. Atkin, S. L., *et al.* ....(A) 895
Inefficacy of thalidomide on rat adjuvant-induced arthritis and lack of arthrogenicity of Hansen bacilli. Tsutsumi, S. and Gidoh, M. ....(A) 721

Assay(s) (see also ELISA),
A comparative evaluation of serological assays for lepromatous leprosy. Mwantha, J., *et al.* ....(A) 138
Appraisal of two *M. leprae*-specific serological assays for monitoring chemotherapy in lepromatous (LL/BL) leprosy patients. Sinha, S., *et al.* ....(O) 24
[Assay of antibody level in sera of leprosy patients with *M. smegmatis* ELISA.] Wu, Q., *et al.* ....(A) 718
Comparison of *in vitro* Fc receptor assay with other methods including mouse foot pad method. Jagannathan, R., *et al.* ....(A) 321
Correlation of *in vitro* Fc receptor assay with *in vivo* mouse foot pad method. Jagannathan, R., *et al.* ....(A) 584
Monoclonal antibody based double antibody sandwich assay for detection of antigen in serum of leprosy patients. Patil, S. A., *et al.* ....(A) 303
Serodiagnostic potentialities of enzyme-linked immunosorbent assay (ELISA) using mannophosphoinositides of *M. tuberculosis* H37Rv. Mehta, P. K. and Khuller, G. K. ....(A) 593
Use of an antigen-capture assay for characterization of monoclonal antibodies to mycobacterial lipoarabinomannan. Khanolkar, S. R., *et al.* ....(A) 901

Autopsy,
Leydig cells observed in autopsy cases of the national leprosarium, Okukomyoen (Japan). Obara, A., *et al.* ....(A) 345

Bacilli,
A concentration method for detection and quantitation of bacillaemia in leprosy and its comparison with other techniques. Nagesha, C. N., *et al.* ....(A) 584
Antigenic profile of ICRC bacilli with special reference to isolation of immunogenic subunit. Chirmule, N. B., *et al.* ....(A) 137
Charting of organic sites showing the presence of bacilli and specific infiltrate on a series of 126 necropsies from leprosy patients. Tentative of association with cause of death. Lombardi, C., *et al.* ....(A) 345
Lepromin conversion induced by a "subunit" vaccine from ICRC bacilli. Bhatki, W. S., *et al.* ....(A) 136
[Tuberculoid leprosy with necrotizing neuritis and numerous bacilli in the fistulae.] de Menezes, J. A., *et al.* ....(A) 569

Bacilli, ICRC,
Antigenic profile of ICRC bacilli with special reference to isolation of immunogenic subunit. Chirmule, N. B., *et al.* ....(A) 137
Lepromin conversion induced by a "subunit" vaccine from ICRC bacilli. Bhatki, W. S., *et al.* ....(A) 136

Bacteremia,
Diagnosis of *Mycobacterium* bacteremia in patients with acquired immunodeficiency syndrome by direct examination of blood films. Eng, R. H. K., *et al.* ....(A) 728

Bacteriology,
Bacteriology of infected hands and feet in leprosy patients. Abdulkadir, S. ....(A) 708

BCG (bacille Calmette-Guérin),
BCG infection induces responsiveness to dead *M. leprae* in hamsters; a Mitsuda-like reaction. Mariano, M. and Ferreira, C. S. A. ....(A) 902
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* ....(A) 914
Immunotherapy of treated BL/LL cases with BCG: histopathological, immunohistological and bacteriological assessments. Katoch, K., *et al.* ....(A) 900
Implications of prior BCG vaccination programmes in the community on the protective efficacy of new antileprosy vaccines. Radhakrishna, S., *et al.* ....(A) 588
Sensitisation by mycobacteria and the effects of BCG on children attending schools in the slums of Bombay. Stanford, J. L., *et al.* ....(A) 595
The distribution and implications of BCG scars in northern Malawi. Fine, P. E. M., *et al.* ....(A) 728

Transformation of BCG with plasmid DNA. Lugosi, L., *et al.* ....(A) 907
Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* ....(A) 717

Belgium,
La lèpre importée en Belgique: diagnostic. Pattyn, S. R. ....(A) 572

Biopsy,
Demonstration of PGL I antigens in skin biopsies in indeterminate leprosy patients: comparison with serological anti-PGL I levels. Huerre, M., *et al.* ....(A) 899
Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. McDougall, A. C. ....(C) 114
Drs. Jacob and Mathai reply. Jacob, M. and Mathai, R. ....(C) 114
Sural nerve biopsy findings in leprosy: a qualitative and quantitative light and electron microscopic study in 4 treated cases of lepromatous spectrum. Gibbels, E., *et al.* ....(A) 137
The role of nerve biopsies in the diagnosis and management of leprosy. Nilsen, R., *et al.* ....(A) 895

Blood,
Altered blood rheology in the pathogenesis of diabetic and other neuropathies. Simpson, L. O. ....(A) 595
Diagnosis of *Mycobacterium* bacteremia in patients with acquired immunodeficiency syndrome by direct examination of blood films. Eng, R. H. K., *et al.* ....(A) 728
[Pathologic changes and bacillation of blood vessels in LL and BL leprosy.] Liu, J., *et al.* ....(A) 578
Reduced numbers of Leu 8(+) cells in peripheral blood of lepromatous leprosy patients (LL). Sasiain, M. de C., *et al.* ....(A) 325

Bone,
[Bone changes in leprosy; a study of distal lesions by means of soft X-rays.] Yebra Sotillo, I., *et al.* ....(A) 574
[Viking-age skeleton exhibiting pathologic changes in the dentition and maxillary and mandibular bones—scurvy or leprosy?] Lorentsen, M. and Solheim, T. ....(A) 564

Book reviews,
A Guide to Leprosy Control (2nd ed.) by the World Health Organization. ....(B) 124
Essays on Leprosy by Oxford Medical Students by R. J. Ryan and A. C. McDougall. ..(B) 124
Fulfillment Through Leprosy by T. N. Jagadisan. ....(B) 122
Handbook of Leprosy (4th edition) by W. H. Jopling and A. C. McDougall. ....(B) 122
How to Diagnose and Classify Leprosy: a Study Guide by R. E. Pfaltzgraff. ....(B) 123
Kalaupapa National Historical Park and the Legacy of Father Damien (a Pictorial History) by Anwei V. Skinses Law and Richard A. Wisniewski. ....(B) 562
La Maladie de Hansen en Haiti by C. Pean. ....(B) 123
Leprosy and Human Dignity by Max Gruner. ....(B) 562
Leprosy for Medical Practitioners and Paramedical Workers by R. H. Thangaraj and S. J. Yawalkar. ....(B) 124
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization. ....(B) 122
Olivia: My Life of Exile in Kalaupapa by Olivia Robello Breitha ....(B) 562
Orientation in Leprosy for Doctors. ....(N) 119
Peripheral Denervation of the Foot by Carl D. Enna. ....(B) 121
Peripheral Denervation of the Hand by Carl D. Enna. ....(B) 121
Proceedings of the International Congress on Medical and Social Rehabilitation of the Disabled in the Third World Countries with Emphasis on the Rehabilitation of the Leprosy Patient. ....(B) 563
Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988. ....(B) 124
Sixth Report of the WHO Expert Committee on Leprosy. ....(B) 125
Studies on Leprosy; Supplement 3 by N. Veeraraghavan. Franzblau, S. G. and Hastings, R. C. ....(B) 705
Tuberculosis and Leprosy by Richard J. W. Rees. Cowley, S. A. ....(B) 888

Borderline leprosy,
A florid case of borderline-lepromatous leprosy. Raman, J. and Fisher, D. ....(A) 896
Comprehensive management of recent nerve damage in borderline leprosy on an outpatient basis. Udaya, K. K. and Suneetha, S. ....(A) 338
Destruction of ala nasi and loss of columella in borderline tuberculoid leprosy—a case report. Siddappa, K., *et al.* ....(A) 711
Effect of multidrug treatment (paucibacillary regimen) on the clinical and histological features of tuberculoid and borderline tuberculoid cases. Kumar, T. S., *et al.* ....(A) 346
Long-term correlation between serological (PGL) and histological parameters in the control of chemotherapy in LL and BL patients. Wabitsch, K. R., *et al.* ....(A) 346
Multiple synovial swellings in BT leprosy; a case report. Chattopadhyay, S. P., *et al.* ..(A) 895
Occurrence of reversal reactions in BT patients during WHO paucibacillary leprosy MDT (1982). Reddy, P. K. ....(A) 131
[Pathologic changes and bacillation of blood vessels in LL and BL leprosy.] Liu, J., *et al.* ....(A) 578
The high prevalence of testicular involvement in lepromatous (LL) as compared to borderline lepromatous (BL) leprosy patients. Gebhard, J. F. and Rea, T. H. ....(A) 344
The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey; a preliminary study. Cem Mat, M., *et al.* ....(A) 144
Type 1 reaction in borderline leprosy—a Dhoolpet experience. Suneetha, S. and Udaya, K. K. ....(A) 315
Un traitement logique des nevrites lepreuses tuberculoides et borderline aigues ou subaigues: la desensibilisation progressive a la lepromine. Saint-André, P., *et al.* ....(A) 339

Brazil,
Brazil rehabilitation expert elected to President's chair at American Leprosy Missions. ....(N) 560
[Epidemiological aspects of hanseniasis in Uberlandia, Minas Gerais (Brazil) (1973–1983).] Livorato, F., *et al.* ....(A) 146
Evaluation of efficiency, efficacy and effectiveness of prevention and treatment of physical disabilities in leprosy control in Brazil. Goncalves, A., *et al.* ....(A) 342
Gradual setting up of multidrug therapy (WHO-MDT) in Brazil. Oliveira, M. L. W., *et al.* ....(A) 333
Induction of the late hypersensitivity reaction to DNCB in patients with different clinical forms of hanseniasis in Brazil. Azulay, R. D. ....(A) 310
Leprosy control in the state of Amazonas, based on MDT (WHO/82). Talhari, S., *et al.* ....(A) 334
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization. ....(B) 122
Results after 5 years of multidrug therapy (MDT) according to WHO recommendations for leprosy patients in Curupaiti (Brazil). Andrade, V. L. G., *et al.* ....(A) 335
The participation of Hansen's disease patient in all the activities of control in Brazil. Nogueira, W. and Pereira, G. F. M. ....(A) 348
The trends of Hansen's disease in Brazil. Paula Motta, C. and Zuniga G., M. ....(A) 333

Burma,
A 15 year survey of Burmese amputees. Pe, H. ....(A) 726

Caribbean,
Genetic susceptibility to leprosy on a Caribbean island: linkage analysis with five markers. Abel, L., *et al.* ....(O) 465

Cell(s),
An *in vitro* evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. Anderson, R., *et al.* ....(A) 727
Effect of preincubation on the proliferative response to antigen by cells from leprosy patients and healthy controls. Mullins, R. J. and Basten, A. ....(O) 777
In vitro analysis of the cellular mechanisms involved in immunity to tuberculosis. Kaufmann, S. H. E. ....(A) 729

Intralesional cellular and soluble immunoregulatory events in type 1 ("reversal") reactions. Scollard, D. M., *et al.* ....(A) 312
Intracellular parasitism of parenchymal cells by *M. leprae*. Job, C. K., *et al.* ....(O) 659
Leydig cells observed in autopsy cases of the national leprosarium, Okukomyoen (Japan). Obara, A., *et al.* ....(A) 345
M. leprae induced suppressor cells in the polar clinical forms of leprosy. Sasiain, M. del C., *et al.* ....(A) 325
[Morphological characteristics of cell cultures from human and animal lepromas and the effect of antileprosy drugs on them.] Vishnevetsky, F. E., *et al.* ....(A) 909
Purification of *M. leprae* with special reference to the effects of purified *M. leprae* vaccines and host macrophage cell functions. Saito, H., *et al.* ....(A) 904
Reduced numbers of Leu 8(+) cells in peripheral blood of lepromatous leprosy patients (LL). Sasiain, M. de C., *et al.* ....(A) 325
Reduced suppressor cell response to *M. leprae* in lepromatous leprosy. Sasiain, M. del C., *et al.* ....(A) 715
Studies in human leprosy lesions *in situ* using suction-induced blisters. 1. Cellular components of new, uncomplicated lesions. Rangdaeng, S., *et al.* ....(O) 492
The role of CD8+ cells in resistance and delayed hypersensitivity reactions in *M. lepraemurium* infection. Curtis, J., *et al.* ....(A) 308

Cells, B,
Development of Epstein-Barr virus transformed human B-cell lines secreting anti-*M. leprae* antibodies. Moudgil, K. D., *et al.* ....(A) 579
IIC8 hybridoma B cells can present recombinant 65-kDa mycobacterial antigen to T cells. Mshana, R. N., *et al.* ....(A) 319
Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* ....(A) 717

Cells, endothelial,
Endothelial cell bacillation in human leprosy–ultrastructural aspects. Mukherjee, A., *et al.* ....(A) 345

Cells, natural killer (NK),
[Determination of ability of producing IL-2 and activity of NK in multibacillary leprosy.] Xiong, S., *et al.* ....(A) 719

Cells, Schwann,
Effect of *M. leprae*-infected Schwann cells and their supernatant on lymphocyte neuroglia interaction. Mehta, R., *et al.* ....(A) 902
Effects of a derivative of serotonin (deoxyfructoserotonin) and other antileprosy drugs on attachment and uptake of *M. leprae* by Schwann cells *in vitro*. Chaudhury, A., *et al.* ....(A) 893
Evidence for phagosome-lyosome fusion in *M. leprae*-infected murine Schwann cells. Steinhoff, U., *et al.* ....(A) 717
In vitro analysis of the role of Schwann cells in leprosy. Steinhoff, U., *et al.* ....(A) 339
In vitro interaction of *M. leprae*-infected Schwann cells and splenic cells. Mehra, R., *et al.* ....(A) 579
Specific lysis by CD8+ T cells of Schwann cells expressing *M. leprae* antigens. Steinhoff, U. and Kaufmann, S. H. E. ....(A) 141
T lymphocytes, mononuclear phagocytes, Schwann cells and *M. leprae*. Kaufmann, S. H. E., *et al.* ....(A) 900

Cells, T,
A *M. leprae*-specific human T cell epitope cross-reactive with an HLA-DR2 peptide. Anderson, D. C., *et al.* ....(A) 136
A peptidoglycan protein complex purified from *M. leprae* cell walls contains most or all immunodominant *M. leprae* T-cell antigens. Mutis, T., *et al.* ....(O) 788
Activation of γδ T cells in the primary immune response to *M. tuberculosis*. Janis, E. M., *et al.* ....(A) 900
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* ....(A) 914

Evidence that *M. leprae* specific helper T cells exist in lepromatous leprosy patients. Gill, H. K., *et al.* ..... (A) 319
Follow up of T cell subsets and anti-trisaccharide IgM antibody levels of leprosy patients during daily multidrug therapy. Desforges, S., *et al.* ..... (A) 899
HLA-DR, -DQ DNA genotyping and T-cell receptor RFLPs in leprosy. Jazwinska, E. C. and Serjeantson, S. W. ..... (A) 145
HLA-DR-restricted antigen-induced proliferation and cytotoxicity mediated by CD4+ T-cell clones from subjects vaccinated with killed *M. leprae*. Mustafa, A. S. and Qvigstad, E. ..... (O) 1
Identification of subpopulations of CD4+ and CD8+ T cells in leprosy granulomas. Rea, T. H. and Modlin, R. L. ..... (A) 327
IICB hybridoma B cells can present recombinant 65-kDa mycobacterial antigen to T cells. Mshana, R. N., *et al.* ..... (A) 319
Killing of human monocytes by specific cytotoxic T cells and nonspecific, MHC unrestricted killer cells after activation by mycobacterial antigens. Kaleab, B., *et al.* ..... (A) 311
Limiting dilution of murine T cell response to mycobacterial antigens. Launois, P., *et al.* ..... (A) 901
Mechanisms of *M. leprae*-specific T-cell deficiency in lepromatous leprosy. Bach, M.-A. and Launois, P. ..... (A) 574
Molecular pattern of the T-cell repertoire in leprosy patients and their relatives. Mendez-Samperio, P., *et al.* ..... (A) 319
Molecular study of the T cell repertoire in family contacts and patients with leprosy. Mendez-Samperio, P., *et al.* ..... (A) 902
Mycobacteria-reactive Lyt-2+ T cell lines. De Libero, G., *et al.* ..... (A) 898
Observations on T-cell subpopulations in type II reactions. Kalyanasundaram, K., *et al.* ..... (A) 714
Regulation of T cell responsiveness against mycobacterial antigens by HLA class 2 immune response genes. de Vries, R. R. P. ..... (A) 713
Screening for T cell reactivity of recombinant *M. leprae* peptides. Jayaraman, T., *et al.* ..... (A) 319
Specific lysis by CD8+ T cells of Schwann cells expressing *M. leprae* antigens. Steinhoff, U. and Kaufmann, S. H. E. ..... (A) 141
T cell epitopes on the 36K and 65K *M. leprae* antigens defined by human T cell clones. van Schooten, W. C. A., *et al.* ..... (A) 141
T cell reactivity of leprosy patients and their household contacts to mycobacterial sonicates and affinity purified antigens. Adams, E., *et al.* ..... (A) 318
T cell responses to fractionated *M. leprae* antigens in leprosy. The lepromatous non-responder defect can be overcome *in vitro* by stimulation with high molecular weight *M. leprae* components. Ottenhoff, T., *et al.* ..... (A) 326
T-cell responses to the *M. leprae* 18 kD antigen. Harris, D. P., *et al.* ..... (A) 319
The classical and alternate pathways of T cell activation are impaired in leprosy. Muthukkaruppan, V., *et al.* ..... (A) 579
Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* ..... (A) 717

Cell-mediated immunity (CMI),
Clinical trial with clofazimine for treating erythema dyschromicum perstans; evaluation of cell-mediated immunity. Piquero-Martin, J., *et al.* ..... (A) 919
Evaluation of cell-mediated immunity on leprosy patients in Taiwan: a preliminary report. Liu, M.-F., *et al.* ..... (A) 901
The effect of clofazimine in cell mediated immunity: interference with antigen processing and presentation by macrophages. Brown, L. M., *et al.* ..... (A) 315
The reconstruction of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. Kaplan, G., *et al.* ..... (A) 714

Chemotherapy (see also Therapy),
Appraisal of two *M. leprae*-specific serological assays for monitoring chemotherapy in lepromatous (LL/BL) leprosy patients. Sinha, S., *et al.* ..... (O) 24
Detection of phenolic glycoplipid I of *M. leprae* for monitoring the chemotherapy of leprosy. Cho, S.-N., *et al.* ..... (A) 303

Effect of chemotherapy on viability of *M. leprae* as determined by ATP content, morphological index and FDA-EB fluorescence staining. Katoch, V. M., *et al.* ..... (O) 615
[Ethionamide in combined chemotherapy.] Carvalho Costa, I. M., *et al.* ..... (A) 565
Evaluation of chemotherapy in leprosy by monitoring *M. leprae* specific antibody titers in patients. Sinha, S., *et al.* ..... (A) 305
Evaluation of *M. leprae* antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., *et al.* ..... (A) 899
Evaluation of two multidrug regimens in hospitalized multibacillary cases. Chattopadhyay, S. P., *et al.* ..... (A) 892
Field trial of short course combined chemotherapy in paucibacillary leprosy. Day, R. S. and Teterissa, M. R. ..... (C) 340
Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council ..... (A) 591
Histopathologic observations on the persistence of *M. leprae* in the skin of multibacillary leprosy patients under chemotherapy. Wabitsch, K. R. and Meyers, W. M. ..... (A) 581
Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., *et al.* ..... (A) 339
Long-term correlation between serological (PGL) and histological parameters in the control of chemotherapy in LL and BL patients. Wabitsch, K. R., *et al.* ..... (A) 346
PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Chanteau, S., *et al.* ..... (O) 735
Possible use of B-lactam antibiotics in the treatment of Hansen's disease. Prabhakaran, K., *et al.* ..... (A) 317
Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988. ..... (B) 124
Progress in chemotherapy research under THELEP programme. Ji, B.-H., *et al.* ..... (A) 336
Receptor-mediated drug delivery to macrophages in chemotherapy of leishmaniasis. Mukhopadhyay, A., *et al.* ..... (A) 918
The design and development of novel broad spectrum antimycobacterial compounds from thioureas. Devasthale, S. V., *et al.* ..... (A) 316
[Tridrug regimen in multibacillary leprosy for two years.] Chen, J., *et al.* ..... (A) 707

Children,
A pilot study of three potential vaccines for leprosy in Bombay school children. Stanford, J. L., *et al.* ..... (A) 350
A report on six cases of histoid variety of lepromatous leprosy in children. Mohan, L., *et al.* ..... (A) 710
Analyses of leprosy incidence in 2261 children of leprosy patients. Chu, Z.-Z., *et al.* ..... (A) 332
Identification of "high risk group" of leprosy in children using serological and lepromin test: a preliminary report. Naik, S. S., *et al.* ..... (A) 910
Indeterminate leprosy in a population survey and in the subsequent follow-up of children. Bechelli, L. M. ..... (A) 305
[Investigation of occurrence of the disease in 2261 children of parents with leprosy.] Chu, Z., *et al.* ..... (A) 723
Leprosy in infants—report on two cases. Girdhar, A., *et al.* ..... (O) 472
Leprosy in young urban children. Sehgal, V. N. and Sehgal, S. ..... (A) 147
Recognition of a category of responders to group ii, slow-grower associated, antigens amongst Kuwaiti senior school children, using a statistical model. McManus, I. C., *et al.* ..... (A) 592
Sensitisation by mycobacteria and the effects of BCG on children attending schools in the slums of Bombay. Stanford, J. L., *et al.* ..... (A) 575
Skin test responsiveness to a series of new tuberculins of children living in three Vietnamese cities. Ly, H. M., *et al.* ..... (A) 724
3299 cases of children leprosy in Fujian. Shao, K.-W., *et al.* ..... (A) 306
Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis. Ghazi Saidi, K., *et al.* ..... (O) 45
Vaccination and skin test studies on the children of leprosy patients. Stanford, J. L., *et al.* ..... (O) 38

China, People's Republic of,
[Endemicity and control of leprosy in Hebai Province.] Tan, D., *et al.* .....(A) 724
[Endemicity of leprosy and its control in Zhejiang Province.] Chen, D. .....(A) 144
[Endemicity of leprosy in Shaanxi Province.] Qian, A., *et al.* .....(A) 587
Investigation of 1692 cases of leprous ophthalmia in Guangdong Province. Lu, B.-X., *et al.* .....(A) 355
Short-term multidrug therapy in multibacillary leprosy; review of 80 cases in two provinces of China. Li, H.-Y., *et al.* .....(A) 336
Studies on social medicine of leprosy in China. Ye, G.-Y., *et al.* .....(A) 353
The possibility of leprosy eradication in Shandong Province by year 2000. Fan, Y.-L. and Zhao, T. .....(A) 333

Cholesterol,
Estimation of high density lipoprotein cholesterol in the diagnosis of lepromatous leprosy. Kumar, N., *et al.* .....(A) 571

Chromatography,
Certain aspects of dapsone metabolism in leprosy patients as studied by high performance liquid chromatography (HPLC) and qualitative screening tests. Irudaya Raj, P. P., *et al.* .....(A) 129
Preliminary results on the detection of mycolic acids from *M. leprae* by gel permeation chromatography and proton nuclear resonance spectroscopy. Gan, S. C., *et al.* .....(A) 583

Ciprofloxacin,
Amikacin, ciprofloxacin, and imipenem treatment for disseminated *M. avium* complex infection of beige mice. Inderlied, C. B., *et al.* .....(A) 591
In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against *M. tuberculosis.* Uttley, A. H. C. and Collins, C. H. .....(A) 151

Classification,
Evolution of the classification of leprosy. Sehgal, V. N., *et al.* .....(A) 890
The reactional tuberculoid—its position in the classification of leprosy. Opromolla, D. V. A., *et al.* .....(A) 314

Clinics,
Factors influencing clinic attendance for treatment of leprosy. Vadher, A. .....(A) 348

Clinical,
A clinical, immunological and histological study in neuritic leprosy patients. Girdhar, B. K., *et al.* .....(A) 338
A double-blind controlled clinical trial to assess the role of antihistamines in the treatment of multibacillary leprosy. Thomas, A., *et al.* .....(A) 568
A quantitative study of the relationship between systemic immunity and local histopathological changes in untreated leprosy. Beck, J. S., *et al.* .....(A) 346
A study into bacteriological positivity and treatment of beggar leprosy patients. Rao, P. S., *et al.* .....(A) 911
Adreno-cortical function in leprosy. Garg, R., *et al.* .....(A) 569
Case study of patients released from observation. Singh, S. L. and Bedenbender, H. ...(A) 307
Chromoblastomycosis in a residual patch of leprosy. Pavithran, K. .....(A) 134
Clinical and laboratory studies of arthritis in leprosy. Atkin, S. L., *et al.* .....(A) 895
Clinical pharmacokinetics of clofazimine; a review. Holdiness, M. R. .....(A) 893
Clinical trial with clofazimine for treating erythema dyschromicum perstans; evaluation of cell-mediated immunity. Piquero-Martin, J., *et al.* .....(A) 919
Controlled clinical trial for evaluation of antimicrobial drug activity against *M. leprae.* Grosset, J. H. and Ji, B.-H. .....(E) 529
Correlation of clinical and histopathologic features in untreated macular lesions of leprosy—a study of 100 cases. Shenoi, S. D. and Siddappa, K. .....(A) 135
Current clinical status of uveitis in leprosy under various drug regimes. Samanta, S. K., *et al.* .....(A) 355
Diagnostic value of cardinal signs/symptoms in paucibacillary leprosy. Sirumban, P., *et al.* .....(A) 125
Disability survey of 1480 cases of leprosy. Zheng, T.-S., *et al.* .....(A) 315

Effect of multidrug treatment (paucibacillary regimen) on the clinical and histological features of tuberculoid and borderline tuberculoid cases. Kumar, T. S., *et al.* .....(A) 346
Immunoregulatory mechanism of endogenous glucocorticoid in leprosy. Sheriff, S., *et al.* .....(A) 312
Interpretation of published papers on controlled clinical trials. Waters, M. F. R. .....(C) 556
Involvement of palate and cheek in leprosy. Kumar, B., *et al.* .....(A) 134
M. avium-intracellulare infection associated with hairy-cell leukemia. Maurice, P. D. L., *et al.* .....(A) 149
M. leprae induced suppressor cells in the polar clinical forms of leprosy. Sasiain, M. del C., *et al.* .....(A) 325
Male hormonal insufficiency in multibacillary Hansen's disease—prevalence and clinical manifestations. Frankel, R. I. .....(A) 313
Morphometric study of stratum corneum in leprosy. Okhandiar, R. P., *et al.* .....(A) 710
[Ocular leprosy—clinical statistics.] Watanabe, I., *et al.* .....(A) 573
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): I. Clinical results. N'Deli, L., *et al.* .....(A) 317
Serology during the clinical course of treated leprosy. Li, F., *et al.* .....(A) 303
Status of multibacillary patients "lost to follow up." Muliyil, J. and Thangavel, N. .....(A) 903
The management of reaction in leprosy. Pfaltzgraff, R. E. .....(E) 103
[Thermography as a method for diagnosing leprosy.] Yebra Sotillo, I., *et al.* .....(A) 574
Thyroid hormones in leprosy patients. Babybin, E. S. .....(A) 895
Tuberculoid granuloma in a clinically normal looking skin. Haldar, S. R., *et al.* .....(A) 133
Tuberculoid leprosy on hairy scalp: a case report. Ghorpade, A., *et al.* .....(A) 133
Turn-over of statum corneum in leprosy. Okhandiar, R. P., *et al.* .....(A) 139

Clofazimine,
Clinical pharmacokinetics of clofazimine; a review. Holdiness, M. R. .....(A) 893
Clinical trial with clofazimine for treating erythema dyschromicum perstans; evaluation of cell-mediated immunity. Piquero-Martin, J., *et al.* .....(A) 919
Clofazimine and dapsone compliance in leprosy. Ellard, G. A., *et al.* .....(A) 128
Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for *M. avium* complex. Lindholm-Levy, P. J. and Heifets, L. B. .....(A) 149
Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. .....(A) 132
[Effects of clofazimine on the patients with ENL dependent upon corticosteroids.] Yu, X., *et al.* .....(A) 568
Evaluation of *M. leprae* antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., *et al.* .....(A) 899
Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine. Zeis, B. M., *et al.* .....(A) 733
The effect of clofazimine in cell mediated immunity: interference with antigen processing and presentation by macrophages. Brown, L. M., *et al.* .....(A) 315
The effect of treatment with rifampicine, clofazimine and dapsone in multibacillary leprosy in the field for three years. Li, W.-Z., *et al.* .....(A) 341
Truitement de la lèpre rurale par une dose unique de rifampicine completée par l'association sulfone clofazimine en autotraitement. Languillon, J. L. .....(A) 341

Cloning,
A cloned DNA fragment for identification of *M. tuberculosis.* Patel, R. J., *et al.* .....(A) 730
Characterization of *M. leprae* cell wall-associated proteins with the use of T lymphocyte clones. Mehra, V., *et al.* .....(A) 715
HLA-DR-restricted antigen-induced proliferation and cytotoxicity mediated by CD4+ T-cell clones from subjects vaccinated with killed *M. leprae.* Mustafa, A. S. and Qvigstad, E. .....(O) 1
Selection of recombinant DNA clones expressing the 12K and 36K *M. leprae* antigens in *E. coli* K12. Hartskeerl, R. A., *et al.* .....(A) 328
Specificity of proliferative response of human CD8 clones to mycobacterial antigens. Rees, A., *et al.* .....(A) 904

T cell epitopes on the 36K and 65K *M. leprae* antigens defined by human T cell clones. van Schooten, W. C. A., *et al.* ..... (A) 141

Complement,

Comprehensive evaluation of complement components in the course of type I (lepra) and type II (ENL) reactions. Sehgal, V. N., *et al.* ..... (A) 716

Differences in uptake of mycobacteria by human monocytes; a role for complement. Swartz, R. P., *et al.* ..... (A) 595

Influence of *in vitro* administered immune complexes on serum levels of complement and circulating immune complexes in *M. leprae* infected mice. Vaishnavi, C., *et al.* ..... (A) 586

Interaction of anti-leprosy drugs with the rat serum complement system. Sahu, A., *et al.* ..... (A) 131

The complement profile in leprosy. He, H.-M., *et al.* ..... (A) 326

The effect of anti-reactional drugs on complement components in the type II, erythema nodusum leprosum, reaction. Sehgal, V. N., *et al.* ..... (A) 135

Congresses,

Proceedings of the International Congress on Medical and Social Rehabilitation of the Disabled in the Third World Countries with Emphasis on the Rehabilitation of the Leprosy Patient. ..... (B) 563

XIII International Leprosy Congress transactions. ..... (S) 229

Control of leprosy,

Comparative epidemiological and operational assessment of a vertical and an integrated leprosy control program. Parkhe, S. M., *et al.* ..... (A) 330

[Endemicity and control of leprosy in Hebai Province.] Tan, D., *et al.* ..... (A) 724

[Endemicity of leprosy and its control in Zhejiang Province.] Chen, D. ..... (A) 144

[Evaluation of effects of leprosy control using the life table.] Yang, Z. ..... (A) 588

Experience in leprosy control in a developing country. Due, L. K., *et al.* ..... (A) 332

Implications of genetics for the epidemiology and control of leprosy. Fine, P. E. M. ..... (A) 586

Integrated leprosy control in the Gambia. Kinteh, S. B. and Bouchier, V. A. ..... (A) 323

Managing leprosy patient care in partnership with local communities. Sorensen, B. H. ..... (A) 331

PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., *et al.* ..... (A) 897

Situacion de los programas de control de la lepra en las Americas. Borges, M. V. ..... (A) 334

The application of a health education model to obtain early and regular treatment of leprosy patients. Matthews, C. M. E. ..... (A) 347

The possibility of leprosy eradication in Shandong Province by year 2000. Fan, Y.-L. and Zhao, T. ..... (A) 333

Corticosteroids,

Amoebic disease precipitated by corticosteroids prescribed for tuberculous pleural effusions. Ratcliffe, G. E. ..... (A) 731

Corynebacteria, leprosy derived (LDC),

Comparative biochemical analysis of the genomes of leprosy associated bacteria (*M. leprae,* LDC and ADM). Coene, M., *et al.* ..... (A) 320

Size and homology of the genomes of leprosy-derived corynebacteria and mycobacteria. Antoine, I., *et al.* ..... (A) 142

Cuba,

[A comparative study of epidemiologic surveys of the incidence of leprosy in the years 1980 to 1984 in the cities of 10 Octubre and Arroyo Naranjo (Cuba).] Alvarez Mesa, M., *et al.* ..... (A) 586

Cultivation,

Cultivation of *M. leprae*: a new approach. Bapat, C. V. ..... (C) 874

In vitro cultivation of *M. leprae* under microaerophilic conditions. Ishaque, M. ..... (A) 321

Investigations into cultivation of *M. leprae* under low oxygen tension. Ishaque, M. .... (C) 115

Cutaneous,
A study of cutaneous lesions of leprosy on male genitalia. Arora, S. K., *et al.* ..... (A) 894
Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. McDougall, A. C. ..... (C) 114
Differential recognition of *Leishmania aethiopica* antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Akuffo, H. O., *et al.* ..... (A) 727
Disseminated cutaneous infection caused by *M. kansasii*: report of a case. Tseng, H. M., *et al.* ..... (A) 732
Drs. Jacob and Mathai reply (diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy). Jacob, M. and Mathai, R. ..... (C) 114
Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine. Zeis, B. M., *et al.* ..... (A) 733
Morphometric study of stratum corneum in leprosy. Okhandiar, R. P., *et al.* ..... (A) 710
The reconstruction of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. Kaplan, G., *et al.* ..... (A) 714
Turn-over of statum corneum in leprosy. Okhandiar, R. P., *et al.* ..... (A) 139

Damien-Dutton Society,
1988 Damien-Dutton Award to Hermann Kober ..... (S) 252

Dapsone (DDS) (see also Sulfones),
Certain aspects of dapsone metabolism in leprosy patients as studied by high performance liquid chromatography (HPLC) and qualitative screening tests. Irudaya Raj, P. P., *et al.* ..... (A) 129
Characteristics of the multiplication of dapsone-resistant strains of *M. leprae* in mice. THELEP Clinical Trials Subcommittee ..... (A) 131
Clofazimine and dapsone compliance in leprosy. Ellard, G. A., *et al.* ..... (A) 128
Double résistance RMP-dapsone dans 12 souches de *M. leprae* en Martinique: étude retrospective, analyse des causes et prospective. Constant-Desportes, M., *et al.* ..... (A) 335
Evaluation of *M. leprae* antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., *et al.* ..... (A) 899
Humoral immune responses in dapsone treated *M. leprae* infected mice. Srinivasan, P. and Rao, P. R. ..... (A) 910
Influence of acetylator phenotype of the leprosy patients on the emergence of dapsone resistant leprosy. Irudaya Raj, P. P., *et al.* ..... (A) 129
Influence of age, sex and body weight on the dapsone acetylation phenotype. Philip, P. A., *et al.* ..... (A) 130
Investigations into the haemolytic effects of dapsone therapy in leprosy patients. Balakrishnan, S., *et al.* ..... (A) 707
Long term follow up of PB patients treated with either a single dose of rifampicin (RMP) followed by one year of DDS (regimen A) or 10 weekly doses of RMP (regimen B). Janssens, L., *et al.* ..... (A) 340
N-Acetylation polymorphism of dapsone in a Japanese population. Horai, Y. and Ishizaki, T. ..... (A) 567
[Photodermatitis induced by DDS in a leprosy patient.] Fumey, S. M. ..... (A) 567
Plasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients. Garg, S. K., *et al.* ..... (A) 708
Relapse rates in paucibacillary leprosy—WHO regimen verus dapsone monotherapy. Jesudasan, K., *et al.* ..... (A) 340
Structure pharmacokinetic relationship in a series of dapsone derivatives. Visser, K., *et al.* ..... (A) 317
Survey of primary dapsone-resistant leprosy. Wang, H., *et al.* ..... (A) 568
The effect of treatment with rifampicine, chlofazimine and dapsone in multibacillary leprosy in the field for three years. Li, W.-Z., *et al.* ..... (A) 341

Deformity,
[A survey of deformity and disability among 1480 cases of leprosy.] Zheng, T., *et al.* ..... (A) 726
Etude epidemiologique des déformations chirurgicalement curables de 1059 patients hanseniens en zone rurale. Gaisne, E., *et al.* ..... (A) 314
[Investigation of deformity and disability in leprosy.] Zhao, X. ..... (A) 148

Leprosy deformities. II. As parameters to monitor the effectivity of leprosy control programme. Mishra, B., *et al.* ....(A) 146
Monitoring of patient peripheral nerve status and deformity in Hansen's disease. Bell-Krotoski, J. ....(A) 337
Productivity loss due to deformity from leprosy in India. Max, E. and Shepard, D. S. ....(O) 476
[Survey of deformity and disability in leprosy.] Zhang, J. ....(A) 148

Deoxyfructoserotonin,
DFS, an anti-leprosy drug without side effects. Ambrose, E. J., *et al.* ....(A) 315
La desoxyfructoserotonine: son effet therapeutique dans le traitement de la lèpre. Mester de Parajd, M., *et al.* ....(A) 893

Dermatology,
A study of dermatological conditions in leprosy in-patients. Patki, A. H., *et al.* ....(A) 710
Dermatology and Leprosy Research Institute. ....(N) 119
The story of sulfones in tropical medicine and dermatology. Wozel, G. ....(A) 707

Dermatoglyphics,
Dermatoglyphics in leprosy: (III) Creases of palm. Ghei, S. K., *et al.* ....(A) 709
[Generation of a linear discriminant function of dermatoglyphics for the detection of high risk groups in leprosy.] Goncalves, A., *et al.* ....(A) 723

DNA,
Restriction map of mycobacteriophage D29 and its deletion mutant F5. Lazraq, R., *et al.* ....(A) 917

Dominican Republic,
Sistema de lucha antileprosa en Republica Dominicana. Diaz, H. B., *et al.* ....(A) 322

Drugs (see also specific drugs),
Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. ....(A) 132
Comparative study of different drug compliance tests available in leprosy. Naik, S. S. and Sahasrabudhe, R. V. ....(A) 130
Comparison of colchicine and aspirin in the treatment of type 2 lepra reaction. Kar, H. K. and Roy, R. G. ....(A) 133
Controlled clinical trial for evaluation of antimicrobial drug activity against *M. leprae.* Grosset, J. H. and Ji, B.-H. ....(E) 529
Correlations among naturally occurring resistances to antituberculosis drugs in *M. avium* complex strains. Tsukamura, M. and Miyachi, T. ....(A) 920
Current clinical status of uveitis in leprosy under various drug regimes. Samanta, S. K., *et al.* ....(A) 355
DFS, an anti-leprosy drug without side effects. Ambrose, E. J., *et al.* ....(A) 315
Direct antimicrobial drug susceptibility testing of *M. tuberculosis* by the radiometric method. Libonati, J. P., *et al.* ....(A) 592
Drug compliance among self-motivated leprosy patients. Girdhar, A., *et al.* ....(A) 567
Effects of a derivative of serotonin (deoxyfructoserotonin) and other antileprosy drugs on attachment and uptake of *M. leprae* by Schwann cells *in vitro.* Chaudhury, A., *et al.* ....(A) 893
[Ethionamide in combined chemotherapy.] Carvalho Costa, I. M., *et al.* ....(A) 565
In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against *M. tuberculosis.* Uttley, A. H. C. and Collins, C. H. ....(A) 151
In vitro screening of antileprosy drugs by mass spectrometric analysis of *M. leprae.* Lindner, B., *et al.* ....(A) 350
Interaction of anti-leprosy drugs with the rat serum complement system. Sahu, A., *et al.* ....(A) 131
Measurement of ATP content of *M. leprae*—its application to the determination of viability and drug sensitivity screening. Katoch, V. M., *et al.* ....(A) 321
[Morphological characteristics of cell cultures from human and animal lepromas and the effect of antileprosy drugs on them.] Vishnevetsky, F. E., *et al.* ....(A) 909
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia,

Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization. ....(B) 122
Multiple drug therapy in Zimbabwe. Matemera, B. O. ....(A) 336
New experimental drugs for the treatment of tuberculosis. Parenti, F. ....(A) 730
Pharmacochemical aspects of leprosy; recent developments and prospects for new drugs. van Saane, P. and Timmerman, H. ....(A) 894
Receptor-mediated drug delivery to macrophages in chemotherapy of leishmaniasis. Mukhopadhyay, A., *et al.* ....(A) 918
Report of Fifth Meeting Ad Hoc Drug Development Subgroup of the THELEP SWG. ..(N) 886
Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on *M. avium* complex. Hoffner, S. E., *et al.* ....(A) 916
The bacteriological examination of slit-skin smears in leprosy control programmes using multiple drug therapy: a plea for radical changes in current operational methodology. Georgiev, G. D. and McDougall, A. C. ....(A) 570
The effect of anti-reactional drugs on complement components in the type II, erythema nodusum leprosum, reaction. Sehgal, V. N., *et al.* ....(A) 135

Electron microscopy (see also Ultrastructure),
An electron microscopic study of lymphatics in the dermal lesions of human leprosy. Mukherjee, A., *et al.* ....(O) 506
Immuno-electron microscopy of mycobacterial granulomas in the sciatic nerves of guinea pigs. Cowley, S. A., *et al.* ....(A) 310

ELISA (enzyme-linked immunosorbent assay) tests,
A competitive ELISA for the detection of mycobacterial antigen in tuberculosis exudates. Ramkisson, A., *et al.* ....(A) 730
An enzyme immunoassay (EIA) based on antibodies against human nerve antigen for diagnosis of all categories of leprosy patients. Itty, B. M., *et al.* ....(A) 304
[Assay of antibody level in sera of leprosy patients with *M. smegmatis* ELISA.] Wu, Q., *et al.* ....(A) 718
Detection of lepromatous leprosy patients shedding *M. leprae* in nasal droppings by enzyme immunoassay. Moudgil, K. D., *et al.* ....(A) 579
Detection of leprosy antigenuria through DOT-ELISA. Singh, N. B. and Choudhary, A. ....(A) 573
Evaluation of an enzyme immunoassay based on sonicate supernatant antigens of *Mycobacterium w* for immunodiagnosis of leprosy. Moudgil, K. D., *et al.* ....(A) 138
Evaluation of FLA-ABS, T/PG1-ELISA and their uses in immunoepidemiologic studies on leprosy. Wu, Q.-X., *et al.* ....(A) 305
Identification of mycobacterial antigens for "ELISA" serology in the diagnosis of leprosy and tuberculosis. Das, P. K., *et al.* ....(A) 898
Quantitative antibody ELISA for leprosy. Hasan, R., *et al.* ....(O) 766
Serodiagnostic potentialities of enzyme-linked immunosorbent assay (ELISA) using mannophosphoinositides of *M. tuberculosis* H37Rv. Mehta, P. K. and Khuller, G. K. ....(A) 593
Serological tests in leprosy. The sensitivity, specificity and predictive value of ELISA tests based on phenolic glycolipid antigens, and the implications for their use in epidemiological studies. Burgess, P. J., *et al.* ....(A) 144

Enzymes,
Urinary excretion of renal brush-border enzymes in lepromatous leprosy—a preliminary investigation. Kohli, M., *et al.* ....(O) 20

Epidemiology,
An epidemiological study on leprosy in southern Taiwan. Chou, P., *et al.* ....(A) 330
Comparative epidemiological and operational assessment of a vertical and an integrated leprosy control program. Parkhe, S. M., *et al.* ....(A) 330
Determination of sample sizes for epidemiological surveys using cluster sampling technique. Jeyaseelan, L. and Rao, P. S. S. ....(A) 723
Endemicity of leprosy and its control in Zhejiang Province. Chen, D. ....(A) 144
Enquetes d'évaluation par sondage de la prévalence de l'endemie lépreuse en Afrique Centrale. Joss, R., *et al.* ....(A) 323
Epidemiology of leprosy in tribals in Adhaura Plateau (India). Kaur, P., *et al.* ....(A) 587

Fit and analysis of the trend curve of leprosy epidemic. Pan, B., *et al.* ....(A) 587
Immuno-epidemiological studies of a hyperendemic pocket in a low endemic area. Yellapurkar, M. V. and Vaidya, M. C. ....(A) 332
Implications of genetics for the epidemiology and control of leprosy. Fine, P. E. M. ...(A) 586
The characteristics and mode of detection of the new patients encountered in the leprosy endemic province of Van (Turkey) within the last five years. Saylan, T., *et al.* .....(A) 911
The epidemiology of leprosy in a high prevalence village in Papua New Guinea. Bagshawe, A., *et al.* ....(A) 722
The rural-urban paradox in leprosy. Fine, P. E. M., *et al.* ....(A) 330
Use of soluble antigens in leprosy epidemiology. Gupte, M. D. and Anantharaman, D. S. ....(A) 577

Erythema nodosum leprosum (ENL),
Changes in circulating levels of agalactosyl IgG during episodes of erythema nodosum leprosum. Rook, G. A. W., *et al.* ....(A) 312
Comparison of colchicine and aspirin in the treatment of type 2 lepra reaction. Kar, H. K. and Roy, R. G. ....(A) 133
Comprehensive evaluation of complement components in the course of type I (lepra) and type II (ENL) reactions. Sehgal, V. N., *et al.* ....(A) 716
[Effects of clofazimine on the patients with ENL dependent upon corticosteroids.] Yu, X., *et al.* ....(A) 568
Leukemoid reaction in erythema nodosum leprosum in a leprosy patient. Chaudhary, S. D., *et al.* ....(A) 569
Serum immune complexes in erythema nodosum leprosum reactions of leprosy. Dharma Rao, T. and Rao, P. R. ....(A) 133
Solubilization of preformed immune complexes in sera of lepromatous patients with erythema nodosum leprosum. Chakrabarty, A. K., *et al.* ....(A) 311
Vitiligo following type II lepra reaction. Pavithran, K. ....(A) 711

Erythromycin,
Cure of bacille Calmette-Guérin vaccination abscesses with erythromycin. Murphy, P. M., *et al.* ....(A) 729

Escherichia coli,
Expression in recombinant *E. coli* of biotinylated proteins of *M. leprae*. Moss, M. T. and Dale, J. W. ....(A) 327
Overproduction and purification of *M. leprae* 65 kD protein in *Escherichia coli*. Nomaguchi, H., *et al.* ....(A) 329
Overproduction, affinity purification and characterization of 65-kDa protein of *M. leprae* in *Escherichia coli*. Nomaguchi, H., *et al.* ....(O) 817
Selection of recombinant DNA clones expressing the 12K and 36K *M. leprae* antigens in *E. coli* K12. Hartskeerl, R. A., *et al.* ....(A) 328
Transformation of *M. smegmatis* with *Escherichia coli* plasmids carrying a selectable resistance marker. Zainuddin, Z. F., *et al.* ....(A) 720
Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* ....(A) 717

Ethambutol,
Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on *M. avium* complex. Hoffner, S. E., *et al.* ....(A) 916

Ethionamide,
[Ethionamide in combined chemotherapy.] Carvalho Costa, I. M., *et al.* ....(A) 565

Ethiopia,
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization. ....(B) 122
Relationship of paralysis to age in leprosy patients in Ethiopia. Smith, V. B. and Abdulkadir, S. ....(A) 314

Experimental leprosy,
Effect of ofloxacin on experimental leprosy. Kohsaka, K., *et al.* ....(A) 316
Recent advances in experimental leprosy: a brief review. Job, C. K. and Hastings, R. C. ....(A) 721
[Reproduction of experimental leprosy infection in mice with previously induced insufficiency of mononuclear phagocyte system.] Vishnevetsky, F. E., *et al.* ....(A) 910
Serologic responses to *M. leprae*-specific phenolic glycoplipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* ....(A) 309
The nude mouse as an experimental lepromatous model (continued): the NSF/N nude mouse as a new model using the intra-upper lip inoculation method. Nakamura, K. and Yogi, Y. ....(A) 721

Eye(s),
Current clinical status of uveitis in leprosy under various drug regimes. Samanta, S. K., *et al.* ....(A) 355
Edge-light pupil cycle time in leprosy. Karacorlu, M. A., *et al.* ....(A) 355
Eye lesions in leprosy. Soshamma, G. and Suryawanshi, N. ....(A) 896
Intraocular pressure in Hansen's disease. Lewallen, S., *et al.* ....(A) 355
Ocular complications of leprosy: methods for control. Courtright, P. and Johnson, C. J. ....(A) 354
Ocular leprosy in the armadillo and man—a histopathological study. Jacob, M. ....(A) 355
[Ocular leprosy—clinical statistics.] Watanabe, I., *et al.* ....(A) 573
[Survey of eye diseases in leprosy patients.] Liu, Z., *et al.* ....(A) 134
Tarsal strip procedure for surgical correction of lagophthalmos. Suryawanshi, N. ....(A) 356
The eye in multidrug therapy. Rajan, M. A. ....(A) 355
The protective effectives of methyl cellulose drops and conoid shields in the presence of lagophthalmos and corneal hypesthesia in ocular leprosy. Karacorlu, M. A., *et al.* ....(A) 354
The results of a multicentre survey of the ocular complications of leprosy. ffytche, T. ..(A) 354

FLA-ABS test,
Evaluation of FLA-ABS, T/PG1-ELISA and their uses in immunoepidemiologic studies on leprosy. Wu, Q.-X., *et al.* ....(A) 305
Use of nonconventional antigen, *M. habana,* in detecting *M. leprae* antibodies from leprosy patients and contacts in FLA-ABS test. Rana, N. S., *et al.* ....(A) 580

Foot,
Bacteriology of infected hands and feet in leprosy patients. Abdulkadir, S. ....(A) 708
Bilateral involvement of sole and palm in leprćsy; a case report. Chattopadhyay, S. P., *et al.* ....(A) 895
Correction of severe foot deformities by a simple technique. Abram, G., *et al.* ....(A) 318
Effect of rocker sole design on plantar forefoot pressures. Nawoczenski, D. A., *et al.* ..(A) 725
Measurement of shock-waves during heel strike. Kahmann, L. R. M., *et al.* ....(A) 343
Spina bifida occulta with atrophy of toes. Talwar, S. ....(A) 136
Peripheral Denervation of the Foot by Carl D. Enna. ....(B) 121
Protective sensation in the foot in leprosy. Hammond, C. J. and Klenerman, P. ....(A) 570
The neuropathic foot—a management scheme: a case report. Nawoczenski, D. A., *et al.* ....(A) 726

Foot pad(s),
Comparison of *in vitro* Fc receptor assay with other methods including mouse foot pad method. Jagannathan, R., *et al.* ....(A) 321
Correlation of *in vitro* Fc receptor assay with *in vivo* mouse foot pad method. Jagannathan, R., *et al.* ....(A) 584
[Effect of removal of the popliteal ganglion on multiplication of *M. leprae* in the mouse foot-pad: preliminary report.] Moreno, O. S. and Silveira, J. R. ....(A) 143
Mouse footpad pathogenicity of the chemoautotrophic nocardioform isolates from human and mouse footpad leprosy tissues. Pal, N. K., *et al.* ....(A) 308
Non-immune clearance of *M. leprae* from the footpads of *M. leprae*-infected, multidrug-treated nude mice. Chehl, S. K., *et al.* ....(A) 349

Gambia,
Integrated leprosy control in the Gambia. Kinteh, S. B. and Bouchier, V. A. ....(A) 323

Genetics, bacterial,
Development of genetic systems for the mycobacteria. Jacobs, W. R., Jr., *et al.* .....(A) 907
Genetic relatedness among *M. paratuberculosis* and *M. avium* complex. Labidi, A. and Thoen, C. O. .....(A) 917
Genetic relatedness among *M. tuberculosis* and *M. bovis*. Labidi, A. and Thoen, C. O. .....(A) 917
Genetic relatedness among *M. leprae, M. tuberculosis,* and candidate leprosy vaccine strains determined by DNA hybridization: identification of an *M. leprae*-specific repetitive sequence. Grosskinsky, C. M., *et al.* .....(A) 719
Use of DNA probes to investigate the genetics of *M. leprae*. McFadden, J., *et al.* .....(A) 328

Genetics, human,
A test statistic for the affected-sib-set method. Lange, K. .....(A) 146
Fiftieth anniversary of the "N-Factor/Hansen-anergic fringe" hypothesis for hanseniasis. Rotberg, A. .....(C) 864
Genetic susceptibility to leprosy on a Caribbean island: linkage analysis with five markers. Abel, K., *et al.* .....(O) 465
Implications of genetics for the epidemiology and control of leprosy. Fine, P. E. M. ...(A) 586

Genome,
Comparative biochemical analysis of the genomes of leprosy associated bacteria (*M. leprae,* LDC and ADM). Coene, M., *et al.* .....(A) 320
Construction of genomic library of *M. leprae* gene and its expression in *Streptomyces lividans*. Makino, M., *et al.* .....(A) 328
Genomic and amino acid sequence of the *M. leprae* 70 kD antigen is homologous to the higher conserved 70 kD heat shock protein (hsp70) of eukaryotes. Garsia, R. J., *et al.* .....(A) 318
Size and homology of the genomes of leprosy-derived corynebacteria, *M. leprae,* and other corynebacteria and mycobacteria. Antoine, I., *et al.* .....(A) 142

Germany, Federal Republic of,
Hermann Kober receives 1988 Damien-Dutton Award. .....(S) 252

Granuloma(s),
Identification of subpopulations of CD4+ and CD8+ T cells in leprosy granulomas. Rea, T. H. and Modlin, R. L. .....(A) 327
Immuno-electron microscopy of mycobacterial granulomas in the sciatic nerves of guinea pigs. Cowley, S. A., *et al.* .....(A) 310
Immunopathology of leprosy granulomas. Modlin, R. L. and Rea, T. H. .....(A) 902
Tuberculoid granuloma in a clinically normal looking skin. Haldar, S. R., *et al.* .....(A) 133

Guadeloupe,
Lepra reactions and disabilities in patients treated with daily MDT in New Caledonia, French Polynesia and Guadeloupe. Bobin, P., *et al.* .....(A) 313
Results after 8 years of a daily multidrug therapy for leprosy patients in Guadeloupe, New Caledonia and Polynesia. Cartel, J. L., *et al.* .....(A) 335

Haiti,
Is prior mycobacterial infection a common predisposing factor to AIDS in Haitians and Africans? Lamoureux, G., *et al.* .....(A) 592
Prévalence et évolution de l'infection au virus humain d'immunodéficience (VIH) chez les lepreux en Haiti. Pean, C., *et al.* .....(A) 306

Hand(s),
A hand biomechanics workstation. Thompson, D. E., *et al.* .....(A) 726
A modification of the surgical correction of the thumb—a long term follow up. Beine, A. O., *et al.* .....(A) 725
Bacteriology of infected hands and feet in leprosy patients. Abdulkadir, S. .....(A) 708
Bilateral involvement of sole and palm in leprosy; a case report. Chattopadhyay, S. P., *et al.* .....(A) 895
Neurolysis: an approach to leprous claw hand. Chattopadhyay, S. P., *et al.* .....(A) 588
Peripheral Denervation of the Hand by Carl D. Enna. .....(B) 121

Hawaii,
Hansen's disease in Hawaii; current status. Frankel, R. I. ..... (A) 587

Hepatitis,
Leprosy and hepatitis B surface antigen. Vaishnavi, C., *et al.* ..... (A) 896
Serological pattern of hepatitis B virus markers (HBsAg, anti-HBs, IgM anti-HBc and HBV specific DNA polymerase) in leprosy patients. Moudgil, K. D., *et al.* ..... (A) 710

Histoid leprosy,
Multiple neurofibromatosis with histoid leprosy. Thomas, J., *et al.* ..... (C) 695

Histopathology,
A comparison of sensory loss tests and histopathology in the diagnosis of leprosy. Ponnighaus, J. M. and Fine, P. E. M. ..... (A) 896
Histology and fine structure of lepromatous nerves, before and after treatment. Dastur, D. K., *et al.* ..... (A) 337
New findings in the histopathology of indeterminate leprosy. Ravindranathan, O. and Sarojini, P. A. ..... (A) 345

History of leprosy,
[On the relation between the ancient poem "Fu Yi" and leprosy.] Liang, Z., and Ma, X. ..... (A) 127
Three times, three places, three authors, and one perspective on leprosy in medieval and early modern Europe. Ell, S. R. ..... (E) 825

HLA,
A *M. leprae*-specific human T cell epitope cross-reactive with an HLA-DR2 peptide. Anderson, D. C., *et al.* ..... (A) 136
Association of tuberculosis and *M. tuberculosis*-specific antibody levels with HLA. Bothamley, G. H., *et al.* ..... (A) 727
HLA-DQ molecules may be products of an immune suppression gene responsible for *M. leprae*-specific nonresponsiveness. Lei, S.-G. and de Vries, R. R. P. ..... (C) 554
[HLA-DR phenotype and B/DR haplotype in patients with sarcoidosis.] Ketova, N. A. (A) 729
HLA-DR, -DQ DNA genotyping and T-cell receptor RFLPs in leprosy. Jazwinska, E. C. and Serjeantson, S. W. ..... (A) 145
HLA-DR-restricted antigen-induced proliferation and cytotoxicity mediated by CD4+ T-cell clones from subjects vaccinated with killed *M. leprae*. Mustafa, A. S. and Qvigstad, E. ..... (O) 1
Regulation of T cell responsiveness against mycobacterial antigens by HLA class 2 immune response genes. de Vries, R. R. P. ..... (A) 713
The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey; a preliminary study. Cem Mat, M., *et al.* ..... (A) 144

Hypersensitivity,
Induction of the late hypersensitivity reaction to DNCB in patients with different clinical forms of hanseniasis in Brazil. Azulay, R. D. ..... (A) 310
The role of CD8+ cells in resistance and delayed hypersensitivity reactions in *M. lepraemurium* infection. Curtis, J., *et al.* ..... (A) 308

IMMLEP (WHO Immunology of Leprosy Scientific Working Group),
The contribution of IMMLEP to recent advances in immunology and molecular biology of *M. leprae*. Engers, H. D., *et al.* ..... (A) 326

Immune complexes,
Effects of *in vitro* formed immune complexes on macrophage functions of *M. leprae* infected mice. Vaishnavi, C., *et al.* ..... (A) 141
Influence of *in vitro* administered immune complexes on serum levels of complement and circulating immune complexes in *M. leprae* infected mice. Vaishnavi, C., *et al.* (A) 586
Persistent reduced solubilization of immune complexes in leprosy patients with reactions. Ramu, G., *et al.* ..... (A) 312
Serum immune complexes in erythema nodosum leprosum reactions of leprosy. Dharma Rao, T. and Rao, P. R. ..... (A) 133
Solubilization of preformed immune complexes in sera of lepromatous patients with erythema nodosum leprosum. Chakrabarty, A. K., *et al.* ..... (A) 311

Immune responses,

Activation of γδ T cells in the primary immune response to *M. tuberculosis*. Janis, E. M., *et al.* ..... (A) 900

Comparison of cell-mediated immune responses to *M. leprae* in mice following successful infection with *M. leprae* or immunization with killed *M. leprae*. Mshana, R. N., *et al.* ..... (A) 309

Humoral immune responses in dapsone treated *M. leprae* infected mice. Srinivasan, P. and Rao, P. R. ..... (A) 910

International Conference on Molecular Aspects of Immune Response and Infectious Diseases. ..... (N) 558

Macrophage mediated immune responses in the sciatic nerves of *M. leprae* infected nude mice with possible bystander and autoimmune demyelination—an electron microscopic study. Stanley, J. N. A., *et al.* ..... (A) 310

Regulation of T cell responsiveness against mycobacterial antigens by HLA class 2 immune response genes. de Vries, R. R. P. ..... (A) 713

Stress proteins and the immune response to mycobacteria—antigens as virulence factors? Young, D. B., *et al.* ..... (A) 582

The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* ..... (A) 577

The role of the 65-kDa protein in the immune response to *M. leprae*. Colston, M. J., *et al.* ..... (A) 325

Immunoglobulins,

Changes in circulating levels of agalactosyl IgG during episodes of erythema nodosum leprosum. Rook, G. A. W., *et al.* ..... (A) 312

[Classes I and II antigens and levels of IgG antibodies in patients with infiltrative tuberculosis of the lungs.] Nikolayan, L. T., *et al.* ..... (A) 918

Comparative studies of serum IgA1, IgA2 and IgM against phenolic glycolipid I in leprosy patients and contacts. Chujor, C. S. N., *et al.* ..... (A) 304

Conformational changes in the IgG molecule of lepromatous sera using laser Radman spectroscopy. Kumar, P., *et al.* ..... (A) 138

Follow up of T cell subsets and anti-trisaccharide IgM antibody levels of leprosy patients during daily multidrug therapy. Desforges, S., *et al.* ..... (A) 899

Glomerular immunoglobulin deposition in the absence of tissue damage in murine leprosy. Rojas-Espinosa, O., *et al.* ..... (C) 879

Immunology,

A clinical, immunological and histological study in neuritic leprosy patients. Girdhar, B. K., *et al.* ..... (A) 338

[Current thoughts on the immunology of leprosy.] Sagaro Delgado, B., *et al.* ..... (A) 580

Expression, purification and immunologic activity of recombinant 65-kilodalton protein of *M. leprae*. Gillis, T. P. and Williams, D. L. ..... (A) 328

Immuno-epidemiological studies of a hyperendemic pocket in a low endemic area. Yellapurkar, M. V. and Vaidya, M. C. ..... (A) 332

Immunological heterogeneity in type 1 reactions. Laal, S., *et al.* ..... (A) 311

Immunological response to homologous and heterologous phenolic glycolipid antigens in tuberculosis and leprosy. Torgal-Garcia, J., *et al.* ..... (A) 905

Immunological tools in leprosy control. Fine, P. E. M. ..... (E) 671

Indications that early events causing nerve damage in leprosy may not be immunologically mediated. Antia, N. H., *et al.* ..... (A) 337

Molecular study of the T cell repertoire in family contacts and patients with leprosy. Mendez-Samperio, P., *et al.* ..... (A) 902

Mucosal immunity in leprosy. Cree, I. A., *et al.* ..... (A) 381

Rapid and precise diagnosis of atypical mycobacterial infection by chemotaxonomical and immunological methods. Ikawa, H., *et al.* ..... (A) 916

Studies of a common idiotype PR4 in autoimmune rheumatic disease. Williams, W., *et al.* ..... (A) 581

The contribution of IMMLEP to recent advances in immunology and molecular biology of *M. leprae*. Engers, H. D., *et al.* ..... (A) 326

Tumor necrosis factor in leprosy patients. Silva, C. L. and Foss, N. T. ..... (A) 712

Immunotherapy,
Immunotherapy of treated BL/LL cases with BCG: histopathological, immunohistological and bacteriological assessments. Katoch, K., *et al.* ....(A) 900

Indeterminate leprosy,
Demonstration of PGL I antigens in skin biopsies in indeterminate leprosy patients: comparison with serological anti-PGL I levels. Huerre, M., *et al.* ....(A) 899
Indeterminate leprosy in a population survey and in the subsequent follow-up of children. Bechelli, L. M. ....(A) 305
Indeterminate leprosy; twenty year study—histologic observations. Abalos, R. M. ....(A) 344
Is the proportion of the new indeterminate leprosy cases dependent on the screening interval? Worth, R. M., *et al.* ....(A) 308
New findings in the histopathology of indeterminate leprosy. Ravindranathan, O. and Sarojini, P. A. ....(A) 345

India,
A pilot study of three potential vaccines for leprosy in Bombay school children. Stanford, J. L., *et al.* ....(A) 350
A pilot study of three potential vaccines for leprosy in Bombay. Ganapati, R., *et al.* ..(O) 33
Bombay Leprosy Project 1989 Antileprosy Week celebrations. ....(N) 700
Changing Face of Leprosy; a film. ....(N) 884
Changing picture of leprosy in North Arcot District, Tamil Nadu, after M.D.T. Ekambaram, V. and Rao, M. K. ....(A) 708
Childhood leprosy in Bombay: a clinico-epidemiological study. Nadkarni, N. J., *et al.* ....(A) 146
Dermatology and Leprosy Research Institute. ....(N) 119
Dr. Claire Vellut honored. ....(N) 884
Dr. Joseph A. Ponniah is new Director of SLR&TC, Karigiri. ....(N) 884
Dr. Rajendra Prasad Gold Medal to Shri R. S. Mani. ....(N) 885
Epidemiology of leprosy in tribals in Adhaura Plateau. Kaur, P., *et al.* ....(A) 587
Experiences with health education strategy being followed under National Leprosy Eradication Programme in India. Dharmshaktu, N. S. and Mittal, B. N. ....(A) 347
Factors influencing voluntary reporting of leprosy patients in Madras, an urban metropolitan city in India. Lobo, D., *et al.* ....(A) 347
XV IAL Conference and new officers. ....(N) 119
Impact of multidrug therapy on leprosy in Baroda District (Gujarat). Chopra, N. K., *et al.* ....(A) 892
Indian Association of Leprologists (IAL). ....(N) 885
Intraspecies differentiation of strains of *M. tuberculosis* obtained from Czechoslovakian, Mongolian and South Indian patients. Venkataraman, P., *et al.* ....(A) 596
JALMA Trust Fund Oration Award to Virendra N. Sehgal. ....(N) 700
Karigiri Video teaching/training materials. ....(N) 701
Leprosy control in a Bombay slum—a general assessment. Goyder, E. C. ....(A) 145
Leprosy teaching in medical colleges in Bombay—a questionnaire study. Sheela, G. R., *et al.* ....(A) 890
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization. ....(B) 122
National Leprosy Eradication Commission reconstituted. ....(N) 885
Observance of Antileprosy Day 30 January 1989. ....(N) 700
Occlusive hydrocolloid dressings applied to chronic neuropathic ulcers. A study of efficacy in patients in a rural south Indian hospital. Mumford, J. W. and Mumford, S. P. ....(A) 148
Poona District Leprosy Committee Annual Report 1987–1988. ....(N) 701
Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988. ....(B) 124
Productivity loss due to deformity from leprosy in India. Max, E. and Shepard, D. S. (O) 476
XVI All India Leprosy Workers Conference 1989. ....(N) 702
XVI Biennial IAL Conference. ....(N) 703
Skin test studies on close contacts of leprosy patients in India. Lord, R., *et al.* ....(O) 801
State Leprosy Conference 1989. ....(N) 886

Surveillance and relapse rates after MDT in over 700 paucibacillary leprosy cases—a two year follow up at Purulia, India. Casablanca, M. N. and Nayagam, A. S. ....(A) 339
Trend of leprosy in Sevagram control unit (Maharashtra, India). Tare, S. P. ....(A) 332

Indonesia,
Sample surveys in leprosy: milestone for Indonesia. Louhenapessy, A. A., *et al.* ....(A) 332
Surabaya urban leprosy control program. Sastrowidjojo, H., *et al.* ....(A) 333
WHO MDT regime in Molucas Province (East Indonesia), January 1982–December 1987. Louhenapessy, A. and Sugiene, R. ....(A) 336

Interferon,
[Correlation between skin tests and the production of gamma-interferon in patients with hanseniasis.] Suso, L., *et al.* ....(A) 905
Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Sibley, L. D., *et al.* ....(A) 140

Interleukin(s),
[Determination of ability of producing IL-2 and activity of NK in multibacillary leprosy.] Xiong, S., *et al.* ....(A) 719
Interleukin-2 receptors in the sera of leprosy patients. Ganguly, N. K., *et al.* ....(C) 870
Intradermal IL-2 injections enhance *in vitro* responses to mycobacterial antigens in lepromatous leprosy patients. Converse, P., *et al.* ....(A) 325
Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Brown, A. R., *et al.* ....(A) 913
The reconstruction of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. Kaplan, G., *et al.* ....(A) 714

International Journal of Leprosy (IJL),
Author Index to Volume 57. ....(—) 167
Reviewers for Volume 57. ....(—) 922
Statement of financial condition. ....(—) 923
Statement of ownership, management, and circulation. ....(—) 926
Subject Index to Volume 57. ....(—) 178
The 1988 JOURNAL—a continuing perspective. Hastings, R. C. ....(E) 82

International Leprosy Association (ILA),
List of Members ....(—) 153
Minutes of the Council meeting, 11 September 1988 ....(S) 236
Officers and Councillors ....(—) 152

International Leprosy Congress, XIII,
Participants ....(S) 239
Pre-Congress Workshop Committees' reports ....(S) 275
Transactions ....(S) 229

Iran,
A comparison of three potential vaccines for leprosy carried out in 59 villages in the Ahar Valley of eastern Azerbaijan, Iran. Ghazi-Saidi, K., *et al.* ....(A) 350
A policy for enhancing protective immunity in close contacts of leprosy patients developed in the Islamic Republic of Iran. Dowlati, Y., *et al.* ....(A) 349
Do environmental mycobacteria influence the distribution of disease in the leprosy spectrum? Bacteriological and skin test studies carried out in Iran. Velayati, A., *et al.* ....(A) 320

Italy,
International Conference on Molecular Aspects of Immune Response and Infectious Diseases. ....(N) 558

Ivory Coast,
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): I. Clinical results. N'Deli, L., *et al.* ....(A) 317
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): II. Biological results. Grosset, J., *et al.* ....(A) 316

Japan,
Leydig cells observed in autopsy cases of the national leprosarium, Okukomyoen. Obara, A., *et al.* ..... (A) 345
N-Acetylation polymorphism of dapsone in a Japanese population. Horai, Y. and Ishizaki, T. ..... (A) 567

Korea,
An analysis of pulmonary tuberculosis data in Taiwan and Korea. Schulzer, M., *et al.* ..... (A) 151
Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., *et al.* ..... (A) 339

Kuwait,
Recognition of a category of responders to group ii, slow-grower associated, antigens amongst Kuwaiti senior school children, using a statistical model. McManus, I. C., *et al.* ..... (A) 592

Lactate dehydrogenase,
Lactate dehydrogenase isoenzymes in leprosy patients on multidrug therapy—a preliminary report. Dhandayuthapani, S. and Bhatia, V. N. ..... (A) 132
Serum lactate dehydrogenase in murine leprosy: source and isozymes. Luna Herrera, J. and Rojas-Espinosa, O. ..... (O) 641

Lepromatous leprosy,
A comparative evaluation of serological assays for lepromatous leprosy. Mwantha, J., *et al.* ..... (A) 138
A florid case of borderline-lepromatous leprosy. Raman, J. and Fisher, D. ..... (A) 896
A report of six cases of histoid variety of lepromatous leprosy in children. Mohan, L., *et al.* ..... (A) 710
Detection of lepromatous leprosy patients shedding *M. leprae* in nasal droppings by enzyme immunoassay. Moudgil, K. D., *et al.* ..... (A) 579
Estimation of high density lipoprotein cholesterol in the diagnosis of lepromatous leprosy. Kumar, N., *et al.* ..... (A) 571
Evidence that *M. leprae* specific helper T cells exist in lepromatous leprosy patients. Gill, H. K., *et al.* ..... (A) 319
Facies leprosa: some recent observations in patients with lepromatous leprosy in Malaysia. Subramaniam, K. and Marks, S. C., Jr. ..... (A) 315
Field trials of combined therapy in lepromatous leprosy. Vijayakumaran, P., *et al.* ..... (A) 337
Hyper-eosinophilic syndrome with lepromatous leprosy. Mehrotra, S. D., *et al.* ..... (A) 895
Immunotherapy of treated BL/LL cases with BCG: histopathological, immunohistological and bacteriological assessments. Katoch, K., *et al.* ..... (A) 900
Intradermal IL-2 injections enhance *in vitro* responses to mycobacterial antigens in lepromatous leprosy patients. Converse, P., *et al.* ..... (A) 325
Local immunomodulation with dinitrochlorobenzene in patients with lepromatous leprosy: immunohistological investigations. Volc-Platzer, B., *et al.* ..... (A) 351
Long-term correlation between serological (PGL) and histological parameters in the control of chemotherapy in LL and BL patients. Wabitsch, K. R., *et al.* ..... (A) 346
Maxillary antrum in lepromatous leprosy (antroscopic study). Soni, N. K. ..... (A) 314
Lèpre lépromateuse: arguments cliniques et électrophysiologiques en faveur d'une multinévrite axonale. Tzourio, C., *et al.* ..... (A) 339
Mechanisms of *M. leprae*-specific T-cell deficiency in lepromatous leprosy. Bach, M.-A. and Launois, P. ..... (A) 574
Multicentric reticulohistiocytosis masquerading as lepromatous leprosy. Razak, E. M. A., *et al.* ..... (A) 572
[Pathologic changes and bacillation of blood vessels in LL and BL leprosy.] Liu, J., *et al.* ..... (A) 578
Presence of *M. leprae*-reactive lymphocytes in lymph nodes of lepromatous leprosy patients. Desai, S. D., *et al.* ..... (A) 137
Radiological study of the paranasal sinuses in lepromatous leprosy. Soni, N. K. ..... (A) 136
Reduced numbers of Leu 8(+) cells in peripheral blood of lepromatous leprosy patients (LL). Sasiain, M. de C., *et al.* ..... (A) 325

Reduced suppressor cell response to *M. leprae* in lepromatous leprosy. Sasiain, M. del C., *et al.* ..... (A) 715
[Secondary amyloidosis as a consequence of inadequate treatment in a lepromatous leprosy patient.] Montserrat Perez and Algaba, F. ..... (A) 134
Single lesion subpolar lepromatous leprosy and its possible mode of origin. Job, C. K., *et al.* ..... (O) 12
Survival of *Staphylococcus epidermidis* on the skin of patients with lepromatous leprosy. Kumar, B., *et al.* ..... (A) 134
Tetanus in patients with lepromatous leprosy (I). Anilkumar, G., *et al.* ..... (A) 132
The high prevalence of testicular involvement in lepromatous (LL) as compared to borderline lepromatous (BL) leprosy patients. Gebhard, J. F. and Rea, T. H. ..... (A) 344
The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey; a preliminary study. Cem Mat, M., *et al.* ..... (A) 144
Trial to determine the capacity of several vaccines to produce skin-test reactivity to a soluble *M. leprae* antigen in treated smear-negative patients with lepromatous leprosy. Fajardo, T. T., *et al.* ..... (A) 318
Tuberculoid relapse in lepromatous leprosy. Waters, M. F. R. and Ridley, D. S. ..... (A) 307
Ultrastructural studies on peripheral nerves in lepromatous leprosy patients. Kumar, V., *et al.* ..... (A) 138
Urinary excretion of renal brush-border enzymes in lepromatous leprosy—a preliminary investigation. Kohli, M., *et al.* ..... (O) 20

Lepromin,
A critique on the interpretation of the lepromin reaction using heat-killed *M. leprae* vaccine. Mistry, N. F. and Antia, N. H. ..... (C) 110
Identification of "high risk group" of leprosy in children using serological and lepromin test: a preliminary report. Naik, S. S., *et al.* ..... (A) 910
Lepromin conversion induced by a "subunit" vaccine from ICRC bacilli. Bhatki, W. S., *et al.* ..... (A) 136
Lymphocyte blastogenesis and lepromin reactivity in leprosy patients and their parents. Foss, N. T., *et al.* ..... (A) 311
PGL-I independence of the lepromin (Mitsuda) reaction in pre-sensitized guinea pigs. Krotoski, W. A., *et al.* ..... (A) 309
Relative cross reactivity of habanin, lepromin and tuberculin in guinea pigs sensitized with homologous and heterologous mycobacteria. Singh, N. B., *et al.* ..... (A) 140
Reply by Gill, Mustafa and Godal (a critique on the interpretation of the lepromin reaction using heat-killed *M. leprae* vaccine). Gill, H. K., *et al.* ..... (C) 112
Ten-year study of lepromin response in child contacts of leprosy patients. Ramu, G. ..... (A) 715
The relationship between reactivities to lepromin A and soluble protein antigen of *M. leprae* and tuberculin. Pemajayantha, V., *et al.* ..... (A) 579
Un traitement logique des névrites lépreuses tuberculoides et borderline aigues ou subaigues: la désensibilisation progressive a la lépromine. Saint-André, P., *et al.* ..... (A) 339

Lesion(s),
A study of cutaneous lesions of leprosy on male genitalia. Arora, S. K., *et al.* ..... (A) 894
A study of palmo-plantar lesions in leprosy: a preliminary report. Arora, S. K., *et al.* ..... (A) 894
An electron microscopic study of lymphatics in the dermal lesions of human leprosy. Mukherjee, A., *et al.* ..... (O) 506
Assessment of histological features in leprosy lesions by histometry. Cree, I. A. and Beck, J. S. ..... (A) 576
Correlation of clinical and histopathologic features in untreated macular lesions of leprosy—a study of 100 cases. Shenoi, S. D. and Siddappa, K. ..... (A) 135
Evolution of leprosy lesions in man. Chacko, C. J. G. ..... (A) 344
Eye lesions in leprosy. Soshamma, G. and Suryawanshi, N. ..... (A) 896
Multibacillary lesions in nerves of patients with primary neuritic leprosy. Jacob, M. and Mathai, R. ..... (A) 338
Relationships between oro-facial lesions, mutilations and periodontal status in leprosy patients in Lo-Sheng Sanatorium at Taiwan. Wong, M.-Y. and Chang, W.-K. ..... (A) 897
Single lesion subpolar lepromatous leprosy and its possible mode of origin. Job, C. K., *et al.* ..... (O) 12
Site of early lesions in leprosy. Mathur, D., *et al.* ..... (A) 306

Skin lesion in strain 13 guinea pig induced by a human non-myelin antigen in dorsal roots. Crawford, C. L., *et al.* ....(A) 308
The anatomical distribution of single leprosy lesions in an African population, and its implications for the pathogenesis of leprosy. Ponnighaus, J. M., *et al.* ....(A) 307

Leukocyte(s),
Leucocytic alkaline phosphatase activity, marker of evolution in leprosy? Guillet, G., *et al.* ....(A) 133
Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine. Zeis, B. M., *et al.* ....(A) 733

Lipid,
Methionine as methyl-group donor in the synthesis of *M. avium* envelope lipids, and its inhibition by DL-ethionine, D-norleucine and DL-norleucine. David, H. L., *et al.* ....(A) 914
Studies on lipids in mycobacterial cell wall: their important structure and function relating to pathogenicity and their biological activity. Bera, A. and Banerjee, A. ....(A) 905

Lipoarabinomannan (LAM),
Lipoarabinomannan and lipomannan. Hunter, S. W. and Brennan, P. J. ....(A) 321
Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Sibley, L. D., *et al.* ....(A) 140
Use of an antigen-capture assay for characterization of monoclonal antibodies to mycobacterial lipoarabinomannan. Khanolkar, S. R., *et al.* ....(A) 901

Lipoprotein,
Estimation of high density lipoprotein cholesterol in the diagnosis of lepromatous leprosy. Kumar, N., *et al.* ....(A) 571

Liver,
A study of incidence of Australia antigen and derangements in liver function tests in leprosy. Nayak, K. C., *et al.* ....(A) 710

Lucio leprosy,
Contemplative immune mechanism of Lucio phenomenon and its global status. Sehgal, V. N., *et al.* ....(A) 135

Lupus,
Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine. Zeis, B. M., *et al.* ....(A) 733

Lymph node(s), lymphatics,
An electron microscopic study of lymphatics in the dermal lesions of human leprosy. Mukherjee, A., *et al.* ....(O) 506
Lymph node studies in 30 necropsies of leprosy patients. Fleury, R. N. and Opromolla, D. ....(A) 344
Presence of *M. leprae*-reactive lymphocytes in lymph nodes of lepromatous leprosy patients. Desai, S. D., *et al.* ....(A) 137

Lymphocyte(s),
[Changes in the system of T-lymphocyte cyclic nucleotides in animals with experimental tuberculosis.] Kostromin, A. P., *et al.* ....(A) 591
Characterization of *M. leprae* cell wall-associated proteins with the use of T lymphocyte clones. Mehra, V., *et al.* ....(A) 715
Differential recognition of *Leishmania aethiopica* antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Akuffo, H. O., *et al.* ....(A) 727
Effect of *M. leprae*-infected Schwann cells and their supernatant on lymphocyte neuroglia interaction. Mehta, R., *et al.* ....(A) 902
Glucocorticoid receptor and lymphocytes in leprosy. Sheriff, S., *et al.* ....(A) 313
Identification of mycobacterial antigens recognized by T lymphocytes. Lamb, J. R., *et al.* ....(A) 714
Immunohistologic pattern of the portal T-lymphocyte infiltration in hepatic allograft rejection. Perkins, J. D., *et al.* ....(A) 918
Lymphocyte blastogenesis and lepromin reactivity in leprosy patients and their parents. Foss, N. T., *et al.* ....(A) 311

Lymphocytotoxins in leprosy. Kaur, I., *et al.* ..... (A) 900
Presence of *M. leprae*-reactive lymphocytes in lymph nodes of lepromatous leprosy patients. Desai, S. D., *et al.* ..... (A) 137
T lymphocytes, mononuclear phagocytes, Schwann cells and *M. leprae*. Kaufmann, S. H. E., *et al.* ..... (A) 900

Macrophage(s),
Aggregation phenomenon of cultivated blood macrophages isolated from leprosy patients. Yamagami, A., *et al.* ..... (C) 873
Bacterial antigen processing in macrophages infected with the obligate intracellular bacterium, *M. avium*. de Chastellier, C. and Lang, T. ..... (A) 914
Comparative intracellular growth of difficult-to-grow and other mycobacteria in a macrophage cell line. Rastogi, N., *et al.* ..... (A) 920
Correlation between macrophage activation and bactericidal function of *M. leprae* antigen presentation in macrophages of leprosy patients and normal individuals. Desai, S. D., *et al.* ..... (A) 712
Effects of *in vitro* formed immune complexes on macrophage functions of *M. leprae* infected mice. Vaishnavi, C., *et al.* ..... (A) 141
Evidence that host-recycling of *M. avium* preserves its ability to hinder macrophage killing functions. Frehel, C., *et al.* ..... (A) 915
Infection with live mycobacteria inhibits *in vitro* detection of Ia antigen on macrophages. Mshana, R. N., *et al.* ..... (A) 150
Macrophage activity in resistant and susceptible mouse strains infected with *M. lepraemurium*. Brett, S. J. and Butler, R. ..... (A) 589
Macrophage mediated immune responses in the sciatic nerves of *M. leprae* infected nude mice with possible bystander and autoimmune demyelination—an electron microscopic study. Stanley, J. N. A., *et al.* ..... (A) 310
Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Sibley, L. D., *et al.* ..... (A) 140
Phagosome-lysosome fusions in macrophages infected with *M. avium*: role of mycosides-C and other cell surface components. Frehel, C. and Rastogi, N. ..... (A) 915
Purification of *M. leprae* with special reference to the effects of purified *M. leprae* vaccines and host macrophage cell functions. Saito, H., *et al.* ..... (A) 904
Receptor-mediated drug delivery to macrophages in chemotherapy of leishmaniasis. Mukhopadhyay, A., *et al.* ..... (A) 918
Resistance of *M. avium* to microbicidal activities in bone-marrow macrophages from naturally susceptible (C57BL/6) and naturally resistant (DBA-2) mice. Rastogi, N. and Frehel, C. ..... (A) 920
Selective coating of *M. leprae* surface antigens by species and genus-specific mycobacterial antibodies and its effect on phagosome-lysosome fusions in *M. leprae*-infected macrophages. Rastogi, N. and Frehel, C. ..... (A) 326
The effect of clofazimine in cell mediated immunity: interference with antigen processing and presentation by macrophages. Brown, L. M., *et al.* ..... (A) 315
The effect of phenolic glycolipid-I from *M. leprae* on the antimicrobial activity of human macrophages. Neill, M. A. and Klebanoff, S. J. ..... (A) 139
The macrophage in leprosy: a review on the current status. Birdi, T. J. and Antia, N. H. ..... (E) 511

Malawi,
A new concept of staging paucibacillary leprosy and its application to the analysis of post-treatment results of a MDT study in Malawi. Boerrigter, G. and Ponnighaus, J. M. ..... (A) 306
Disabilities in leprosy patients ascertained in a total population survey in Karonga District, northern Malawi. Ponnighaus, I. M., *et al.* ..... (A) 314
Leprosy in Malawi. 1. Sensitivity and specificity of the diagnosis and the search for risk factors for leprosy. Ponnighaus, J. M. and Fine, P. E. M. ..... (A) 572
Leprosy in Malawi. 2. Background, design and prospects of the Karonga Prevention Trial, a leprosy vaccine trial in northern Malawi. Fine, P. E. M. and Ponnighaus, J. M. ..... (A) 586
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia,

Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization. ..... (B) 122
The distribution and implications of BCG scars in northern Malawi. Fine, P. E. M., *et al.* ..... (A) 728

Martinique,
Double résistance RMP-dapsone dans 12 souches de *M. leprae* en Martinique: étude rétrospective, analyse des causes et prospective. Constant-Desportes, M., *et al.* ..... (A) 335

Metabolism,
Certain aspects of dapsone metabolism in leprosy patients as studied by high performance liquid chromatography (HPLC) and qualitative screening tests. Irudaya Raj, P. P., *et al.* ..... (A) 129
Lymphocytic purine metabolic disorders in tuberculin anergic mice. Senesi, S., *et al.* ..... (A) 594
Metabolism in *M. leprae, M. tuberculosis* and other pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. ..... (A) 143
Plasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients. Garg, S. K., *et al.* ..... (A) 708

Mice, murine,
A histopathological study of pulmonary infection of mice with *M. lepraemurium.* Ha, D. K. K., *et al.* ..... (A) 590
Amikacin, ciprofloxacin, and imipenem treatment for disseminated *M. avium* complex infection of beige mice. Inderlied, C. B., *et al.* ..... (A) 591
Characteristics of the multiplication of dapsone-resistant strains of *M. leprae* in mice. THELEP Clinical Trials Subcommittee ..... (A) 131
Comparison of cell-mediated immune responses to *M. leprae* in mice following successful infection with *M. leprae* or immunization with killed *M. leprae.* Mshana, R. N., *et al.* ..... (A) 309
[Development of experimental infection with *M. lepraemurium* in two strains of mice.] Roggero, E., *et al.* ..... (A) 731
Effect of suppressor cells on antibody producing cells in mice infected with *M. leprae.* Vaishnavi, C., *et al.* ..... (A) 718
Effects of *in vitro* formed immune complexes on macrophage functions of *M. leprae* infected mice. Vaishnavi, C., *et al.* ..... (A) 141
Evaluation of the efficacy of candidate vaccines against *M. leprae* infection in mice. Sreevatsa and Desikan, K. V. ..... (A) 141
Evaluation of the efficacy of candidate vaccines against *M. leprae* infection in mice. Desikan, K. V. and Sreevatsa ..... (A) 349
Evidence for phagosome-lysosome fusion in *M. leprae*-infected murine Schwann cells. Steinhoff, U., *et al.* ..... (A) 717
Glomerular immunoglobulin deposition in the absence of tissue damage in murine leprosy. Rojas-Espinosa, O., *et al.* ..... (C) 879
Humoral immune responses in dapsone treated *M. leprae* infected mice. Srinivasan, P. and Rao, P. R. ..... (A) 910
Influence of *in vitro* administered immune complexes on serum levels of complement and circulating immune complexes in *M. leprae* infected mice. Vaishnavi, C., *et al.* (A) 586
Limiting dilution of murine T cell response to mycobacterial antigens. Launois, P., *et al.* ..... (A) 901
Lymphocytic purine metabolic disorders in tuberculin anergic mice. Senesi, S., *et al.* ..... (A) 594
Macrophage activity in resistant and susceptible mouse strains infected with *M. lepraemurium.* Brett, S. J. and Butler, R. ..... (A) 589
Pefloxacin and ofloxacin activities against *M. leprae* in the mouse. Guelpa-Lauras, C.-C., *et al.* ..... (A) 316
Protection of mice by vaccines from cell walls of *M. leprae.* Gelber, R., *et al.* ..... (A) 349
[Reproduction of experimental leprosy infection in mice with previously induced insufficiency of mononuclear phagocyte system.] Vishnevetsky, F. E., *et al.* ..... (A) 910
Resistance of *M. avium* to microbicidal activities in bone-marrow macrophages from naturally susceptible (C57BL/6) and naturally resistant (DBA-2) mice. Rastogi, N. and Frehel, C. ..... (A) 920

Response of the murine hematopoietic system to chronic infection with *M. lepraemurium*. Resnick, M., *et al.* ....(A) 593
Serum lactate dehydrogenase in murine leprosy: source and isozymes. Luna Herrera, J. and Rojas-Espinosa, O. ....(O) 641
The activity of minocycline against *M. leprae*-infected mice. Gelber, R., *et al.* ....(A) 317
Vaccination of mice against *M. leprae* infection. Singh, N. B., *et al.* ....(A) 717

Mice, nude,
Attempts to select rifampicin-resistant *M. leprae* in nude mice. McDermott-Lancaster, R. D., *et al.* ....(A) 350
Effect of lyophilization on viability of *M. leprae* multiplied in nude mouse. Nakamura, M. and Kohsaka, K. ....(A) 908
M. leprae-susceptibility of NOD hybrid nude mice. Yogi, Y. and Nakamura, K. ....(A) 722
Macrophage mediated immune responses in the sciatic nerves of *M. leprae* infected nude mice with possible bystander and autoimmune demyelination—an electron microscopic study. Stanley, J. N. A., *et al.* ....(A) 310
Non-immune clearance of *M. leprae* from the footpads of *M. leprae*-infected, multidrug-treated nude mice. Chehl, S. K., *et al.* ....(A) 349
The nude mouse as an experimental lepromatous leprosy model (continued): the NFS/N nude mouse as a new model using the intra-upper lip inoculation method. Nakamura, K. and Yogi, Y. ....(A) 721

Microscopy,
Immuno-electron microscopy of mycobacterial granulomas in the sciatic nerves of guinea pigs. Cowley, S. A., *et al.* ....(A) 310
Reliability of direct skin smear microscopy in leprosy. Gupte, M. D., *et al.* ....(A) 570

Minocycline,
The activity of minocycline against *M. leprae*-infected mice. Gelber, R., *et al.* ....(A) 317

Mitsuda reaction,
Specific anti-*M. leprae* PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., *et al.* ....(O) 794

Monkey(s),
Intraocular pressure changes with posture in experimentally induced Hansen's disease of mangabey and African green monkeys. Hussein, N., *et al.* ....(A) 354
Leprosy in three species of monkeys—an overview. Walsh, G. P., *et al.* ....(A) 310
Ontogenesis of antibodies in rhesus monkeys infected with *M. leprae*. Mukherjee, R., *et al.* ....(A) 309
Serologic responses to *M. leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* ....(A) 309

Monocyte(s),
Differences in uptake of mycobacteria by human monocytes; a role for complement. Swartz, R. P., *et al.* ....(A) 595
Killing of human monocytes by specific cytotoxic T cells and nonspecific, MHC unrestricted killer cells after activation by mycobacterial antigens. Kaleab, B., *et al.* ....(A) 311
Suppression of monocyte oxidative response by phenolic glycolipid I of *M. leprae*. Vachula, M., *et al.* ....(A) 718

Morocco,
Bilan de sept années d'énquetes systématiques de la lèpre au Maroc. Sekkat, A., *et al.* ....(A) 324

Morphology,
An electron microscopic study of alterations in the morphology and permeability of purified *M. leprae*. Prabhakaran, K., *et al.* ....(A) 720
Hepatic morphology in reactional states of leprosy. Patnaik, J. K., *et al.* ....(O) 499
Morphology of *M. leprae* (?) in VS3E medium—a preliminary communication. Bhatia, V. N. and Rao, S. ....(A) 906

Morphological index (MI),
Effect of chemotherapy on viability of *M. leprae* as determined by ATP content, morphological index and FDA-EB fluorescent staining. Katoch, V. M., *et al.* ....(O) 615

Multidrug therapy (MDT),
A bacteriological assessment of multibacillary cases in leprosy colonies after 4½ years of multidrug therapy. Naik, S. S., *et al.* ..... (A) 129
A new concept of staging paucibacillary leprosy and its application to the analysis of post-treatment results of a MDT study in Malawi. Boerrigter, G. and Ponnighaus, J. M. ..... (A) 306
Changes in epidemiological indices following introduction of WHO MDT into domiciliary HD programme. Rose, P. ..... (A) 333
Computerized management information system (COMIS) for monitoring MDT programme for leprosy. Revankar, C. R., *et al.* ..... (A) 331
Effect of multidrug therapy on the levels of antibodies to *M. leprae* glycolipid-I in the leprosy spectrum. Vaishnavi, C., *et al.* ..... (A) 580
[Effects of MDT on multibacillary leprosy for three years.] Li, W., *et al.* ..... (A) 567
Epidemiological impact of multidrug therapy in Gudiyatham control area, Karigiri. Rao, P. S. S., *et al.* ..... (A) 331
[Factors influencing the compliance of patients in MDT therapy in Anhui Province.] Xu, R., *et al.* ..... (A) 131
Five years of experience with MDT in the ALERT leprosy control programme. Desta, Z. and Becx-Bleumink, M. ..... (A) 335
Follow up of T cell subsets and anti-trisaccharide IgM antibody levels of leprosy patients during daily multidrug therapy. Desforges, S., *et al.* ..... (A) 899
Gradual setting up of multidrug therapy (WHO-MDT) in Brazil. Oliveira, M. L. W., *et al.* ..... (A) 333
[Guinea: detection of leprosy and multidrug therapy.] Bourée, P., *et al.* ..... (A) 565
Impact of MDT on incidence rates of leprosy among household contacts. Part 1. Baseline data. Sundar Rao, P. S. S., *et al.* ..... (O) 647
Impact of MDT on leprosy as measured by selective indicators. Jesudasan, K., *et al.* ..... (A) 145
Impact of multidrug therapy on leprosy in Baroda District (Gujarat). Chopra, N. K., *et al.* ..... (A) 892
Lactate dehydrogenase isoenzymes in leprosy patients on multidrug therapy—a preliminary report. Dhandayuthapani, S. and Bhatia, V. N. ..... (A) 132
Lepra reactions and disabilities in patients treated with daily MDT in New Caledonia, French Polynesia and Guadeloupe. Bobin, P., *et al.* ..... (A) 313
Leprosy control in the state of Amazonas, based on MDT (WHO/82). Talhari, S., *et al.* ..... (A) 334
Leprosy control through multidrug therapy using primary health care approach. Lopez-Bravo, L. and Noordeen, S. K. ..... (A) 330
Multidrug therapy—an effective tool in leprosy control programme. Rao, B. R. ..... (A) 331
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization. ..... (B) 122
Multidrug therapy for treatment of paucibacillary leprosy: the western Kenya experience. Orege, P. A., *et al.* ..... (A) 341
Multidrug therapy in paucibacillary leprosy—a five year experience. Grugni, A., *et al.* ..... (A) 567
Multiterapia de la lepra. Terencio de las Aguas, J. and Gomez Echevarria, J. R. ..... (A) 324
Operational aspects of multidrug therapy. Becx-Bleumink, M. ..... (E) 540
Patterns of relapses in paucibacillary leprosy patients treated with MDT (WHO 1982). Reddy, P. K. and Mohinuddin, S. K. ..... (A) 568
Paucibacillary leprosy: a comparative study of different schedules of multidrug therapy. Ramakrishnan, K. R., *et al.* ..... (A) 567
Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988. ..... (B) 124
Reactions in leprosy: a study of 250 patients in MDT project, Baroda District (Gujarat). Chopra, M. K., *et al.* ..... (A) 313
Relapse of paucibacillary leprosy after short course multidrug therapy. Pavithran, K. ..... (A) 130
Relapses after multidrug therapy for leprosy: a preliminary report on 22 cases in West Nepal. van Brakel, W., *et al.* ..... (A) 894
Results after 5 years of multidrug therapy (MDT) according to WHO recommendations for leprosy patients in Curupaiti (Brazil). Andrade, V. L. G., *et al.* ..... (A) 335

Results after 8 years of a daily multidrug therapy for leprosy patients in Guadeloupe, New Caledonia and Polynesia. Cartel, J. L., *et al.* ..... (A) 335
Selection of MDT strategies through epidemiometric modeling. Lechat, M. F., *et al.* .. (A) 323
Short-term multidrug therapy in multibacillary leprosy—review of 80 cases in two provinces of China (1983–1988). Li, H.-Y., *et al.* ..... (O) 622
Surveillance and relapse rates after MDT in over 700 paucibacillary leprosy cases—a two years follow up at Purulia, India. Casablanca, M. N. and Nayagam, A. S. ..... (A) 339
Technical problems related to multidrug therapy in leprosy control. Sansarricq, H. .... (A) 324
The eye in multidrug therapy. Rajan, M. A. ..... (A) 355
The global leprosy situation and the implementation of leprosy control through multidrug therapy. Noordeen, S. K. and Lopez-Bravo, L. ..... (A) 324
[Treatment of multibacillary leprosy with MDT for one year.] Cui, C., *et al.* ..... (A) 128
WHO MDT regime in Molucas Province (East Indonesia), January 1982–December 1987. Louhenapessy, A. and Sugiene, R. ..... (A) 336
WHO multidrug therapy—a review of 956 domiciliary patients starting MDT between December 1981 and December 1987. Benjamin-Huntley, R. and Rose, P. ..... (A) 335

Mycobacteria (see also individual species),
Analysis of mycobacterial ribosomal RNA. Estrada-G., I., *et al.* ..... (A) 327
Comparative intracellular growth of difficult-to-grow and other mycobacteria in a macrophage cell line. Rastogi, N., *et al.* ..... (A) 920
Comparative studies of antigenic glycolipids of mycobacteria related to the leprosy bacillus. Minnikin, D. E., *et al.* ..... (A) 908
Comparison of sensitivity of *Mycobacterium* spp. to combinations of clavulanic acid & penicillins with certain antitubercular agents. Bhattacharya, C. P., *et al.* ..... (A) 589
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* ..... (A) 914
[Determination of antibodies to mycobacterial antigens in tuberculosis by the method of erythroimmunoadsorption with a rosette marker.] Plaksin, D. Y., *et al.* ..... (A) 140
Development of genetic systems for the mycobacteria. Jacobs, W. R., Jr., *et al.* ..... (A) 907
Differences in uptake of mycobacteria by human monocytes; a role for complement. Swartz, R. P., *et al.* ..... (A) 595
Do environmental mycobacteria influence the distribution of disease in the leprosy spectrum? Bacteriological and skin test studies carried out in Iran. Velayati, A., *et al.* ..... (A) 320
Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65 kDa) in culture filtrates of mycobacteria. de Bruyn, J., *et al.* ..... (A) 590
Effects of freezing-thawing of *M. leprae* and cultivable mycobacteria. Portaels, F., *et al.* ..... (A) 329
Further evidence for an extended capsule of pathogenic mycobacteria. Draper, P. ..... (A) 321
Identification of mycobacterial antigens recognized by T lymphocytes. Lamb, J. R., *et al.* ..... (A) 714
In vitro activity of seventeen antimicrobial compounds against seven species of mycobacteria. Collins, C. G. and Uttley, A. H. C. ..... (A) 728
Insertion elements in mycobacteria. Green, E. P., *et al.* ..... (A) 916
Investigation of the effect of heat enhancement on the growth of mycobacteria in radiometric medium. Cutler, S. J. ..... (A) 589
Isoenzyme profiles in slowly growing and difficult-to-grow mycobacteria. Blom-Potar, M.-C., *et al.* ..... (A) 912
LDH isoenzyme as a tool for the identification of mycobacteria. Dhandayuthanpani, S., *et al.* ..... (A) 728
Non-cultivable mycobacteria in ulcers of the skin. Salem, J. I., *et al.* ..... (A) 920
Pyrimidine biosynthesis in *M. leprae* and other intracellular mycobacteria. Wheeler, P. R. ..... (A) 909
Rapid and precise diagnosis of atypical mycobacterial infection by chemotaxonomical and immunological methods. Ikawa, H., *et al.* ..... (A) 916
Reduction of tellurite and deesterification of fluorescein diacetate are not well correlated with the viability of mycobacteria. Mor, N., *et al.* ..... (A) 142
Sensitisation by mycobacteria and the effects of BCG on children attending schools in the slums of Bombay. Stanford, J. L., *et al.* ..... (A) 595

Serology of mycobacteria: characterization of antigens recognized by monoclonal antibodies. Young, D. B. and Mehlert, A. ..... (A) 719
Serum antibody responses to mycobacteria in leprosy patients and their contacts. Cree, I. A., *et al.* ..... (A) 576
Size and homology of the genomes of leprosy-derived corynebacteria, *M. leprae,* and other corynebacteria and mycobacteria. Antoine, I., *et al.* ..... (A) 142
Stress proteins and the immune response to mycobacteria—antigens as virulence factors? Young, D. B., *et al.* ..... (A) 582
Structure and function of mycobacterial glycolipids and glycopeptidolipids. Chatterjee, D., *et al.* ..... (A) 906
Structure of mycobacteria: recent developments in defining cell wall carbohydrates and proteins. Brennan, P. J. ..... (A) 712
Studies on lipids in mycobacterial cell wall: their important structure and function relating to pathogenicity and their biological activity. Bera, A. and Banerjee, A. ..... (A) 905
Studies on ribosomal RNA genes of mycobacteria including *M. leprae.* Katoch, V. M., *et al.* ..... (A) 907
The 65 kilodalton antigen of mycobacteria. Shinnick, T. ..... (A) 329
The influence of associated mycobacteria on the growth and pathogenicity of *M. leprae.* Kazda, J. ..... (A) 322
Use of a cutoff range in identifying mycobacteria by the Gen-Probe rapid diagnostic system. Sherman, I., *et al.* ..... (A) 594
Use of monoclonal antibodies in the identification of mycobacterial antigens. Kolk, A. H. J., *et al.* ..... (A) 322

***Mycobacterium avium, M. avium* complex,**

Ability of smooth and rough variants of *M. avium* and *M. intracellulare* to multiply and survive intracellularly: role of C-mycosides. Rastogi, N., *et al.* ..... (A) 730
Amikacin, ciprofloxacin, and imipenem treatment for disseminated *M. avium* complex infection of beige mice. Inderlied, C. B., *et al.* ..... (A) 591
Antimicrobial synergism against *M. avium* complex strains isolated from patients with acquired immune deficiency syndrome. Yajko, D. M., *et al.* ..... (A) 596
Bacterial antigen processing in macrophages infected with the obligate intracellular bacterium, *M. avium.* de Chastellier, C. and Lang, T. ..... (A) 914
Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for *M. avium* complex. Lindholm-Levy, P. J. and Heifets, L. B. ..... (A) 149
Comparative *in vitro* and *in vivo* activity of rifabutin and rifampicin against *M. avium* complex. Saito, H., *et al.* ..... (A) 150
Concentration of *M. avium* by hospital hot water systems. du Moulin, G. C., *et al.* ..... (A) 590
Correlations among naturally occurring resistances to antituberculosis drugs in *M. avium* complex strains. Tsukamura, M. and Miyachi, T. ..... (A) 920
Evidence that host-recycling of *M. avium* preserves its ability to hinder macrophage killing functions. Frehel, C., *et al.* ..... (A) 915
Genetic relatedness among *M. paratuberculosis* and *M. avium* complex. Labidi, A. and Thoen, C. O. ..... (A) 917
Host defense against *M. avium* complex. Schnittman, S., *et al.* ..... (A) 594
Human gut wall reactivity to monoclonal antibodies against *M. avium* glycolipid in relation to Crohn's disease (preliminary results). Blaauwgeers, J. L. G., *et al.* ..... (A) 912
Identification and partial characterization of *M. avium* and *M. intracellulare* by using DNA probes. Saito, H., *et al.* ..... (A) 731
Improved detection of *M. avium* complex with the BACTEC radiometric system. Hoffner, S. E. ..... (A) 590
M. avium-intracellulare infection associated with hairy-cell leukemia. Maurice, P. D. L., *et al.* ..... (A) 149
Methionine as methyl-group donor in the synthesis of *M. avium* envelope lipids, and its inhibition by DL-ethionine, D-norleucine and DL-norleucine. David, H. L., *et al.* ..... (A) 914
Phagosome-lysosome fusions in macrophages infected with *M. avium*: role of mycosides-C and other cell surface components. Frehel, C. and Rastogi, N. ..... (A) 915

Resistance of *M. avium* to microbicidal activities in bone-marrow macrophages from naturally susceptible (C57BL/6) and naturally resistant (DBA-2) mice. Rastogi, N. and Frehel, C. ..... (A) 920
Serologic and immunocytochemical analysis of the *M. avium* cell envelope. David, H. L., *et al.* ..... (A) 914
Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on *M. avium* complex. Hoffner, S. E., *et al.* ..... (A) 916
Susceptibilities of *M. leprae* and *M. avium* complex to the H_2O_2-Fe-mediated halogenation system supplemented with antimicrobial agents. Tomioka, H., *et al.* ..... (O) 628
The hamster model of chronic *M. avium* complex infection. Yangco, B. G., *et al.* ..... (A) 732
The use of DNA probes identifying restriction-fragment-length polymorphisms to examine the *M. avium* complex. McFadden, J. J., *et al.* ..... (A) 149

Mycobacterium bovis,
Genetic relatedness among *M. tuberculosis* and *M. bovis.* Labidi, A. and Thoen, C. O. ..... (A) 917
Homology of the 70-kilodalton antigens from *M. leprae* and *M. bovis* with the *M. tuberculosis* 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., *et al.* ..... (A) 583
In-vitro susceptibility of *M. tuberculosis, M. bovis* and *M. kansasii* to amoxycillin and ticarcillin in combination with clavulanic acid. Wong, C. S., *et al.* ..... (A) 732
Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* ..... (A) 717

Mycobacterium fortuitum,
Beta-lactamase production and biological characteristics in nitrosoguanidine induced *M. fortuitum* mutants. Fattorini, L., *et al.* ..... (A) 914
Isoenzymes as tools to discriminate various subdivisions in the *M. fortuitum* complex. Blom-Potar, M.-C., *et al.* ..... (A) 913
Structure of pAL5000, a plasmid from *M. fortuitum* and its utilization in transformation of mycobacteria. Gicquel-Sanzey, B., *et al.* ..... (A) 906

Mycobacterium habana,
Use of nonconventional antigen, *M. habana,* in detecting *M. leprae* antibodies from leprosy patients and contacts in FLA-ABS test. Rana, N. S., *et al.* ..... (A) 580

Mycobacterium intracellulare,
Ability of smooth and rough variants of *M. avium* and *M. intracellulare* to multiply and survive intracellularly: role of C-mycosides. Rastogi, N., *et al.* ..... (A) 730
Identification and partial characterization of *M. avium* and *M. intracellulare* by using DNA probes. Saito, H., *et al.* ..... (A) 731

Mycobacterium leprae,
A 28-kDa protein from *M. leprae* is a target of the human antibody response in lepromatous leprosy. Cherayil, B. J. and Young, R. A. ..... (A) 575
A component of *M. leprae* as a serodiagnostic tool for leprosy. Ranade, A. and Mahadevan, P. R. ..... (A) 903
A critique on the interpretation of the lepromin reaction using heat-killed *M. leprae* vaccine. Mistry, N. F. and Antia, N. H. ..... (C) 110
A *M. leprae*-specific human T cell epitope cross-reactive with an HLA-DR2 peptide. Anderson, D. C., *et al.* ..... (A) 136
A peptidoglycan protein complex purified from *M. leprae* cell walls contains most or all immunodominant *M. leprae* T-cell antigens. Mutis, T., *et al.* ..... (O) 788
A protein antigen of *M. leprae* is related to a family of small heat shock proteins. Nerland, A. H., *et al.* ..... (A) 585
A species-specific repetitive sequence in *M. leprae* DNA. Clark-Curtiss, J. E. and Docherty, M. A. ..... (A) 583
A study of the relatedness of *M. leprae* isolates using restriction fragment length polymorphism analysis. Williams, D. L. and Gillis, T. P. ..... (A) 909
An electron microscopic study of alterations in the morphology and permeability of purified *M. leprae.* Prabhakaran, K., *et al.* ..... (A) 720
Appraisal of two *M. leprae*-specific serological assays for monitoring chemotherapy in lepromatous (LL/BL) leprosy patients. Sinha, S., *et al.* ..... (O) 24

Attempts to select rifampicin-resistant *M. leprae* in nude mice. McDermott-Lancaster, R. D., *et al.* ..... (A) 350
Benefits of recombinant DNA technology for the study of *M. leprae.* Clark-Curtiss, J. E. ..... (A) 906
Characteristics of the multiplication of dapsone-resistant strains of *M. leprae* in mice. THELEP Clinical Trials Subcommittee ..... (A) 131
Characterization and taxonomic implications of the rRNA genes of *M. leprae.* Sela, S., *et al.* ..... (A) 585
Characterization of an antibody-binding epitope from the 18-kDa protein on *M. leprae.* Doherty, T. M., *et al.* ..... (A) 719
Characterization of *M. leprae* cell wall-associated proteins with the use of T lymphocyte clones. Mehra, V., *et al.* ..... (A) 715
Comparative biochemical analysis of the genomes of leprosy associated bacteria (*M. leprae,* LDC and ADM). Coene, M., *et al.* ..... (A) 320
Construction of genomic library of *M. leprae* gene and its expression in *Streptomyces lividans.* Makino, M., *et al.* ..... (A) 328
Cultivation of *M. leprae*: a new approach. Bapat, C. V. ..... (C) 874
Detection of a specific *M. leprae* antigen in the urine of leprosy patients. Mahon, A. C., *et al.* ..... (A) 326
[Determination of the viability of *M. leprae* with fluorescent staining.] Meng, M., *et al.* ..... (A) 584
Double résistance RMP-dapsone dans 12 souches de *M. leprae* en Martinique: étude rétrospective, analyse des causes et prospective. Constant-Desportes, M., *et al.* ..... (A) 335
Effect of chemotherapy on viability of *M. leprae* as determined by ATP content, morphological index and FDA-EB fluorescent staining. Katoch, V. M., *et al.* ..... (O) 615
Effect of lyophilization on viability of *M. leprae* multiplied in nude mouse. Nakamura, M. and Kohsaka, K. ..... (A) 908
Effect of *M. leprae*-infected Schwann cells and their supernatant on lymphocyte neuroglia interaction. Mehta, R., *et al.* ..... (A) 902
[Effect of removal of the popliteal ganglion on multiplication of *M. leprae* in the mouse foot-pad: preliminary report.] Moreno, O. S. and Silveira, J. R. ..... (A) 143
Effects of a derivative of serotonin (deoxyfructoserotonin) and other antileprosy drugs on attachment and uptake of *M. leprae* by Schwann cells *in vitro.* Chaudhury, A., *et al.* ..... (A) 893
Effects of freezing-thawing of *M. leprae* and cultivable mycobacteria. Portaels, F., *et al.* ..... (A) 329
Evidence for phagosome-lysosome fusion in *M. leprae*-infected murine Schwann cells. Steinhoff, U., *et al.* ..... (A) 717
Expression in recombinant *E. coli* of biotinylated proteins of *M. leprae.* Moss, M. T. and Dale, J. W. ..... (A) 327
Expression of the *M. leprae* 18 kD protein. Stoker, N. G., *et al.* ..... (A) 329
Expression, purification and immunologic activity of recombinant 65-kilodalton protein of *M. leprae.* Gillis, T. P. and Williams, D. L. ..... (A) 328
Filamentous phase in life cycle of *M. leprae*(?): a preliminary communication. Bhatia, V. N. ..... (A) 142
Fluorescent staining procedure (FDA/EB) for determining the viability of *M. leprae.* Meng, M.-B., *et al.* ..... (A) 322
Genetic relationships among *M. leprae, M. tuberculosis,* and candidate leprosy vaccine strains determined by DNA hybridization: identification of an *M. leprae*-specific repetitive sequence. Grosskinsky, C. M., *et al.* ..... (A) 719
Genomic and amino acid sequence of the *M. leprae* 70 kD antigen is homologous to the higher conserved 70 kD heat shock protein (hsp70) of eukaryotes. Garsia, R. J., *et al.* ..... (A) 318
Homology of the 70-kilodalton antigens from *M. leprae* and *M. bovis* with the *M. tuberculosis* 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., *et al.* ..... (A) 583
Identification of *M. leprae* antigens in tissues of leprosy patients using monoclonal antibodies. Khanolkar, S. R., *et al.* ..... (O) 652
Immunogold labeling method for *M. leprae*-specific phenolic glycolipid in glutaraldehyde-osmium-fixed and araldite-embedded leprosy lesions. Boddingius, J. and Dijkman, H. P. ..... (A) 913

In vitro cultivation of *M. leprae* under microaerophilic conditions. Ishaque, M. .....(A) 321
In vitro interaction of *M. leprae*-infected Schwann cells and splenic cells. Mehra, R., *et al.* .....(A) 579
In vitro screening of antileprosy drugs by mass spectrometric analysis of *M. leprae.* Lindner, B., *et al.* .....(A) 350
Intracellular parasitism of parenchymal cells by *M. leprae.* Job, C. K., *et al.* .....(O) 659
Investigations into cultivation of *M. leprae* under low oxygen tension. Ishaque, M. ....(C) 115
Isolation and characterization of the highly immunogenic cell wall-associated protein of *M. leprae.* Hunter, S. W., *et al.* .....(A) 713
Limited *in vitro* multiplication of *M. leprae.* Dhople, A. M., *et al.* .....(A) 320
M. leprae persisters in patients treated with rifampicin and acedapsone. Gonzalez, A. B., *et al.* .....(A) 335
Measurement of ATP content of *M. leprae*—its application to the determination of viability and drug sensitivity screening. Katoch, V. M., *et al.* .....(A) 321
Metabolism in *M. leprae, M. tuberculosis* and other pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. .....(A) 143
Molecular relatedness among *M. leprae* isolates defined using recombinant DNA probe. Clark-Curtiss, J. E. .....(A) 327
Monitoring of *in vivo* response of *M. leprae* to antileprosy therapies. Haas, M., *et al.* ..(A) 350
Morphology of *M. leprae* (?) in VS3E medium—a preliminary communication. Bhatia, V. N. and Rao, S. .....(A) 906
New data on the ultrastructure of the membrane of *M. leprae.* Silva, M. T., *et al.* .....(O) 54
Non-immune clearance of *M. leprae* from the footpads of *M. leprae*-infected, multidrug-treated nude mice. Chehl, S. K., *et al.* .....(A) 349
Preliminary results on the detection of mycolic acids from *M. leprae* by gel permeation chromatography and proton nuclear resonance spectroscopy. Gan, S. C., *et al.* .....(A) 583
Presence of mycobactin-like substance in *M. leprae.* Dhople, A. M. and Osborne, L. J. .....(A) 142
Purification of *M. leprae* with special reference to the effects of purified *M. leprae* vaccines and host macrophage cell functions. Saito, H., *et al.* .....(A) 904
Pyrimidine biosynthesis *de novo* in *M. leprae.* Wheeler, P. R. .....(A) 720
Pyrimidine biosynthesis in *M. leprae* and other intracellular mycobacteria. Wheeler, P. R. .....(A) 909
Pyrimidine scavenging by *M. leprae.* Wheeler, P. R. .....(A) 720
Recognition of M. leprae Antigens. Ottenhoff, T. and de Vries, R. R. P. .....(A) 139
Relapse in LL patients after antileprosy ICRC vaccine: its significance to antigenic variability of *M. leprae.* Bapat, C. V. .....(A) 349
Selective coating of *M. leprae* surface antigens by species and genus-specific mycobacterial antibodies and its effect on phagosome-lysosome fusions in *M. leprae*-infected macrophages. Rastogi, N. and Frehel, C. .....(A) 326
Size and homology of the genomes of leprosy-derived corynebacteria, *M. leprae,* and other corynebacteria and mycobacteria. Antoine, I., *et al.* .....(A) 142
Structure-activity relationships of selected phenazines against *M. leprae in vitro.* Franzblau, S. G. and O'Sullivan, J. F. .....(A) 566
Studies on energy synthesis in *M. leprae.* Bharadwaj, V. P., *et al.* .....(A) 906
Studies on ribosomal RNA genes of mycobacteria including *M. leprae.* Katoch, V. M., *et al.* .....(A) 907
Susceptibilities of *M. leprae* and *M. avium* complex to the H_2O_2-Fe-mediated halogenation system supplemented with antimicrobial agents. Tomioka, H., *et al.* .....(O) 628
T cell epitopes on the 36K and 65K *M. leprae* antigens defined by human T cell clones. van Schooten, W. C. A., *et al.* .....(A) 141
T cell responses to fractionated *M. leprae* antigens in leprosy. The lepromatous non-responder defect can be overcome *in vitro* by stimulation with high molecular weight *M. leprae* components. Ottenhoff, T., *et al.* .....(A) 326
The influence of associated mycobacteria on the growth and pathogenicity of *M. leprae.* Kazda, J. .....(A) 322
The large molecular mass cell wall protein of *M. leprae.* Hunter, S. W., *et al.* .....(A) 320
The primary structure of the 16SrRNA of *M. leprae*: its use in phylogeny and development of DNA probes. Stackebrandt, E., *et al.* .....(A) 908

The role of the 65-kDa protein in the immune response to *M. leprae.* Colston, M. J., *et al.* ....(A) 325
The use of a "universal" yeast expression vector to produce an antigenic protein of *M. leprae.* Booth, R. J., *et al.* ....(A) 575
Use of DNA probes to investigate the genetics of *M. leprae.* McFadden, J., *et al.* ....(A) 328
Viability of *M. leprae* in soil and dead armadillo tissue and its significance. Harris, E. B., *et al.* ....(A) 323

Mycobacterium lepraemurium,
A histopathological study of pulmonary infection of mice with *M. lepraemurium.* Ha, D. K. K., *et al.* ....(A) 590
[Development of experimental infection with *M. lepraemurium* in two strains of mice.] Roggero, E., *et al.* ....(A) 731
Macrophage activity in resistant and susceptible mouse strains infected with *M. lepraemurium.* Brett, S. J. and Butler, R. ....(A) 589
The role of CD8+ cells in resistance and delayed hypersensitivity reactions in *M. lepraemurium* infection. Curtis, J., *et al.* ....(A) 308

Mycobacterium marinum,
Specificity and antigenicity of mycoside G and other glycolipids from *M. marinum.* Cruaud, P., *et al.* ....(A) 913
Studies on adenylate kinase (ATP:AMP phosphotransferase) of *M. marinum* (ATCC 927). Batra, P. P., *et al.* ....(A) 912

Mycobacterium microti,
Biosynthesis of phenolic glycolipids in *M. microti.* Thurman, P. and Draper, P. ....(A) 920

Mycobacterium paratuberculosis,
Genetic relatedness among *M. paratuberculosis* and *M. avium* complex. Labidi, A. and Thoen, C. O. ....(A) 917

Mycobacterium smegmatis,
[Assay of antibody level in sera of leprosy patients with *M. smegmatis* ELISA.] Wu, Q., *et al.* ....(A) 718
Expression of heterologous genes by lysates of *M. smegmatis.* Lamb, F. I., *et al.* ....(A) 328
Human disease due to *M. smegmatis.* Wallace, R. J., Jr., *et al.* ....(A) 596
Transformation of *M. smegmatis* with *Escherichia coli* plasmids carrying a selectable resistance marker. Zainuddin, Z. F., *et al.* ....(A) 720

Mycobacterium tuberculosis,
A cloned DNA fragment for identification of *M. tuberculosis.* Patel, R. J., *et al.* ....(A) 730
Activation of γδ T cells in the primary immune response to *M. tuberculosis.* Janis, E. M., *et al.* ....(A) 900
Association of tuberculosis and *M. tuberculosis*-specific antibody levels with HLA. Bothamley, G. H., *et al.* ....(A) 727
Direct antimicrobial drug susceptibility testing of *M. tuberculosis* by the radiometric method. Libonati, J. P., *et al.* ....(A) 592
Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* ....(A) 917
Genetic relatedness among *M. tuberculosis* and *M. bovis.* Labidi, A. and Thoen, C. O. ....(A) 917
Genetic relationships among *M. leprae, M. tuberculosis,* and candidate leprosy vaccine strains determined by DNA hybridization: identification of an *M. leprae*-specific repetitive sequence. Grosskinsky, C. M., *et al.* ....(A) 719
Homology of the 70-kilodalton antigens from *M. leprae* and *M. bovis* with the *M. tuberculosis* 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., *et al.* ....(A) 583
In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against *M. tuberculosis.* Uttley, A. H. C. and Collins, C. H. ....(A) 151
In-vitro susceptibility of *M. tuberculosis, M. bovis* and *M. kansasii* to amoxycillin and ticarcillin in combination with clavulanic acid. Wong, C. S., *et al.* ....(A) 732

Intraspecies differentiation of strains of *M. tuberculosis* obtained from Czechoslovakian, Mongolian and South Indian patients. Venkataraman, P., *et al.* ..... (A) 596
Metabolism in *M. leprae, M. tuberculosis* and other pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. ..... (A) 143
Monoclonal antibodies to 33 kD protein of *M. tuberculosis* with varying epitope specificities. Rambukkana, A., *et al.* ..... (A) 903
Preliminary evaluation of a *M. tuberculosis* phenolglycolipid antigen in the serologic diagnosis of tuberculosis. Torgal-Garcia, J., *et al.* ..... (A) 151
Serodiagnostic potentialities of enzyme-linked immunosorbent assay (ELISA) using mannophosphoinositides of *M. tuberculosis* H37Rv. Mehta, P. K. and Khuller, G. K. ..... (A) 729
Serological responses of patients with lepromatous and tuberculoid leprosy to 30-, 31-, and 32-kilodalton antigens of *M. tuberculosis.* Rumschlag, H. S., *et al.* ..... (A) 140
Serological specificity of *M. tuberculosis* glycolipids. Papa, F., *et al.* ..... (A) 918

Mycobacterium ulcerans,
Immunosuppressive properties of the soluble toxin from *M. ulcerans.* Pimsler, M., *et al.* ..... (A) 919

Mycobacterium vaccae,
Inyecciones de *M. vaccae* muertas inducen respuestas intradermicas frente antigenos solubles del *M. leprae* en 50% de pacientes lepromatosos. Torres, P., *et al.* ..... (A) 320

Mycobacterium w,
Results of one year of phase II/phase III trials with the candidate antileprosy vaccine *Mycobacterium w.* Zaheer, S. A., *et al.* ..... (A) 351

Mycobacterium xenopi,
Capillary gas chromatographic analysis of mycolic acid cleavage products, cellular fatty acids, and alcohols of *M. xenopi.* Luquin, M., *et al.* ..... (A) 917

Mycobactin,
Presence of mycobactin-like substance in *M. leprae.* Dhople, A. M. and Osborne, L. J. ..... (A) 142

Nepal,
Relapses after multidrug therapy for leprosy: a preliminary report on 22 cases in West Nepal. van Brakel, W., *et al.* ..... (A) 894

Nerve(s),
An enzyme immunoassay (EIA) based on antibodies against human nerve antigen for diagnosis of all categories of leprosy patients. Itty, B. M., *et al.* ..... (A) 304
An experimental model of chronic nerve compression and the effect of *M. leprae* infection on a nerve with chronic compression neuropathy. Doyle, D., *et al.* ..... (A) 309
Calcification of ulnar nerve in a patient with tuberculoid leprosy—a case report. Siddappa, K., *et al.* ..... (A) 711
Calcification of ulnar nerve in leprosy—a case report. Arora, S. K., *et al.* ..... (A) 709
Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistry. Karanth, S. S., *et al.* ..... (A) 578
Chemical and mechanical neurolysis. Yanez Ordas, R. and Hernandez Angula, M. .... (A) 344
Comprehensive management of recent nerve damage in borderline leprosy on an outpatient basis. Udaya, K. K. and Suneetha, S. ..... (A) 338
Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. McDougall, A. C. ..... (C) 114
Drs. Jacob and Mathai reply (diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy). Jacob, M. and Mathai, R. ..... (C) 114
Gangliosides (Cronassial) and nerve regeneration in leprosy; a multicentre trial: preliminary results. Salafia, A., *et al.* ..... (A) 317
Histology and fine structure of lepromatous nerves, before and after treatment. Dastur, D. K., *et al.* ..... (A) 337
Immuno-electron microscopy of mycobacterial granulomas in the sciatic nerves of guinea pigs. Cowley, S. A., *et al.* ..... (A) 310
Indications that early events causing nerve damage in leprosy may not be immunologically mediated. Antia, N. H., *et al.* ..... (A) 337

Light- and electron-microscopic study of *M. leprae*-infected armadillo nerves. Liu, T.-C., *et al.* ..... (O) 65
Macrophage mediated immune responses in the sciatic nerves of *M. leprae* infected nude mice with possible bystander and autoimmune demyelination—an electron microscopic study. Stanley, J. N. A., *et al.* ..... (A) 310
Monitoring of patient peripheral nerve status and deformity in Hansen's disease. Bell-Krotoski, J. ..... (A) 337
Multibacillary lesions in nerves of patients with primary neuritic leprosy. Jacob, M. and Mathai, R. ..... (A) 338
Nerve damage in leprosy. Job, C. K. ..... (E) 532
Nerves and Veins in Leprosy by A. Mukherjee. Dharmendra ..... (B) 888
New boundaries for the indications for nerve decompressions. Theuvenet, W. J., *et al.* ..... (A) 344
Out patient treatment of nerve damage requiring corticosteroids in the ALERT leprosy control programme. Berhe, D. and Becx-Bleumink, M. ..... (A) 337
Preliminary results about a controlled double-blind study with three different kinds of treatment in severe nerve damage. Dietz, M. and Yemaneberhan, T. ..... (A) 338
Serum antibodies of normals and leprosy patients show equal binding to peripheral nerve. Ghaswala, P. S., *et al.* ..... (C) 690
Sural nerve biopsy findings in leprosy: a qualitative and quantitative light and electron microscopic study in 4 treated cases of the lepromatous spectrum. Gibbels, E., *et al.* ..... (A) 137
Surgical exploration of peripheral nerve enlargement. Dong, L.-W., *et al.* ..... (A) 342
The role of nerve biopsies in the diagnosis and management of leprosy. Nilsen, R., *et al.* ..... (A) 895
The significance of facial patches in relation to facial nerve damage in paucibacillary leprosy. Hogeweg, M., *et al.* ..... (A) 314
Traitement palliatif de la paralysie sciatique poplité externa—étude critique—à propos de 30 cas. Oberlin, C. ..... (A) 343
Ultrastructural studies on peripheral nerves in lepromatous leprosy patients. Kumar, V., *et al.* ..... (A) 138

Netherlands, The,
4th Immunodermatology Symposium. ..... (N) 558
XIII International Leprosy Congress. ..... (S) 229

Neuritis,
Essai comparé randomise de traitement des névrites hanséniennes par les corticoides seuls ou associés à une neurolyse. Boucher, P., *et al.* ..... (A) 342
[Five cases of recurring leprous neuritis; surgical treatment.] Redondo, A., *et al.* ..... (A) 148
Neuritis—surgical decompression relieves intractable pain, tenderness and hyperaesthesia. Srinivasan, T., *et al.* ..... (A) 343
Surgical management of ulnar neuritis by hemicircumferential epineurotomy. Solomon, S. and Fritschi, E. P. ..... (A) 343
[Surgical treatment of leprous neuritis; results of 114 operations.] Nores, J. M., *et al.* ..... (A) 588
[Tuberculoid leprosy with necrotizing neuritis and numerous bacilli in the fistulae.] de Menezes, J. A., *et al.* ..... (A) 569
Quelle orientation du traitement des névrites hanséniennes. Carayon, A., *et al.* ..... (A) 342

Neuropathy,
An experimental model of chronic nerve compression and the effect of *M. leprae* infection on a nerve with chronic compression neuropathy. Doyle, D., *et al.* ..... (A) 309
The pathology of early leprous neuropathy. Shetty, V. P., *et al.* ..... (A) 716

New Caledonia,
Specific anti-*M. leprae* PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., *et al.* ..... (O) 794

Nigeria,
An evaluation of 35 years of leprosy control in northern Nigeria as demonstrated in the original pilot project Katsina. Waaldijk, K. ..... (A) 324
Courses at a specialist leprosy hospital for the training of medical students and paramedical workers in Nigeria. Attah, E. B. and Davies, E. M. ..... (A) 347

The role of a geographer in leprosy research and control: case study from Nigeria. Brightmer, M. I. ..... (A) 322

Nose,
Bacillaemia in leprosy: correlation with slit-skin and nasal smears. Chatterjee, G., *et al.* ..... (A) 569
Detection of lepromatous leprosy patients shedding *M. leprae* in nasal droppings by enzyme immunoassay. Moudgil, K. D., *et al.* ..... (A) 579
Epistaxis and leprosy. Soni, N. K. ..... (A) 573

Obituaries,
Christian, Melville by Hastings, R. C. ..... (Ob) 697
Desta, Zerihun by Becx-Bleumink, M. ..... (Ob) 552
Gatti, Juan C. by Olivares, L. M. ..... (Ob) 698
Ma Haide by Ye, G.-Y. ..... (Ob) 117
Matthews, C. M. E. by Cherian, J. ..... (Ob) 883
Møller-Christensen, Vilhelm by Jopling, W. H. ..... (Ob) 553

Ofloxacin,
Effect of ofloxacin on experimental leprosy. Kohsaka, K., *et al.* ..... (A) 316
Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., *et al.* ..... (A) 325
Pefloxacin and ofloxacin activities against *M. leprae* in the mouse. Guelpa-Lauras, C.-C., *et al.* ..... (A) 316
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): I. Clinical results. N'Deli, L., *et al.* ..... (A) 317
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): II. Biological results. Grosset, J., *et al.* ..... (A) 316

Papua New Guinea,
The epidemiology of leprosy in a high prevalence village in Papua New Guinea. Bagshawe, A., *et al.* ..... (A) 722

Pathology,
The pathology of early leprous neuropathy. Shetty, V. P., *et al.* ..... (A) 716

Pefloxacin,
Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Gorzynski, E. A., *et al.* ..... (A) 915
Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., *et al.* ..... (A) 325
Pefloxacin and ofloxacin activities against *M. leprae* in the mouse. Guelpa-Lauras, C.-C., *et al.* ..... (A) 316
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): I. Clinical results. N'Deli, L., *et al.* ..... (A) 317
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): II. Biological results. Grosset, J., *et al.* ..... (A) 316

Phagocyte(s),
Measurement of phagocyte chemiluminescence using a microtitre plate luminometer. Blair, A. L., *et al.* ..... (A) 575
Reactive oxygen intermediates inactivate *M. leprae* in the phagocytes from human peripheral blood. Marolia, J. and Mahadevan, P. R. ..... (O) 483
[Reproduction of experimental leprosy infection in mice with previously induced insufficiency of mononuclear phagocyte system.] Vishnevetsky, F. E., *et al.* ..... (A) 910
T lymphocytes, mononuclear phagocytes, Schwann cells and *M. leprae*. Kaufmann, S. H. E., *et al.* ..... (A) 900

Pharmacokinetics,
Clinical pharmacokinetics of clofazimine; a review. Holdiness, M. R. ..... (A) 893
Structure pharmacokinetic relationship in a series of dapsone derivatives. Visser, K., *et al.* ..... (A) 317

Phenolic glycolipid(s),
A preliminary study on serological activity of phenolic glycolipid and its application in diagnosis of leprosy. Wu, Q., *et al.* ..... (A) 581
Arabinogalactan; a complementary antigen to phenolic glycolipid in leprosy diagnosis. Roy, A., *et al.* ..... (A) 580
Biosynthesis of phenolic glycolipids in *M. microti.* Thurman, P. and Draper, P. ..... (A) 920
Comparative studies of serum IgA1, IgA2 and IgM against phenolic glycolipid I in leprosy patients and contacts. Chujor, C. S. N., *et al.* ..... (A) 304
Demonstration of PGL I antigens in skin biopsies in indeterminate leprosy patients: comparison with serological anti-PGL I levels. Huerre, M., *et al.* ..... (A) 899
Detection of phenolic glycolipid I of *M. leprae* and antibodies to the antigen in sera from leprosy patients and their contacts. Cho, S.-N., *et al.* ..... (A) 897
Detection of phenolic glycolipid I of *M. leprae* for monitoring the chemotherapy of leprosy. Cho, S.-N., *et al.* ..... (A) 303
Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* ..... (A) 917
Evaluation of natural phenolic glycolipid (GP1) and artificial antigen in the serodiagnosis of leprosy. Wu, Q.-Z., *et al.* ..... (A) 305
Frequency and polyreactivity of human antibodies to phen GL-1 from leprosy patients defined by anti-idiotypes. Zumla, A., *et al.* ..... (A) 304
Human gut wall reactivity to monoclonal antibodies against *M. avium* glycolipid in relation to Crohn's disease (preliminary recults). Blaauwgeers, J. L. G., *et al.* ..... (A) 912
Human monoclonal antibodies to phenolic glycolipid-I from leprosy patients crossreact with poly(ADP-ribose) polynucleotides and tissue bound antigens. Zumla, A., *et al.* ..... (A) 582
Immunogold labeling method for *M. leprae*-specific phenolic glycolipid in glutaraldehyde-osmium-fixed and araldite-embedded leprosy lesions. Boddingius, J. and Dijkman, H. P. ..... (A) 913
Immunological response to homologous and heterologous phenolic glycolipid antigens in tuberculosis and leprosy. Torgal-Garcia, J., *et al.* ..... (A) 905
Long-term correlation between serological (PGL) and histological parameters in the control of chemotherapy in LL and BL patients. Wabitsch, K. R., *et al.* ..... (A) 346
Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., *et al.* ..... (A) 325
PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., *et al.* ..... (A) 897
PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Chanteau, S., *et al.* ..... (O) 735
PGL-I independence of the lepromin (Mitsuda) reaction in pre-sensitized guinea pigs. Krotoski, W. A., *et al.* ..... (A) 309
Preliminary evaluation of a *M. tuberculosis* phenolglycolipid antigen in the serologic diagnosis of tuberculosis. Torgal-Garcia, J., *et al.* ..... (A) 151
Relationships between structure and biological activity of the mycolic acid-containing glycolipids from *Nocardia asteroides* "sensu stricto" and related species. Han, Y., *et al.* ..... (A) 916
Serologic responses to *M. leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* ..... (A) 309
Serological tests in leprosy. The sensitivity, specificity and predictive value of ELISA tests based on phenolic glycolipid antigens, and the implications for their use in epidemiological studies. Burgess, P. J., *et al.* ..... (A) 144
Specific anti-*M. leprae* PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., *et al.* ..... (O) 794
Synthesis and immunoreactivity of neoglycoproteins containing the trisaccharide unit of phenolic glycolipid I of *M. leprae.* Chatterjee, D., *et al.* ..... (A) 712
The effect of phenolic glycolipid-I from *M. leprae* on the antimicrobial activity of human macrophages. Neill, M. A. and Klebanoff, S. J. ..... (A) 139

Philippines, The,
Evaluation of *M. leprae* antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., *et al.* ..... (A) 899

Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., *et al.* ....(A) 339

Polynesia,
Lepra reactions and disabilities in patients treated with daily MDT in New Caledonia, French Polynesia and Guadeloupe. Bobin, P., *et al.* ....(A) 313
[Leprosy in French Polynesian archipelagoes from 1967–1987.] Cartel, J.-L., *et al.* ....(A) 722
PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., *et al.* ....(A) 897
Results after 8 years of a daily multidrug therapy for leprosy patients in Guadeloupe, New Caledonia and Polynesia. Cartel, J. L., *et al.* ....(A) 335

Pregnancy,
[Hanseniasis and pregnancy; an evaluation of sulfone therapy.] dos Santos, I. B., *et al.* ....(A) 707

Prostaglandin,
Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. ....(A) 132
Prostaglandins and leprosy. A role for aspirin? Klenerman, P. ....(A) 901

Protein(s),
A 28-kDa protein from *M. leprae* is a target of the human antibody response in lepromatous leprosy. Cherayil, B. J. and Young, R. A. ....(A) 575
A peptidoglycan protein complex purified from *M. leprae* cell walls contains most or all immunodominant *M. leprae* T-cell antigens. Mutis, T., *et al.* ....(O) 788
A protein antigen of *M. leprae* is related to a family of small heat shock proteins. Nerland, A. H., *et al.* ....(A) 585
Characterization of an antibody-binding epitope from the 18-kDa protein on *M. leprae.* Doherty, T. M., *et al.* ....(A) 719
Characterization of *M. leprae* cell wall-associated proteins with the use of T lymphocyte clones. Mehra, V., *et al.* ....(A) 715
Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65 kDa) in culture filtrates of mycobacteria. de Bruyn, J., *et al.* ....(A) 590
Expression in recombinant *E. coli* of biotinylated proteins of *M. leprae.* Moss, M. T. and Dale, J. W. ....(A) 327
Expression of the *M. leprae* 18 kD protein. Stoker, N. G., *et al.* ....(A) 329
Expression, purification and immunologic activity of recombinant 65-kilodalton protein of *M. leprae.* Gillis, T. P. and Williams, D. L. ....(A) 328
Genomic and amino acid sequence of the *M. leprae* 70 kD antigen is homologous to the higher conserved 70 kD heat shock protein (hsp70) of eukaryotes. Garsia, R. J., *et al.* ....(A) 318
Homology of the 70-kilodalton antigens from *M. leprae* and *M. bovis* with the *M. tuberculosis* 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., *et al.* ....(A) 583
Isolation and characterization of the highly immunogenic cell wall-associated protein of *M. leprae.* Hunter, S. W., *et al.* ....(A) 713
Monoclonal antibodies to 33 kD protein of *M. tuberculosis* with varying epitope specificities. Rambukkana, A., *et al.* ....(A) 903
Overproduction and purification of *M. leprae* 65 kD protein in *Escherichia coli.* Nomaguchi, H., *et al.* ....(A) 329
Overproduction, affinity purification and characterization of 65-kDa protein of *M. leprae* in *Escherichia coli.* Nomaguchi, H., *et al.* ....(O) 817
Polyspecificity of human monoclonal antibodies reactive with *M. leprae,* mitochondria, ssDNA, cytoskeletal proteins, and the acetylcholine receptor. Duggan, D. B., *et al.* ..(A) 576
Stress proteins and the immune response to mycobacteria—antigens as virulence factors? Young, D. B., *et al.* ....(A) 582
Structure of mycobacteria: recent developments in defining cell wall carbohydrates and proteins. Brennan, P. J. ....(A) 712
The large molecular mass cell wall protein of *M. leprae.* Hunter, S. W., *et al.* ....(A) 320

The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* ....(A) 577
The relationship between reactivities to lepromin A and soluble protein antigen of *M. leprae* and tuberculin. Pemajayantha, V., *et al.* ....(A) 579
The role of the 65-kDa protein in the immune response to *M. leprae*. Colston, M. J., *et al.* ....(A) 325
The use of a "universal" yeast expression vector to produce an antigenic protein of *M. leprae*. Booth, R. J., *et al.* ....(A) 575
Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* ....(A) 717

Psycho-social,
A study on risk factors in social displacement of leprosy patients. Thomas, M. V. ....(A) 353
Bringing leprosy into the open. Chen, P. C. Y. ....(A) 127
Care after cure in leprosy. Thomas, A. and Thomas, R. A. ....(A) 353
Coping strategies for making the transition from isolation back into the community. Malo, W. and Malo, E. ....(A) 353
Experience on trying to transform a "colony hospital" into "community institute." Amaral, R. R. and Barroso, M. S. ....(A) 351
Experience with a multi-ethnic support group in the treatment of Hansen's disease. Gillen, J. and Gelber, R. ....(A) 352
Governmental responsibilities in addressing the social stigma attached to individuals afflicted with Hansen's disease. Bellinger, R. ....(A) 346
Hansen's disease: the stigma, the fear, the solution. Punikai'a, B. K. ....(A) 353
Knowledge and attitude of leprosy workers: a case study in status analysis. Wele, D. S. ....(A) 348
On being diagnosed a "leper." Olivier, H. R. ....(A) 565
[Personality analysis of leprosy patients.] Zhou, D., *et al.* ....(A) 589
Problems in the analysis of socio-economic risk factors in leprosy. Maine, N., *et al.* ....(A) 352
Social science research on social dimensions of leprosy: where are we going from here? Valencia, L. B. ....(E) 847
The leper's dilemma. Fleming, S. ....(A) 127
The paradoxical stigma of leprosy. Meisels-Navon, L. ....(A) 348
The stigma of leprosy. Gonzalez del Cerro, S. M. A. ....(A) 911

Purified protein derivative (PPD),
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* ....(A) 914
Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the sero-diagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* ....(A) 917
The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* ....(A) 577

Purines,
Lymphocytic purine metabolic disorders in tuberculin anergic mice. Senesi, S., *et al.* ..(A) 594

Radioimmunoassay,
A monoclonal antibody based competition radioimmunoassay for monitoring anti-*M. leprae* antibodies in leprosy patients and contacts. Sinha, S., *et al.* ....(A) 573

Rat(s),
Inefficacy of thalidomide on rat adjuvant-induced arthritis and lack of arthrogenicity of Hansen bacilli. Tsutsumi, S. and Gidoh, M. ....(A) 721
Interaction of anti-leprosy drugs with the rat serum complement system. Sahu, A., *et al.* ....(A) 131

Reactions, leprosy,
Comparison of colchicine and aspirin in the treatment of type 2 lepra reaction. Kar, H. K. and Roy, R. G. ....(A) 133

Reactions in leprosy: a study of 250 patients in MDT project, Baroda District (Gujarat). Chopra, N. K., *et al.* ..... (A) 313
The management of reaction in leprosy. Pfaltzgraff, R. E. ..... (E) 103
Vitiligo following type II lepra reaction. Pavithran, K. ..... (A) 711

Rehabilitation,
Beyond charity: devising rehabilitation projects for a competitive economic world. Freitas, P. ..... (A) 352
Motivating and training for reconstructive surgery and rehabilitation in a South American setting. Duerksen, F., *et al.* ..... (A) 347
Posterior chamber intraocular lenses in the rehabilitation of leprosy patients. Alexander, T. A., *et al.* ..... (A) 354
Proceedings of the International Congress on Medical and Social Rehabilitation of the Disabled in the Third World Countries with Emphasis on the Rehabilitation of the Leprosy Patient. ..... (B) 563
Study on socio-economic rehabilitation. Gopal, P. K. ..... (A) 352

Relapse(s),
[Calculation of relapse rate in leprosy and its significance.] Sun, X., *et al.* ..... (A) 147
Patterns of relapses in paucibacillary leprosy patients treated with MDT (WHO 1982). Reddy, P. K. and Mohinuddin, S. K. ..... (A) 568
Rate and time distribution of relapses in multibacillary leprosy. Kurz, X. M., *et al.* ... (O) 599
Relapse in LL patients after antileprosy ICRC vaccine: its significance to antigenic variability of *M. leprae.* Bapat, C. V. ..... (A) 349
Relapse of paucibacillary leprosy after short course multidrug therapy. Pavithran, K. .. (A) 130
Relapse or late reversal reaction? Pannikar, V., *et al.* ..... (E) 526
Relapse or reversal reaction: the case for a therapeutic trial of steroids. Ramachandran, A. and Seshadri, P. S. ..... (A) 135
Relapse rate in paucibacillary patients during surveillance after multidrug treatment—preliminary report. Babu, G. R., *et al.* ..... (A) 341
Relapse rates in paucibacillary leprosy—WHO regimen versus dapsone monotherapy. Jesudasan, K., *et al.* ..... (A) 340
Relapses after multidrug therapy for leprosy: a preliminary report on 22 cases in West Nepal. van Brakel, W., *et al.* ..... (A) 894
Relapses in paucibacillary patients after treatment with three short-term regimens containing rifampin. Katoch, K., *et al.* ..... (O) 458
Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Grosset, J. H., *et al.* ..... (O) 607
Surveillance and relapse rates after MDT in over 700 paucibacillary leprosy cases—a two years follow up at Purulia, India. Casablanca, M. N. and Nayagam, A. S. ..... (A) 339
The effect of leprosy relapse on the basic elimination of leprosy. Yang, X.-Q., *et al.* ... (A) 334
Tuberculoid relapse in lepromatous leprosy. Waters, M. F. R. and Ridley, D. S. ..... (A) 307
When do relapses appear after treatment of MB leprosy with rifampicin containing regimens? Pattyn, S. R., *et al.* ..... (A) 336

Rifampin,
[Adverse effect of intermittent use of rifampin for leprosy treatment.] Papaiordanou, P. M. de O., *et al.* ..... (A) 708
Attempts to select rifampicin-resistant *M. leprae* in nude mice. McDermott-Lancaster, R. D., *et al.* ..... (A) 350
Comparative *in vitro* and *in vivo* activity of rifabutin and rifampicin against *M. avium* complex. Saito, H., *et al.* ..... (A) 150
Evaluation of three short term regimens containing rifampin for treatment of paucibacillary leprosy. Katoch, K., *et al.* ..... (A) 340
Flu like syndrome with rifampicin pulse therapy. Parking, A. A. and Shah, B. H. ..... (A) 894
Implementation of chemoprophylaxis of leprosy in the Southern Marquesas with a single dose of 25 mg per kg rifampin. Cartel, J.-L., *et al.* ..... (O) 810
[Intermittent treatment with rifampin compared to intensive treatment in leprosy.] Salafia, A. and Ignatia. ..... (A) 131
Long term follow up of PB patients treated with either a single dose of rifampicin (RMP) followed by one year of DDS (regimen A) or 10 weekly doses of RMP (regimen B). Janssens, L., *et al.* ..... (A) 340

M. leprae persisters in patients treated with rifampicin and acedapsone. Gonzalez, A. B., *et al.* ....(A) 335
Relapses in paucibacillary patients after treatment with three short-term regimens containing rifampin. Katoch, K., *et al.* ....(O) 458
Rifampicin induced uterine bleeding. Nigam, P. K., *et al.* ....(A) 130
Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Grosset, J. H., *et al.* ....(O) 607
The effect of treatment with rifampicin, clofazimine and dapsone in multibacillary leprosy in the field for three years. Li, W.-Z., *et al.* ....(A) 341
Traitement de la lèpre rurale par une dose unique de rifampicine completée par l'association sulfone clofazimine en autotraitement. Languillon, J. L. ....(A) 341
When do relapses appear after treatment of MB leprosy with rifampicin containing regimens? Pattyn, S. R., *et al.* ....(A) 336

Sarcoidosis,
[HLA-DR phenotype and B/DR haplotype in patients with sarcoidosis.] Ketova, N. A. ....(A) 729

Senegal,
[Epidemiologic study of the orodental health of the lepers in MBalling (MBour-Senegal).] Ndiaye, N., *et al.* ....(A) 572
Une "cordonnerié mobile" pour les malades hanséniens du Senegal: 4 annes d'évolution. Parent, M., *et al.* ....(A) 343

Sensation(s),
An evaluation of the Semmes-Weinstein 6.10 monofilament as compared with 6 nylon in leprosy patients. Dorairaj, A., *et al.* ....(A) 147
Protective sensation in the foot in leprosy. Hammond, C. J. and Klenerman, P. ....(A) 570
Sensory evaluation in leprosy patients using nylon filaments. Brandsma, J. W., *et al.* ..(A) 306

Sensitivity, drug,
Measurement of ATP content of *M. leprae*—its application to the determination of viability and drug sensitivity screening. Katoch, V. M., *et al.* ....(A) 321

Serodiagnosis,
A trial to compare serodiagnostic tests for leprosy. Abe, M., *et al.* ....(A) 303
Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* ....(A) 917
Evaluation of natural phenolic glycolipid (GP1) and artificial antigen in the serodiagnosis of leprosy. Wu, Q.-Z., *et al.* ....(A) 305
Gelatin particle agglutination test for serodiagnosis of leprosy—a new simple test useful for field application. Izumi, S., *et al.* ....(A) 304
Serodiagnosis of leprosy infection in 9 banded armadillos. Eggelte, T. A., *et al.* ....(A) 310

Serum,
Antineural antibodies in leprosy sera: further characterization of the antigens. Benjamins, J. A., *et al.* ....(A) 711
[Assay of antibody level in sera of leprosy patients with *M. smegmatis* ELISA.] Wu, Q., *et al.* ....(A) 718
Comparative studies of serum IgA1, IgA2 and IgM against phenolic glycolipid I in leprosy patients and contacts. Chujor, C. S. N., *et al.* ....(A) 304
Conformational changes in the IgG molecule of lepromatous sera using laser Radman spectroscopy. Kumar, P., *et al.* ....(A) 138
Detection of phenolic glycolipid I of *M. leprae* and antibodies to the antigen in sera from leprosy patients and their contacts. Cho, S.-N., *et al.* ....(A) 897
Failure to detect antibodies to HIV-1 in sera from patients with mycobacterial infections. Malkovsky, M., *et al.* ....(C) 866
Influence of *in vitro* administered immune complexes on serum levels of complement and circulating immune complexes in *M. leprae* infected mice. Vaishnavi, C., *et al.* ....(A) 586
Interaction of anti-leprosy drugs with the rat serum complement system. Sahu, A., *et al.* ....(A) 131
Interleukin-2 receptors in the sera of leprosy patients. Ganguly, N. K., *et al.* ....(C) 870

Monoclonal antibody based double antibody sandwich assay for detection of antigen in serum of leprosy patients. Patil, S. A., *et al.* ..... (A) 303
Recognition of mycobacterial antigens by sera from patients with leprosy. Vega-Lopez, F., *et al.* ..... (A) 581
Serum antibodies of normals and leprosy patients show equal binding to a peripheral nerve. Ghaswala, P. S., *et al.* ..... (C) 690
Serum antibodies to defined carbohydrate antigens during the course of treated leprosy. Gelber, R. H., *et al.* ..... (O) 744
Serum antibody responses to mycobacteria in leprosy patients and their contacts. Cree, I. A., *et al.* ..... (A) 576
Serum ferritin in lepra reactions. Saha, K., *et al.* ..... (C) 867
Serum immune complexes in erythema nodosum leprosum reactions of leprosy. Dharma Rao, T. and Rao, P. R. ..... (A) 133
Serum lactate dehydrogenase in murine leprosy: source and isozymes. Luna Herrera, J. and Rojas-Espinosa, O. ..... (O) 641
Solubilization of preformed immune complexes in sera of lepromatous patients with erythema nodosum leprosum. Chakrabarty, A. K., *et al.* ..... (A) 311

Skin,
Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistry. Karanth, S. S., *et al.* ..... (A) 578
Histopathologic observations on the persistence of *M. leprae* in the skin of multibacillary leprosy patients under chemotherapy. Wabitsch, K. R. and Meyers, W. M. ..... (A) 581
Non-cultivable mycobacteria in ulcers of the skin. Salem, J. I., *et al.* ..... (A) 920
Skin lesion in strain 13 guinea pigs induced by a human non-myelin antigen in dorsal roots. Crawford, C. L., *et al.* ..... (A) 308
Survival of *Staphylococcus epidermidis* on the skin of patients with lepromatous leprosy. Kumar, B., *et al.* ..... (A) 134
The control of infective skin diseases—the lessons of leprosy research. Hay, R. J. ..... (A) 564
The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* ..... (A) 577
Tuberculoid granuloma in a clinically normal looking skin. Haldar, S. R., *et al.* ..... (A) 133

Skin smear(s),
Reliability of direct skin smear microscopy in leprosy. Gupte, M. D., *et al.* ..... (A) 570
The bacteriological examination of slit-skin smears in leprosy control programmes using multiple drug therapy: a plea for radical changes in current operational methodology. Georgiev, G. D. and McDougall, A. C. ..... (A) 570

Skin test(s),
A critique on the interpretation of the lepromin reaction using heat-killed *M. leprae* vaccine. Mistry, N. F. and Antia, N. H. ..... (C) 110
BCG infection induces responsiveness to dead *M. leprae* in hamsters; a Mitsuda-like reaction. Mariano, M. and Ferreira, C. S. A. ..... (A) 902
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* ..... (A) 914
[Correlation between skin tests and the production of gamma-interferon in patients with hanseniasis.] Suso, L., *et al.* ..... (A) 905
Do environmental mycobacteria influence the distribution of disease in the leprosy spectrum? Bacteriological and skin test studies carried out in Iran. Velayati, A., *et al.* ..... (A) 320
Identification of "high risk group" of leprosy in children using serological and lepromin test: a preliminary report. Naik, S. S., *et al.* ..... (A) 910
Lepromin conversion induced by a "subunit" vaccine from ICRC bacilli. Bhatki, W. S., *et al.* ..... (A) 136
Lymphocyte blastogenesis and lepromin reactivity in leprosy patients and their parents. Foss, N. T., *et al.* ..... (A) 311
PGL-I independence of the lepromin (Mitsuda) reaction in pre-sensitized guinea pigs. Krotoski, W. A., *et al.* ..... (A) 309
Relative cross reactivity of habanin, lepromin and tuberculin in guinea pigs sensitized with homologous and heterologous mycobacteria. Singh, N. B., *et al.* ..... (A) 140

Reply by Gill, Mustafa and Godal (a critique on the interpretation of the lepromin reaction using heat-killed *M. leprae* vaccine). Gill, H. K., *et al.* ....(C) 112
Skin test responsiveness to a series of new tuberculins of children living in three Vietnamese cities. Ly, H. M., *et al.* ....(A) 724
Skin test studies on close contacts of leprosy patients in India. Lord, R., *et al.* ....(O) 801
Specific anti-*M. leprae* PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., *et al.* ....(O) 794
Ten-year study of lepromin response in child contacts of leprosy patients. Ramu, G. ..(A) 715
The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* ....(A) 577
The relationship between reactivities to lepromin A and soluble protein antigen of *M. leprae* and tuberculin. Pemajayantha, V., *et al.* ....(A) 579
Un traitement logique des névrites lépreuses tuberculoides et borderline aigues ou subaigues: la désensibilisation progressive à la lépromine. Saint-André, P., *et al.* ....(A) 339
Use of skin tests with *M. leprae* soluble antigen for epidemiological studies and vaccination trials. Zuniga, M. ....(A) 334
Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis. Ghazi Saidi, K., *et al.* ....(O) 45
Vaccination and skin test studies on the children of leprosy patients. Stanford, J. L., *et al.* ....(O) 38

Spain,
Analisis de los registros de lepra en Espana. Garranza Martinez, J. M., *et al.* ....(A) 323
[Clinico-diagnostic aspects of leprosy in the province of Jaen (Spain).] Extremera Castillo, F., *et al.* ....(A) 569
Fontilles international courses 1989. ....(N) 558
Reorientacion del Instituto Leprologico de Trillo para su integracion en el marco de la reforma sanitaria en Espana. Carrasco Gellida, S., *et al.* ....(A) 351

Sri Lanka,
The current state of leprosy control activities in Sri Lanka. Dewapura, D. R. ....(A) 910

Stain(s),
[Determination of the viability of *M. leprae* with fluorescent staining.] Meng, M., *et al.* ....(A) 584
Effect of chemotherapy on viability of *M. leprae* as determined by ATP content, morphological index and FDA-EB fluorescent staining. Katoch, V. M., *et al.* ....(O) 615
Fluorescent staining procedure (FDA/EB) for determining the viability of *M. leprae.* Meng, M.-B., *et al.* ....(A) 322

Steroids,
Relapse or reversal reaction: the case for a therapeutic trial of steroids. Ramachandran, A. and Seshadri, P. S. ....(A) 135

Subclinical,
Immuno-epidemiological studies on subclinical infection in leprosy. Bharadwaj, V. P., *et al.* ....(A) 329
Immunodiagnostic approaches to the early detection of subclinical infection in leprosy. Bharadwaj, V. P. ....(A) 574
Immunoepidemiological studies on subclinical infection among leprosy household contacts in Thailand. Sampattavanich, S., *et al.* ....(O) 752
Subclinical infection and the relative risk of developing leprosy: a statistical approach. Rajagopalan, M. S., *et al.* ....(A) 911

Sulfones (see also Dapsone),
Biorésistance en géneral—chimiorésistance comparée sulfonorésistance du bacille de Hansen ce qu'il faut firé en verité pour gagner le combat contre la lèpre. Floch, H. A. and Floch, H. H. ....(A) 566
[Hanseniasis and pregnancy; an evaluation of sulfone therapy.] dos Santos, I. B., *et al.* ....(A) 707
The story of sulfones in tropical medicine and dermatology. Wozel, G. ....(A) 707
Traitement de la lèpre rurale par une dose unique de rifampicine completée par l'association sulfone clofazimine en autotraitement. Languillon, J. L. ....(A) 341

Surgery,
A modification of the surgical correction of the thumb—a long term follow up. Beine, A. O., *et al.* ..... (A) 725
Etude epidémiologique des déformations chirurgicalement curables de 1059 patients hanséniens en zone rurale. Gaisne, E., *et al.* ..... (A) 314
Motivation and training for reconstructive surgery and rehabilitation in a South American setting. Duerksen, F., *et al.* ..... (A) 347

Switzerland,
Grants for social and economic research in tropical diseases. ..... (N) 703
New type TDR grant for scientist. ..... (N) 559
Report available on joint meeting for leprosy field research. ..... (N) 703
Report of Fifth Meeting Ad Hoc Drug Development Subgroup of the THELEP SWG. ..... (N) 886
Report of Fifth Meeting of THELEP SWG. ..... (N) 886
TDR research capability strengthening. ..... (N) 703
TDR support for telefax equipment. ..... (N) 559

Taiwan,
An epidemiological study on leprosy in southern Taiwan. Chou, P., *et al.* ..... (A) 330

Tetanus,
Tetanus in leprosy patient (II). Anilkumar, G., *et al.* ..... (A) 132
Tetanus in leprosy patients: report of 5 cases. Hodes, R. M. and Teferedegne, B. ..... (A) 307
Tetanus in patients with lepromatous leprosy (I). Anilkumar, G., *et al.* ..... (A) 132
Tetanus with leprosy. Tibrewala, K. D., *et al.* ..... (A) 896

Thailand,
Immunoepidemiological studies on subclinical infection among leprosy household contacts in Thailand. Sampattavanich, S., *et al.* ..... (O) 752
Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., *et al.* ..... (A) 339

Thalidomide,
Inefficacy of thalidomide on rat adjuvant-induced arthritis and lack of arthrogenicity of Hansen bacilli. Tsutsumi, S. and Gidoh, M. ..... (A) 721
Thalidomide for treatment of graft-versus-host disease. Vogelsang, G. B., *et al.* ..... (A) 732
Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Youle, M., *et al.* ..... (A) 733

The Leprosy Mission (TLM),
Awards to TLM staff. ..... (N) 560
The Leprosy Mission International change of address. ..... (N) 119

THELEP (WHO Chemotherapy of Leprosy Scientific Working Group),
Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988. ..... (B) 124
Progress in chemotherapy research under THELEP programme. Ji, B.-H., *et al.* ..... (A) 336
Report of Fifth Meeting Ad Hoc Drug Development Subgroup of the THELEP SWG. ..... (N) 886
Report of Fifth Meeting of THELEP SWG. ..... (N) 886

Therapy (see also Chemotherapy, Multidrug therapy),
Field trials of combined therapy in lepromatous leprosy. Vijayakumaran, P., *et al.* ..... (A) 337
Flu like syndrome with rifampicin pulse therapy. Parking, A. A. and Shah, B. H. ..... (A) 894
[Hanseniasis and pregnancy; an evaluation of sulfone therapy.] dos Santos, I. B., *et al.* ..... (A) 707
Investigations into the haemolytic effects of dapsone therapy in leprosy patients. Balakrishnan, S., *et al.* ..... (A) 707

Tissue(s),
Glomerular immunoglobulin deposition in the absence of tissue damage in murine leprosy. Rojas-Espinosa, O., *et al.* ..... (C) 879
Human monoclonal antibodies to phenolic glycolipid-I from leprosy patients crossreact with poly(ADP-ribose) polynucleotides and tissue bound antigens. Zumla, A., *et al.* ..... (A) 582

Identification of *M. leprae* antigens in tissues of leprosy patients using monoclonal antibodies. Khanolkar, S. R., *et al.* ....(O) 652
Mouse footpad pathogenicity of the chemoautotrophic nocardioform isolates from human and mouse footpad leprosy tissues. Pal, N. K., *et al.* ....(A) 308
Viability of *M. leprae* in soil and dead armadillo tissue and its significance. Harris, E. B., *et al.* ....(A) 323

Training,
Application of a health education model to obtain early and regular treatment of leprosy patients. Matthews, C. M. E. ....(E) 844
Courses at a specialist leprosy hospital for the training of medical students and paramedical workers in Nigeria. Attah, E. B. and Davies, E. M. ....(A) 347
Involvement of students in a leprosy health education programme—an experiment. Naik, S. S., *et al.* ....(A) 128
Karigiri Video teaching/training materials. ....(N) 701
Knowledge and attitude of leprosy workers: a case study in status analysis. Wele, D. S. ....(A) 348
Leprosy teaching in medical colleges in Bombay—a questionnaire study. Sheela, G. R., *et al.* ....(A) 890
Monitoring and evaluation of training programmes. Chacko, P., *et al.* ....(A) 346
Motivating and training for reconstructive surgery and rehabilitation in a South American setting. Duerksen, F., *et al.* ....(A) 347
Operational efficiency of paramedical workers in leprosy survey: a time motion study. Kumar, A., *et al.* ....(A) 330
Orientation in Leprosy for Doctors. ....(N) 119
Training needs for leprosy eradication through primary health care. Thangaraj, E. S. ..(A) 348
The application of a health education model to obtain early and regular treatment of leprosy patients. Matthews, C. M. E. ....(A) 347

Trials,
Field trials of combined therapy in lepromatous leprosy. Vijayakumaran, P., *et al.* ....(A) 337
Interpretation of published papers on controlled clinical trials. Waters, M. F. R. ....(C) 556
Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., *et al.* ....(A) 339
Results of one year of phase II/phase III trials with the candidate antileprosy vaccine *Mycobacterium w.* Zaheer, S. A., *et al.* ....(A) 351
Use of skin tests with *M. leprae* soluble antigen for epidemiological studies and vaccination trials. Zuniga, M. ....(A) 334

Tuberculin,
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* ....(A) 914
Lymphocytic purine metabolic disorders in tuberculin anergic mice. Senesi, S., *et al.* ..(A) 594
Relative cross reactivity of habanin, lepromin and tuberculin in guinea pigs sensitized with homologous and heterologous mycobacteria. Singh, N. B., *et al.* ....(A) 140
Skin test responsiveness to a series of new tuberculins of children living in three Vietnamese cities. Ly, H. M., *et al.* ....(A) 724
The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* ....(A) 577
The relationship between reactivities to lepromin A and soluble protein antigen of *M. leprae* and tuberculin. Pemajayantha, V., *et al.* ....(A) 579

Tuberculoid leprosy,
Calcification of ulnar nerve in a patient with tuberculoid leprosy—a case report. Siddappa, K., *et al.* ....(A) 711
Destruction of ala nasi and loss of columella in borderline tuberculoid leprosy—a case report. Siddappa, K., *et al.* ....(A) 711
Serological responses of patients with lepromatous and tuberculoid leprosy to 30-, 31-, and 32-kilodalton antigens of *M. tuberculosis.* Rumschlag, H. S., ...(A) 140
Tuberculoid leprosy on hairy scalp: a case report. Ghorpade, A., *et al.* ....(A) 133
[Tuberculoid leprosy with necrotizing neuritis and numerous bacilli in the fistulae.] de Menezes, J. A., *et al.* ....(A) 569

Tuberculosis,
A competition ELISA for the detection of mycobacterial antigen in tuberculosis exudates. Ramkisson, A., *et al.* ....(A) 730
[A nutriological survey in leprosy and tuberculosis patients.] Zhou, D., *et al.* ....(A) 726
Amoebic disease precipitated by corticosteroids prescribed for tuberculous pleural effusions. Ratcliffe, G. E. ....(A) 731
An analysis of pulmonary tuberculosis data in Taiwan and Korea. Schulzer, M., *et al.* ....(A) 151
Association of tuberculosis and *M. tuberculosis*-specific antibody levels with HLA. Bothamley, G. H., *et al.* ....(A) 727
[Changes in the system of T-lymphocyte cyclic nucleotides in animals with experimental tuberculosis.] Kostromin, A. P., *et al.* ....(A) 591
[Classes I and II antigens and levels of IgG antibodies in patients with infiltrative tuberculosis of the lungs.] Nikolayan, L. T., *et al.* ....(A) 918
[Determination of antibodies to mycobacterial antigens in tuberculosis by the method of erythroimmunoadsorption with a rosette marker.] Plaksin, D. Y., *et al.* ....(A) 140
Epidemic of pulmonary tuberculosis in geriatric homes. Morris, C. D. W. and Nell, H. ....(A) 149
Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* ....(A) 917
Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council ....(A) 591
Identification of mycobacterial antigens for "ELISA" serology in the diagnosis of leprosy and tuberculosis. Das, P. K., *et al.* ....(A) 898
Immunological response to homologous and heterologous phenolic glycolipid antigens in tuberculosis and leprosy. Torgal-Garcia, J., *et al.* ....(A) 905
In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against *M. tuberculosis*. Uttley, A. H. C. and Collins, C. H. ....(A) 151
In vitro analysis of the cellular mechanisms involved in immunity to tuberculosis. Kaufmann, S. H. E. ....(A) 729
Longhouse dwelling, social contact and the prevalence of leprosy and tuberculosis among native tribes of Sarawak. Chen, P. C. Y. ....(A) 145
New experimental drugs for the treatment of tuberculosis. Parenti, F. ....(A) 730
Preliminary evaluation of a *M. tuberculosis* phenolglycolipid antigen in the serologic diagnosis of tuberculosis. Torgal-Garcia, J., *et al.* ....(A) 151
Prevalence of HIV infection among patients with leprosy and tuberculosis in rural Zambia. Meeran, K. ....(A) 709
Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Brown, A. R., *et al.* ....(A) 913
Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria. Mehta, P. K. and Khuller, G. K. ....(A) 592
[Tuberculosis and anti-HIV seropositivity in Kinshasa, Zaire.] Williams, J. C., *et al.* ....(A) 921
Tuberculosis and Leprosy by Richard J. W. Rees. Cowley, S. A. ....(B) 888
Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis. Ghazi Saidi, K., *et al.* ....(O) 45

Turkey,
Close-contact surveys and mass-screening studies for leprosy in Turkey. Aytekin, A. H. and Saylan, T. ....(A) 143
Leprosy in Turkey. Aytekin, A. H. and Saylan, T. ....(A) 144
The characteristics and mode of detection of the new patients encountered in the leprosy endemic province of Van within the last five years. Saylan, T., *et al.* ....(A) 324
The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey; a preliminary study. Cem Mat, M., *et al.* ....(A) 144

U.K.,
Application for LEPRA research grants in U.K. ....(N) 559
Awards to TLM staff. ....(N) 560
Leprosy—a learning package—The Wellcome Tropical Institute. ....(N) 887

Robert Cochrane Fund for Leprosy. ....(N) 703
The Leprosy Mission International change of address. ....(N) 119
Wellesley Bailey Scholarship. ....(N) 560

Ulcer(s),
Bacterial flora of ulcers treated by three types of dressings. Cherian, E., *et al.* ....(A) 132
Carcinoma in plantar ulcers of leprosy patients. Majoroh, T. O. and Imongan, W. I. ..(A) 709
Malignant transformation of trophic ulcer in leprosy. Anilkumar, G., *et al.* ....(A) 132
Non-cultivable mycobacteria in ulcers of the skin. Salem, J. I., *et al.* ....(A) 920
Occlusive hydrocolloid dressings applied to chronic neuropathic ulcers. A study of efficacy in patients in a rural south Indian hospital. Mumford, J. W. and Mumford, S. P. ....(A) 148
Relationship between hallux limitus and ulceration of the great toe. Birke, J. A., *et al.* ....(A) 725
Squamous cell carcinoma in trophic ulcer in leprosy. Naik, R., *et al.* ....(A) 134
Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Youle, M., *et al.* ....(A) 733

Ultrastructure (see also Electron Microscopy),
New data on the ultrastructure of the membrane of *M. leprae*. Silva, M. T., *et al.* ....(O) 54

Urine,
Detection of a specific *M. leprae* antigen in the urine of leprosy patients. Mahon, A. C., *et al.* ....(A) 326

U.S.A.,
Comparison of the distribution of indigenous human and armadillo leprosy in Louisiana, U.S.A. Truman, R. W. and Kumaresan, J. A. ....(A) 334
Damien-Dutton 1988 award to Hermann Kober. ....(S) 252
Leprosy cases, 1978–1987. ....(N) 119
Leprosy in six isolated residents of northern Louisiana. West, B. C., *et al.* ....(A) 147
Number of new leprosy patients. ....(N) 561
Regional Hansen's disease centers. ....(N) 119
2nd Annual Course on Infectious, Parasitic and Tropical Diseases. ....(N) 704
The Heiser Program for Research in Leprosy 1990. ....(N) 887
12th International Conference on Missionary Medicine. ....(N) 704

Vaccination,
Comments on leprosy vaccination. Kato, L. ....(C) 693
Cure of bacille Calmette-Guérin vaccination abscesses with erythromycin. Murphy, P. M., *et al.* ....(A) 729
Hypothesis: Does vaccination with bacille Calmette-Guérin protect against AIDS? Kallenius, G., *et al.* ....(A) 729
Implications of prior BCG vaccination programmes in the community on the protective efficacy of new antileprosy vaccines. Radhakrishna, S., *et al.* ....(A) 588
Prospects for new generation vaccines for leprosy: progress, barriers and future strategies. Watson, J. D. ....(E) 834
[The leprosy bacillus; expectations for culturing and vaccination.] Portaels, F. ....(A) 585
Use of skin tests with *M. leprae* soluble antigen for epidemiological studies and vaccination trials. Zuniga, M. ....(A) 334
Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis. Ghazi Saidi, K., *et al.* ....(O) 45
Vaccination and skin test studies on the children of leprosy patients. Stanford, J. L., *et al.* ....(O) 38
Vaccination of mice against *M. leprae* infection. Singh, N. B., *et al.* ....(A) 717

Veins,
Nerves and Veins in Leprosy by A. Mukherjee. Dharmendra. ....(B) 888
Vascular involvement in leprosy. Kaur, S. and Abraham, A. ....(A) 901

Venezuela,
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization. ....(B) 122

World Health Organization (WHO),
A Guide to Leprosy Control (2nd ed.) by the World Health Organization. ..... (B) 124
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization. ..... (B) 122
Sixth Report of the WHO Expert Committee on Leprosy. ..... (B) 125

Zaire,
[Tuberculosis and anti-HIV seropositivity in Kinshasa, Zaire.] Williams, J. C., *et al.* ..(A) 921

Zambia,
Prevalence of HIV infection among patients with leprosy and tuberculosis in rural Zambia. Meeran, K. ..... (A) 709

Zimbabwe,
Multiple drug therapy in Zimbabwe. Matemera, B. O. ..... (A) 336

Zinc,
Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65 kDa) in culture filtrates of mycobacteria. de Bruyn, J., *et al.* ..... (A) 590
Study of serum zinc level in leprosy. Saxena, N., *et al.* ..... (A) 573

ACKNOWLEDGMENT

The Board of Directors of the INTERNATIONAL JOURNAL OF LEPROSY gratefully acknowledges the financial assistance from special grantors and sustaining members which, with the special donations of certain members, has made possible the continuation of publication of the JOURNAL directly by the International Leprosy Association. Without this assistance the official organ of the ILA, so essential to leprosy workers everywhere, could not be published.

SPECIAL GRANTORS

***Aide aux Lépreux Emmaus-Suisse,** 9 Spitalgasse, CH-3011 Berne, Switzerland.

***American Leprosy Missions, Inc.,** One Broadway, Elmwood Park, New Jersey 07407, U.S.A.

***Amici dei Lebbrosi,** Fondazione Italiana Raoul Follereau, Via Borselli 4, 40135 Bologna, Italy.

Damien-Dutton Society, 616 Bedford Avenue, Bellmore, New York 11710, U.S.A.

***Damien Foundation (DF/APD),** 16 Rue Stevin, B-1040 Bruxelles, Belgium.

***Deutsches Aussatzigen-Hilfswerk e. V.,** Dominikanerplatz 4, Postfach 348, D-8700 Wurzburg 11, Germany.

***Le Secours aux Lépreux (Canada),** 235 Côte Vertu, bureau 125, Montréal H4N 2W9, Canada.

***Netherlands Leprosy Relief Association,** Wibautstraat 135, 1097 DN Amsterdam, The Netherlands.

***Sasakawa Memorial Health Foundation,** The Sasakawa Hall 6F, 3-12-12 Mita Minato-ku, Tokyo 108, Japan.

***The Leprosy Mission International,** 50 Portland Place, London W1N 3DG, England.

***The Leprosy Trust Board,** Private Bag, Christchurch, New Zealand.

The Order of Charity, 61 Berners Street, Ipswich, Suffolk, England.

SUSTAINING MEMBERS

***Fondation Follereau (France),** 33 Rue de Dantzig, 75015 Paris, France.

Japanese Leprosy Association, % National Institute for Leprosy Research, 2-1, 4-Chome, Aobacho, Higashimuryama-shi, Tokyo 189, Japan.

* ILEP member/association.